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ABSTRACT 
Andra Lea Wilkinson: Patterns of Binge Drinking, Marijuana Use, and Depressive Symptoms 
from Adolescence to Young Adulthood: Testing the Self-Medication and Stress Models  
(Under the direction of Carolyn T. Halpern) 
 
Understanding the relationships between substance use and depression could inform 
prevention and treatment efforts. Previous studies provide conflicting support for both depression 
leading to substance use—the Self-Medication Model—and substance use leading to 
depression—the Stress Model. Much of this prior literature focuses only on adolescence, 
examines only one direction, and/or fails to examine potential mediators or whether associations 
vary by biological sex.  
Using data from Waves I, III, and IV of the National Longitudinal Study of Adolescent to 
Adult Health, mixed effects models were used to test the relationships between depressive 
symptoms and frequency of alcohol use and marijuana use across development, and whether 
these associations were moderated by sex. Regression models were used to examine potential 
mediators and one moderator for both the Self-Medication and Stress Models.  
Adolescent depressive symptoms were significantly associated with a steeper predicted 
increase in marijuana use frequency across development. Further, persistent binge drinking or 
marijuana use across development were concurrently positively associated with the depressive 
symptom growth curve, and associations were stronger for females. Results also indicate the 
association between depressive symptoms and later binge drinking frequency may be mediated 
by sensation seeking and adherence to gender norms for males and females; adherence to gender 
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norms also moderated this association for males. For females, the association between depressive 
symptoms and later marijuana use frequency may also be mediated by sensation seeking.  
These results inform how to target and integrate screenings for adolescent substance use 
and depressive symptoms, both newly covered under the Affordable Care Act. For example, if 
adolescents screen positive for high or increasing depressive symptoms, it seems they should 
also be screened for marijuana use. Binge drinking screening could be targeted towards 
adolescents with higher sensation seeking and depressive symptoms. The findings also indicate 
substance use and depression prevention and treatment programs should be integrated—as 
comorbidity is common—and tailored by sex—as the links between substance use and 
depression seem to differ by sex. Better yet, substance use and mental health programs for youth 
could challenge the gender norms that promote substance use and self-medication to begin with.   
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CHAPTER 1 - INTRODUCTION 
Specific Aims 
 Adolescence is characterized by increasing substance use and depressive symptoms, both 
of which can have short- and long-term implications.1–4 Many studies have found strong 
correlations between substance use and depression, though it is not clear if the association is 
causal, and if it is, in which direction(s) the process operates. Some studies find that depression 
leads to substance use, possibly by lowering the accuracy of risk perceptions and decreasing 
impulse control; we label this pathway the Self-Medication Model.4–6 Other studies suggest 
substance use leads to depression.5,7,8 We label this pathway the Stress Model, as a hypothesized 
mechanism underlying it involves the stress response, the body’s endocrine reaction to novelty 
exposure, which can be stimulated by risk taking and, when chronic, can lead to depression.9–13 
Complicating potential causal pathways, there are biological sex (sex) differences in the 
prevalence of substance use and depression, as well as differences in responsiveness to stress.4,14–
16 Findings to date suggest the Self-Medication Model may be more relevant for males, whereas 
females might be better represented by the Stress Model.10,11,16–18  
Although there is a vast literature on adolescent substance use, much of the research 
examining associations between adolescent substance use and depression is cross-sectional, or if 
longitudinal, is based on non-representative samples, is vulnerable to endogeneity, tests only one 
direction of association, does not test moderation by sex, does not test mediation, and/or captures 
time periods limited to adolescence.6–8,18–23 This project addresses these important limitations by 
using survey and biomarker data from the National Longitudinal Study of Adolescent to Adult 
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Health (Add Health), which includes a representative sample of more than 20,000 adolescents in 
grades 7-12 in the 1994-95 school year who have been followed prospectively for 15 years as 
they transitioned to young adulthood. Present analyses addressed the following two study aims: 
Aim 1. Evaluate empirical support for the Self-Medication and Stress Models by estimating 
growth curves of alcohol use, marijuana use, and depressive symptoms and testing whether these 
trajectories are conditioned by biological sex and/or are related to each other.  
Aim 2. Using regression models, examine potential mediators (sensation seeking, stress 
biomarkers, and gender norm adherence) and a moderator (gender norm adherence) of the 
relationships between substance use and depressive symptoms and whether the relationships 
differ by biological sex.  
Background & Significance 
During adolescence, sensation seeking increases while impulse control is still developing; 
this creates a developmental window where adolescents often experiment with facets of adult 
behavior, like substance use.4,24 Risk taking can also facilitate peer group bonding, which is a 
critical aspect of development as adolescents distance themselves from parents and family.3 
However, too much risk taking, and certain types of risk taking, can be harmful. Most substance 
use is initiated in adolescence, a developmental period often recognized as lasting from age 12 to 
19.4,15 The trajectory typically begins with alcohol and tobacco use before or early in high 
school, then may escalate to use of illicit drugs (e.g., heroin) during high school.4 According to 
the 2013 Youth Risk Behavior Survey, more than one-third of high school students report current 
alcohol use, and smoking marijuana (23.4%) is now more common than smoking cigarettes 
(15.7%) among adolescents.25 Alcohol and marijuana are the two most commonly used 
substances among U.S. adolescents, they are both illegal for adolescents, and both can lead to 
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significant psychological changes.4,25 Therefore alcohol and marijuana use are the focus of this 
research project. 
The quantity and frequency of alcohol and drug use typically peak between 18-25 years 
of age in the United States.4 On average, adolescent males use more substances and use them 
more frequently than females, though this can vary by age, with females engaging in more 
substance use than males in early adolescence.4,25,26 By middle to late adolescence, males are 
more likely to engage in regular substance use. By comparison, females may accelerate faster 
than males from initiating use to experiencing problems from use.4,27 Substance use in 
adolescence can have significant health effects (e.g., substance dependency or abuse, adverse 
effects on brain development) as well as deleterious effects on a wide range of developmental 
outcomes (e.g., educational attainment).4  
Depression is also prevalent in adolescence. The International Classification of Diseases 
characterizes depression as including some or all of the following symptoms: a depressed mood, 
loss of interest and enjoyment, reduced activity, disturbed sleep and appetite, decreased self-
esteem, and/or guilt. Diagnoses of mild, moderate, or severe depression depend on the number of 
symptoms a person experiences and the degree to which a person can continue with their daily 
activities.28 A systematic review conducted for the United States Preventive Services Task Force 
(USPSTF) estimates that the prevalence of current or recent depression in adolescence is 6% and 
the lifetime prevalence of major depressive disorders among adolescents is as high as 20%.2 In 
adolescence and beyond, females are more likely to experience depression than males.14 Early 
onset depression (before age 21) is associated with an increased risk of suicide attempts, death by 
suicide, longer episodes of depression and higher rates of recurrence.2,29 Adolescent depression 
can have negative effects in the short-term (e.g., decreased school performance, strained family 
4 
 
relationships) and the long-term (e.g., decreased educational attainment).1,2,29 At a population 
level, depression is one of the most burdensome diseases globally because of its early age of 
onset, tendency to be chronic, impairment of normal activities, and high lifetime prevalence.22  
Depression and substance use are often comorbid.23,30 For example, results from the 2013 
National Survey on Drug Use and Health revealed 11.8% of 12-17 year-olds without a major 
depressive episode in the past year reported marijuana use in the past year compared to 25.7% of 
adolescents who did have a major depressive episode in the past year.31 Comorbidity of 
substance use and depression in adolescence is associated with multiple negative outcomes 
including more severe mental health issues, increases in substance use, delays in substance abuse 
recovery, longer depressive episodes, and elevated suicide risk.21 The comorbidity between 
substance use and depression could indicate several possible relationships between the two. 
Fleming et al. outlined four possible forms of relationships underlying the comorbidity.32 First, it 
is possible the levels of depression and substance use are concurrently associated across time. 
Second, change in one may be associated with change in the other across development. Third, it 
is possible the two conditions are only related at specific time points during development. 
Finally, the relationship may be predictive, meaning one generally precedes and predicts the 
other; both the Self-Medication and Stress Models are examples of predictive relationships.32     
Understanding the relationship between substance use and depressive symptoms during 
development is important because it could inform screening, prevention, and treatment practices. 
Surveys of physicians indicate approximately less than half screen their patients for substance 
use or depression, and it is likely even rarer for adolescent patients.33,34 As a consequence, most 
cases of substance use problems and depression in adolescence go untreated.2,33,35 This is a 
significant missed opportunity to prevent or start treating conditions early, especially as an 
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estimated 50% of mental health and substance use conditions begin by age 14.2,35–37 Though the 
Affordable Care Act (ACA) now ensures insurance companies will cover screening, it does not 
mandate that physicians provide the screening.38 Surveys of physicians indicate they feel time 
constrained and uncomfortable treating or providing referrals for substance use or depression 
issues.2,39 Therefore, understanding, for example, that depression generally precedes substance 
use issues, especially in males, helps physicians target screening and integrate treatment and 
referral steps accordingly.   
Self-Medication Model 
The Self-Medication Model, first articulated in the 1990s by Harvard Psychiatrist Dr. 
Edward Khantzian, holds that people struggling with depression may engage in substance use in 
an attempt to ameliorate their symptoms.40–42 This pathway is facilitated by the process of 
depression impairing cognitive function and memory, decreasing impulse control, and impairing 
psychosocial functioning, (e.g., motivation), all of which can impair accurate risk perceptions.4,42 
Adolescents may be especially vulnerable to these processes because of existing imbalances 
between impulsivity and reasoned decisions, and their lesser experience with self-regulation.24 
Evidence for this model includes the finding that adolescents taking antidepressants experience 
consequent declines in substance use.43 Expanding beyond depression to internalizing symptoms 
in general (e.g., anxiety), many studies have connected internalizing symptoms/problems in 
childhood to substance use in adolescence and young adulthood.44 Further, studies have found 
reports of self-medication as a primary reason for addiction among certain populations.42,44   
Stress Model 
Risk taking increases throughout adolescence and can induce stress, which has both 
short- and long-term health implications.4 The Stress Model asserts substance use can induce 
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stress and chronic stress can harm the body; one possible harm is increased depressive 
symptoms.45 If the brain perceives risk taking such as substance use as a threat, it stimulates both 
the sympathetic-adrenal-medullary axis and the hypothalamic-pituitary axis, leading to, among 
other things, cortisol release.9,45 Chronically elevated cortisol levels can lead to dysregulated 
affect, possibly by changing the functional connectivity of the amygdala-ventromedial prefrontal 
cortex, which is positively associated with depression.12,13 The stress response also increases 
inflammation.46,47 Inflammation can contribute to depression through effects on neurotransmitter 
metabolism, neuroendocrine function, synaptic plasticity, and information processing.48,49 Past 
studies have tested whether substance use is associated with later increases in depressive 
symptoms, but few have articulated conceptual grounding for it.5–8  
Past Literature 
Many prior studies have attempted to tease apart the comorbidity between depression or 
depressive symptoms and substance use. The bulk of this research has been motivated by the 
Self-Medication Model, and several longitudinal studies have found support for this 
model.6,21,22,42 For example, Burns et al. followed a sample of 64 rural adolescents from ages 12 
to 18 and found baseline depression was significantly associated with substance abuse at follow-
up, controlling for sex.50 Henry et al. analyzed a birth cohort of over 700 males and females in 
New Zealand at ages 11 and 15 and, after stratifying by sex, found baseline depression was 
associated with later substance use, but only for males.40 However, using Waves I and II of Add 
Health, Hallfors et al. found depression did not increase the odds of either experimental or high 
risk substance use in males, but it did increase the odds of high risk substance use among females 
already experimenting with substances at Wave I. Contrary to the Self-Medication Model, they 
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found depression actually decreased the odds of substance use among females abstaining from 
substances at Wave I.5  
More recent studies have used methods that allow analysis of individual trajectories (e.g., 
growth curve and latent growth curve analysis, hierarchical linear modeling, growth mixture 
modeling). Repetto, Zimmerman, and Caldwell used hierarchical linear models with data from 
over 600 African American youth surveyed annually for six years to estimate the growth curves 
of marijuana use and depression and test their inter-relationships as well as potential moderators. 
One finding, among others, was that higher depressive symptoms predicted increases in later 
marijuana use, but only for males. For females, those with lower depressive symptoms used 
more marijuana than those with higher depressive symptoms, somewhat matching the results 
from Hallfors et al.5,21 Hooshmand, Willoughby, and Good used latent growth curve models to 
analyze data from over 4,000 Canadian high school students and found that adolescents with 
higher depressive symptoms in grade 9 had faster increases in marijuana use frequency during 
high school, but not the other way around and not for alcohol use.6  
Studies have also found support for the Stress Model (i.e., substance use associated with 
later depression). Hallfors et al. tested the Stress Model using Waves I and II Add Health data. 
They found that high levels of risk taking (i.e., high frequency substance use and sexual risk 
behavior) increased odds of later depression for males, and both high and experimental risk 
taking increased odds of later depression for females.5 Pahl, Brook, and Koppel used growth 
mixture modeling and found similar results with a sample of over 400 African American and 
Puerto Rican women who were interviewed five times between the ages of 14 and 32. They 
found three marijuana use trajectories: “increasers,” “quitters,” and “nonusers.” “Increasers” had 
higher levels of later depressive symptoms than quitters, supporting a potential causal argument 
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for the Stress Model.7 Fergusson et al., with a sample of over 1,000 late adolescents followed 
into emerging adulthood, tested both potential directions of the association between alcohol 
abuse or dependence and depression, and found the best fitting model supported a pathway 
leading from alcohol problems to depression.51 Three recent reviews found evidence of alcohol 
or marijuana use being associated with later depression.52–54   
At least two studies have had more nuanced results. First, Needham used data from Add 
Health Waves I, II, and III to test sex-stratified latent growth curve models of both directions of 
the association.22 Adolescent males and females with higher depressive symptoms at Wave I had 
higher levels of binge drinking at Wave I but the smallest odds of further increases in binge 
drinking compared to those with lower depressive symptoms at Wave I. Similarly, adolescent 
females with higher depressive symptoms at Wave I had higher levels of illicit substance use at 
Waves I, II, and III though smaller odds of further increases in illicit substance use compared to 
females with lower depressive symptoms at Wave I. The author interpreted these results as 
support for the Self-Medication Model, even though she did not find support for an expected 
accumulation in disadvantage (i.e., increases in substance use over time). Findings for the Stress 
model followed a similar pattern; adolescents with higher binge drinking or substance use at 
Wave I had consistently higher depressive symptoms, though they declined at a faster rate, than 
their peers who were not using any substances at Wave I. The author interpreted the results 
overall as support for a bi-directional relationship between substance use and depression, though 
the results could also be interpreted as a concurrent relationship in adolescence that faded with 
development.22 Similarly, Costello et al. used latent trajectory analysis to model trajectories of 
depressive symptoms using Waves I, II, and III of Add Health.8 They found adolescents who 
were using alcohol, tobacco, or other drugs on a weekly basis at Wave I were more likely to 
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show a depressive symptom trajectory characterized by high levels at Wave I that declined over 
time.8,22 However, despite the decline, substance using adolescents had consistently higher levels 
of depressive symptoms compared to adolescents who did not use substances. 
Interestingly, another study used longitudinal mixed effects models with Add Health data 
and found support for a bidirectional relationship.55 In support of the Self-Medication Model, a 
five-point increase in depressive symptoms at an earlier wave was significantly associated with 
approximately a half-day increase in cigarette smoking frequency at a later wave, but only for 
females. In support of the Stress Model, a 5-day increase in cigarette smoking frequency in the 
past month at an earlier wave was associated with a 0.02-point increase for males and a 0.05-
point increase for females in depressive symptoms at a later wave. Marijuana use and binge 
drinking were also tested but no significant associations were found.  
Finally, at least one analysis has had null findings. Fleming et al. used multivariate latent 
trajectory modeling with data from over 1,000 males and females surveyed annually from 8th to 
11th grade in the Pacific Northwest of the United States to test cross-sectional, concurrent over 
time (longitudinal), and predictive (e.g., earlier measure predicting a later change) relationships 
between depressive symptoms and substance use. While they found significant concurrent 
relationships, perplexingly, they found no significant predictive relationships that supported 
either Model. However, they did find that higher levels of depressive symptoms predicted a 
slower increase in alcohol use compared to lower levels of depressive symptoms, which is a 
challenge to the Self-Medication Model.32  
Limitations of Past Literature 
In summary, findings are inconsistent, with mixed support for the Self-Medication and 
Stress Models. Though studies with strong designs have been done to analyze the directionality 
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of the relationship between adolescent substance use and depression, they still share many 
limitations. Prior trajectory analyses in this topic area have disproportionately examined the Self-
Medication Model, failing to test the Stress Model. Further, many studies seem restricted to 
small, non-representative samples (e.g., school- or clinic-based samples) that are followed only 
during adolescence (e.g., 9th through 12th grade). Also, the studies have been focused on the 
temporal relationship between substance use and depressive symptoms and therefore have left 
other relevant research questions like moderation by sex and potential mediators largely 
untested. In fact, two reviews of this literature have called for more studies examining 
differences by biological sex.53,54 The aims of this study address each of these limitations.  
Conceptual basis 
The current study tested the Self-Medication and Stress Models. These models, and the 
hypothesized mediating and moderating pathways, are shown in Figure 1.1 below. The models 
are broadly framed by the Life Course Model. The Life Course Model asserts that human 
development can be characterized as patterns of transitions or trajectories over time that occur 
within a social context. Social interactions of individuals within their contexts contribute to 
cumulative trends over time.56 The Life Course Model provides a framework for our analysis of 
adolescent developmental trajectories into adulthood.  
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Figure 1.1: Conceptual models for the Self-Medication and Stress Models 
   
 
Self-Medication Model 
The top of the figure illustrates the Self-Medication Model. As previously described, the 
Self-Medication Model holds that adolescents struggling with depression may engage in 
substance use in an attempt to ameliorate their symptoms.5,40,41 There is evidence to support 
people self-medicating with both marijuana and alcohol. Marijuana is generally believed to act as 
a euphoriant that produces temporary improvements in mood.57 As such, some researchers 
interpret the initiation of marijuana use in adolescence as a way to cope with the potential stress 
of changing roles and increased responsibilities.21 By comparison, alcohol can provide the 
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illusion of relieving depressive symptoms such as isolation and emptiness.42 As such, alcohol use 
for adolescents could be used to feel relief from social isolation amid new peer groups, for 
example, and gain a sense of belonging from engaging in a normative activity.6  
An important potential mediator for the Self-Medication Model is sensation seeking. 
Sensation seeking has been found to predict alcohol and substance use in adolescents.58 
Sensation seeking has also been implicated in the relationship between depressive symptoms and 
substance use. Researchers with data from over 4,000 Canadian adolescents who were surveyed 
each year of high school used latent class growth analysis to determine that adolescents who 
scored high in sensation seeking were at a higher risk of being in the trajectory of co-occurring 
depressive symptoms and alcohol use compared to singular trajectories of either one. Further, 
adolescents who scored low in novelty seeking were much less likely to be in the alcohol use 
trajectory.59 Pahl, Brook, and Koppel controlled for sensation seeking when assessing the 
relationship between marijuana use and depressive symptoms and the relationship persisted, 
indicating sensation seeking was not confounding the association as a shared predictor.7 Given 
this, it seems reasonable to test whether it is a mediator. Adherence to gender norms will be 
discussed as a potential mediator and/or moderator in a later section.  
Stress Model 
The Stress Model is illustrated at the bottom of Figure 1.1. According to the Stress 
Model, risk taking can increase stress, which then has implications for depressive symptoms. As 
adolescents are negotiating their desire for new experiences along with peer expectations and 
parental monitoring, even normative experimentation could result in strong stress responses.5,10 
Stress can increase inflammation, which is then associated with depressive symptoms. The 
physiological mechanism for these associations starts with stress stimulating the sympathetic-
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adrenal-medullary axis and the hypothalamic-pituitary axis, which then activates the release of 
catecholamines and glucocorticoids to ready the body for fight or flight.45 These responses are 
acutely adaptive but when repeatedly stimulated can cause the downstream systems to first 
overcompensate and then dysregulate.45 In the brain, this can result in remodeling of dendrites 
and synapses, suppression of new cell growth, and changes in neurotransmitter metabolism and 
overall neuroendocrine functioning; all of which are implicated in depression.45,48,49 For 
example, changes in the metabolisms of serotonin, dopamine, or norepinephrine—the 
neurotransmitters targeted by depression medications—would likely induce depression.48 
Further, hypersecretion of corticotrophin-releasing hormone—a key regulator of hormonal 
responses to stress—is often found in patients with depression.48  
Biological Sex and Gender Differences in Self-Medication and Stress Models 
Adolescent females have higher rates of depression and lower rates of risk taking than 
males, suggesting the possibility that the relationship between substance use and depressive 
symptoms will differ for males and females. Starting with the Self-Medication Model, we have 
reason to expect females will be less likely to self-medicate and males will be more likely to. 
First, using data from over 400 adolescents followed for 16 years as part of the Oregon 
Adolescent Depression Project, Essau et al. determined females had a higher incidence of 
depression, a higher chance of recurrence, and, in response to early onset depression, had more 
subsequent depressive episodes than males.60 If females experience more severe or chronic 
depression, they may lack the motivation for sensation seeking and self-medication.5,21 Second, 
internalizing emotions like depressive symptoms are considered more compliant with gender 
norms for females (i.e., in comparison to externalizing behaviors like delinquency), as are most 
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emotional coping mechanisms and so females, even if they experience depression in similar 
ways to males, may still have less incentive to use substances in an attempt to self-medicate.17  
By comparison, we have reason to expect depressive symptoms to have a stronger 
relationship with sensation seeking and substance use for males. First, compared to females, 
males are less likely to emotionally regulate and more likely to practice impulsive or reward-
seeking behavior, especially drinking alcohol.17,61,62 Males experiencing depressive symptoms 
may have or perceive they have no means of regulating or coping with their emotions beyond 
sensation seeking. In fact, among a sample of social drinkers, males were more likely than 
females to report drinking in order to regulate negative affect.63 Second, where depressive 
symptoms are considered socially acceptable for females, for males they can be perceived as a 
violation of masculine gender norms like invulnerability.64 A male experiencing depressive 
symptoms may feel he is weak or vulnerable due to a perceived lack of emotion regulation tools 
and/or the perceived violation of masculine norms. From this place of vulnerability, substance 
use may be an easily accessible means of engaging in risk taking, a key way to demonstrate 
adherence to masculine gender norms for young men.22,65       
For the Stress Model, evidence suggests females may be more likely to experience stress 
and subsequent depression from substance use. Female gender norms can emphasize risk 
aversion and, to the degree these norms are enforced, this can in turn influence how much stress 
females may experience from substance use.18 For example, parental regulation is usually 
stronger or lasts longer for female children, and so they may come to perceive more negative 
consequences from risk taking that defies gender norms, and thus may have a stronger stress 
response to substance use.10,66 Additionally, females are thought to have both greater sensitivity 
and stronger negative reactivity to interpersonal stress.10,11 Therefore, even if both males and 
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females experienced interpersonal stressors from substance use (e.g., parental or peer 
disapproval), females may be more likely to perceive the stress and react negatively to it. If 
substance use increases interpersonal stress with peers, parents, and/or teachers, this process 
might account for females’ greater vulnerability to depressive symptoms.3,18,67 Finally, females 
may be more vulnerable to inflammation, strengthening the relationship between stress and 
depressive symptoms for them compared to males. During adolescence, females develop higher, 
on average, baseline levels of inflammation compared to males. A cross-sectional analysis of age 
cohorts spanning from childhood to young adulthood using the National Health and Nutrition 
Examination Survey found that between ages 16 and 19 a gap emerges in inflammation levels 
between males and females, with the latter being significantly higher. It is important to note this 
gap emerges at an unusual time point as it does not coincide with the onset of puberty and thus 
may be due to behavioral or social, rather than biological, differences in males and females.68 
Therefore, even if risk taking elicits a similar stress response in males and females, with higher 
baseline inflammation levels, females could still be more vulnerable to a depressive response.47,68 
In contrast, for males, there are both social and biological reasons to expect less support 
for the Stress Model. In general, risk taking is much more common among adolescent males 
compared to adolescent females. For example, young men are less likely to wear bike helmets, 
more likely to drive recklessly, have more sexual partners on average, and are less likely to seek 
health care compared to young women.64,65 This sex disparity in risk taking behavior could be 
due to the fact that men, on average, perceive less risk than women do when confronted with the 
same situation.69 Alternatively,  risk taking is a key way for young men to demonstrate 
adherence to masculine norms (e.g., dominance, denial of vulnerability, emotion and physical 
control).65,70 Indeed, several studies have connected measures of men’s masculine traits to their 
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levels of substance use.71–74 In addition to this social explanation for adolescent males’ apparent 
affinity for risk taking, there is a potential biological explanation. Cortisol, the main hormone of 
the stress response, is inhibited by testosterone, which is at higher levels in males than females. 
In fact, one study of 150 young adult males found their cortisol responsiveness to stress varied 
and those with weaker responses were more likely to engage in high-risk sexual behaviors.3 
Given the prevalence of risk taking behaviors, including substance use, among males and the 
potential social explanations, it seems reasonable to expect a null or even negative relationship 
between substance use, stress, and subsequent depressive symptoms for males.6,42,57,62 Overall, 
biological sex and/or gender differences could influence the direct associations between 
depressive symptoms and substance use as well as potential mediation paths in both the Self-
Medication and Stress Models.  
 
Aim 1 Methods 
 
Aim 1. Evaluate empirical support for the Self-Medication and Stress Models by 
estimating growth curves of alcohol use, marijuana use, and depressive symptoms and testing 
whether these trajectories are conditioned by biological sex and/or are related to each other.  
Study Sample 
Add Health has to date collected one in-school and four in-home interviews with a 
nationally representative sample of U.S. adolescents who were in grades 7-12 in the 1994-95 
school year. This study used data from Add Health Waves I, III, and IV. The Wave I in-home 
interview occurred in 1995 when the 20,745 respondents were mostly between ages 12-19. 
Though twenty years have passed since the Add Health respondents were adolescents, the 
prevalence of depression and substance use (with the exception of cigarette smoking) have 
changed little during this time, meaning the adolescent data retain relevance.31,75 The Wave II 
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interview data are excluded from these analyses because it was just one year later and by design 
did not include the Wave I seniors. Wave III interviews (n=15,197) were completed in 2001-02, 
when respondents were ages 18-26. Response rates exceeded 75% at all waves. Wave IV 
interviews occurred in 2008-09 when respondents were ages 24-32. An 80% re-interview rate 
was achieved for Wave IV, yielding information for 15,701 original Add Health respondents. 
Aim 1 Measures 
  Depressive Symptoms: Depressive symptoms were measured using the Center for 
Epidemiologic Studies Depression Scale (CES-D), first created in 1977 it remains a common 
scale for depression epidemiology.76 The items in the scale are designed to capture the frequency 
of types of depression symptoms (e.g., symptoms related to sadness, appetite, being tired, etc.) 
outlined in the American Psychiatric Association Diagnostic and Statistical Manual, though it is 
not a diagnostic tool.76  Nine items from the CES-D were included in the Wave I, III, and IV 
surveys. Summed scores range from 0-27; higher scores indicate more and/or more frequent 
symptoms. The CES-D captures depressive symptoms within the past week (e.g., felt sad, tired 
all the time) (Table 1.1), though 12-month re-test reliability ranges from 0.4-0.7.76 Adjusting the 
CES-D scores for participants using antidepressants was not possible, as measures of 
antidepressant use were only collected at Wave IV, and thus similar adjustments could not be 
made at all waves of data used in the analysis.  
Table 1.1: Depressive symptom items for the CES-D (Waves I, III, and IV) 
Item Wording Item Response 
How often was the following true during the past 
week? 
 
You felt sad  0: Never or rarely 
You felt you were just as good as other people 1: Sometimes 
You felt that people disliked you  2: A lot of the time 
You felt depressed 3: Most/all of the time 
You felt you were too tired to do things 6: Refused 
You enjoyed life 8: Don’t know 
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You were bothered by things that usually don’t 
bother you 
 
You had trouble keeping your mind on what you 
were doing 
 
You felt that you could not shake off the blues, even 
with help from your family and your friends 
 
 
  Table 1.2 below shows the reliability estimates for the CES-D in this sample, or their 
coherence in measuring the same thing. The Cronbach’s alpha value estimates the proportion of 
each item’s variation that is shared with variation in the latent construct of depressive symptoms. 
Table 1.2: Cronbach’s alpha for the CES-D for males and females (Waves I, III, and IV) 
  
Wave I CES-D 0.79 
Wave III CES-D 0.80 
Wave IV CES-D 0.81 
 
  Substance Use: For substance use, we focused on the two most commonly used 
substances (alcohol and marijuana), both of which have in-depth measurement at each wave 
(Tables 1.3 and 1.4).25 For marijuana use, at Waves I and III, respondents were asked how many 
times they used in the past thirty days (e.g., 0 to >900). At Wave IV, the question changed to 
measure on how many days respondents used marijuana in the past thirty using a 0 to 6 ordinal 
scale for none to nearly every day. To make the measures of marijuana use frequency 
comparable at each wave, we derived the number of days of use in a given time period from the 
times of use reported in Waves I and III (Table 1.5). This derived measure assumes that someone 
reporting four times of use in the past month at Wave I used about once per week rather than 
four times in one day, but for this research we care more about the frequency of use and less 
about the distribution of use.  
  For alcohol use, as it is a much more commonly reported behavior among adolescents 
than marijuana, we used a measure of binge drinking frequency to try to capture more 
proportional levels of risk taking between marijuana and alcohol use.25 Binge drinking frequency 
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was assessed for the past year using the same ordinal variable of 0 for none to 6 for nearly every 
day. At Waves I and III, binge drinking was defined as drinking five or more drinks in a row, but 
at Wave IV the measure was specified as four or more drinks for women and five or more drinks 
for men to match the definition of binge drinking from the Centers for Disease Control and 
Prevention.77,78 Originally, the measures for both binge drinking and marijuana use were derived 
as the midpoint from the range of number of days of use, but these measures had too much 
weight in the tail, so we moved to a rank category measure for marijuana use and kept the 
ordinal measure for binge drinking frequency. The Bayesian Information Criterion (BIC) model 
fit index was used to compare the models using the midpoint frequency and rank category 
measures and they were very similar.    
Table 1.3: Binge drinking items (Waves I, III and IV)  
Wave I   Wave III   Wave IV   
In the past twelve 
months, on how days 
did you drink five or 
more drinks in a row? 
In the past twelve 
months, on how days 
did you drink five or 
more drinks in a row? 
During the past 12 months, on 
how many days did you drink 
[5 or more (males)/4 or more 
(females)] drinks in a row? 
1: Every day/almost  0: None 0: None 
2:  3-5 days/week  1: 1-2 days/year 1: 1-2 days/year 
3: 1-2 days/week 2: 1 day/month or less 2: 1 day/month or less 
4: 2-3 days/month 3: 2-3 days/month 3: 2-3 days/month 
5: 1 day/month or less  4: 1-2 days/week 4: 1-2 days/week 
6: 1-2 days/year  5: 3-5 days/week 5: 3-5 days/week 
7: Never 6: Every day/almost 6: Every day/almost 
96: Refused 96: Refused 96: Refused 
97: Legitimate skip 97: Legitimate skip 97: Legitimate skip 
98: Don't know 98: Don't know 98: Don't know 
 99: Not applicable  
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Table 1.4: Marijuana use items (Waves I, III, and IV) 
Wave I 
   
Wave III   Wave IV 
During the past 30 days, 
how many times have you 
used marijuana? 
During the past 30 days, 
how many times have 
you used marijuana? 
During the past 30 days, 
on how many days did 
you use marijuana? 
0: Minimum value 0: Minimum value 0: None 
900: Maximum value 999: Maximum value 1: 1 day 
996: Refused 9996: Refused 2: 2-3 days  
997: Legitimate skip 9997: Legitimate skip 3: 1 day/week 
998: Don't know 9998: Don't know 4: 2 days/week  
999: Not applicable 9999: Not applicable 5: 3-5 days/week  
     6: Every day/almost 
     96: Refused 
     97: Legitimate skip 
     98: Don't know 
 
Table 1.5: Measure transformations for marijuana use 
Original Measure  
(# times/past 30) 
Derived Measure  
(# days/past 
month) 
0 0 
1 1: 1 day/month 
2,3 2: 2-3 days/month 
4,5 3: 1 day/week 
6-10 4: 2 days/week 
11-25 5: 3-5 days/week 
26-900 
6: Every 
day/almost 
 
  Confounders:  
 Respondent self-identified race/ethnicity from Wave I (Hispanic and non-Hispanic White, 
Black, Asian, Native American, and Other).  
 Parental educational attainment from Wave I (less than high school, high school graduate, 
some college, or college graduate or higher) as a proxy for socioeconomic status. Though 
parental education may change at later waves, we are interested in the respondent’s 
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approximate socioeconomic status during adolescence, when they are most likely to still be 
residing in the parental home.  
 Childhood maltreatment, a categorical variable that captures frequency (never; once; twice; 
three times; four or more times) of experiencing emotional, physical, or sexual abuse before 
age 18 or physical or supervisory neglect before Wave III by a parent or an adult caregiver. 
This variable captures frequency of maltreatment rather than type because recent evidence 
suggests the chronicity of maltreatment is a better indicator of potentially negative 
consequences than the type.79 Childhood maltreatment is important to control for as there is 
evidence it can be a shared risk factor for both substance use and depression in adulthood.80  
 Levels of the dependent variable before Wave I were included as binary variables; these were 
constructed from retrospective Wave I measures and included a depression diagnosis, 
drinking a full alcoholic beverage, and using marijuana. 
Aim 1 Analyses 
Growth curve modeling enabled us to test both directions of the association over the 
developmental trajectory and also reduced potential endogeneity by helping to control for time-
invariant unobserved individual characteristics.81 Mixed effects modeling was used to model 
growth curves of binge drinking frequency, marijuana use frequency, and depressive symptoms 
from adolescence (Wave I) to emerging adulthood (Wave III) to young adulthood (Wave IV). 
First, unconditional growth curve models with random intercepts by respondent ID were 
estimated with just the dependent variable, age, and a measure of age squared. From this first 
model the intraclass correlation coefficient (ICC) was calculated (formula below) to determine 
the percentage of variance in the outcome that was due to variance between individuals. We 
looked for the ICC to be greater than zero, indicating there is individual heterogeneity in the 
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growth curves over time. The survey weights needed to analyze Add Health data rendered it 
infeasible to formally test if the ICC was significantly different from zero.82 Fortunately, it was 
unlikely for the ICC to be near zero in these models. However, even if the ICC was essentially 
zero, it would still have provided valuable information because it would demonstrate that the 
developmental trend, including high-risk periods, are similar across respondents and that 
respondents’ prior values are not predictive of their future values. We calculated the ICC again in 
the final growth curve model in order to compare the two and see how much variance between 
individuals had been explained by our predictor variables. 
 
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 (𝑌𝑖𝑡) =  𝜏00 + 𝜎
2 
𝐼𝐶𝐶 =  
𝜏00
𝜏00 + 𝜎2
 
𝜏00 = 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑛𝑡𝑠 
𝜎2 = 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑤𝑖𝑡ℎ𝑖𝑛 𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑒𝑛𝑡𝑠 
 
Second, measures of all of the confounders were added to the model. Third, two models 
were estimated that allowed the hypothesized coefficients for either age or age squared to 
randomly vary; at this point we determined whether the growth curve for the variable of interest 
was best approximated by a linear or quadratic form, judging by the significance of the effect 
estimate. Typical fit indices (e.g., BIC) are likely invalid due to the sampling weights and so 
were used with caution, where necessary, for simple comparisons. The fourth set of models 
tested how the growth curves were moderated by sex by interacting the age and age squared 
coefficients with sex. If the interaction terms were significant—indicating the slopes of the 
growth curves for males and females were significantly different from each other—then we did 
post hoc probing of the moderation. To start, we graphed the growth curves for depressive 
symptoms, for example, for males and females, with all other covariates at their referent values. 
Then, we tested the simple slopes to confirm both lines from the model parameters were 
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significantly different from zero. To reduce possible collinearity with the intercept in the model 
and to improve interpretability of the moderation results, mean centering variables is encouraged 
but was not used here. The substance use frequency measures were not centered as the mean 
value is likely no or little use, and the zero values in these measures are conceptually meaningful. 
Further, the age variable does not need to be centered because the intercept was interpreted as the 
average value of the dependent variable at the earliest age. The results from these first four sets 
of models helped us assess the shapes of the growth curves for binge drinking frequency, 
marijuana use frequency, and depressive symptoms and whether they were moderated by sex.      
  The next set of models tested how levels and trends in the key variables of interest are 
related to the growth curves and whether these relationships are moderated by sex. Keeping with 
the depressive symptoms example, we next added an adolescent measure of binge drinking 
frequency (marijuana use frequency was tested in a separate model) to see how it was associated 
with the intercept, or adolescent measure, of the depressive symptoms growth curve. To test how 
the starting point in binge drinking frequency was associated with the trend in depressive 
symptoms, we also tested a model where substance use frequency was interacted with age and 
age squared. These models tested the relationship between a key variable in adolescence and the 
intercept and trend of another key variable. These models help address the potentially 
bidirectional relationships between substance use and depressive symptoms. Again, we tested 
moderation by sex with the models in both directions to try to address whether there was more 
support for the Stress Model for females and the Self-Medication Model for males. To illustrate, 
support for the hypotheses was determined by examining the direction and significance of the 
interaction term between adolescent substance use frequency and age in the depressive symptom 
growth curve model. The coefficient was interpreted as whether the slope of depressive 
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symptoms over time for female respondents varied by binge drinking frequency in adolescence. 
In this example, we expected this coefficient would be statistically significant or would be larger 
in magnitude than the sum of this coefficient and the estimate of the interaction term between 
age, sex, and adolescent binge drinking frequency. The sum is interpreted as whether the slope of 
depressive symptoms over time for male respondents varies by binge drinking frequency in 
adolescence. If this latter interaction term were to be significant and the sum of the coefficients 
smaller than the interaction term for females, this would be interpreted as greater support for the 
Stress Model among females. An example equation of these models is included below along with 
some example coefficient interpretations. In practice, the model with three-way interactions with 
age also included all of the same interactions with age squared, but this was excluded below for 
simplicity.  
Example Equation 
𝐶𝐸𝑆 − 𝐷𝑖𝑡 =  𝛽0𝑖 + 𝛽1𝑖(𝐴𝑔𝑒𝑖𝑡) + 𝜀𝑖𝑡 
𝛽0𝑖 =  𝛽0 +  𝛽2(𝑀𝑎𝑙𝑒𝑖) + 𝛽3(𝑅𝑎𝑐𝑒𝑖) + 𝛽4(𝑃𝑎𝑟𝑒𝑛𝑡𝑎𝑙 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖)
+ 𝛽5(𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖)
+ 𝛽6(𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖 ∗ 𝑀𝑎𝑙𝑒𝑖) + 𝑈0𝑖 
𝛽1𝑖 = 𝛽1 + 𝛽7(𝑀𝑎𝑙𝑒𝑖) + 𝛽8(𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖)
+ 𝛽9(𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖 ∗ 𝑀𝑎𝑙𝑒𝑖) + 𝑈1𝑖 
𝐶𝐸𝑆 − 𝐷𝑖𝑡 = 𝛽0 + 𝛽1(𝐴𝑔𝑒𝑖𝑡) + 𝛽2(𝑀𝑎𝑙𝑒𝑖) + 𝛽3(𝑅𝑎𝑐𝑒𝑖) + 𝛽4(𝑃𝑎𝑟𝑒𝑛𝑡𝑎𝑙 𝐸𝑑𝑢𝑐𝑎𝑡𝑖𝑜𝑛𝑖)
+ 𝛽5(𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖)
+ 𝛽6(𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖 ∗ 𝑀𝑎𝑙𝑒𝑖) + 𝛽7(𝐴𝑔𝑒𝑖𝑡 ∗ 𝑀𝑎𝑙𝑒𝑖)
+ 𝛽8(𝐴𝑔𝑒𝑖𝑡 ∗ 𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖) + 𝛽9(𝐴𝑔𝑒𝑖𝑡
∗ 𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖 ∗ 𝑀𝑎𝑙𝑒𝑖) + 𝑈0𝑖 + 𝑈1𝑖(𝐴𝑔𝑒𝑖𝑡) + 𝜀𝑖𝑡 
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Example Interpretations 
𝛽1(𝐴𝑔𝑒𝑖𝑡) =The slope of depressive symptoms over time for females (assuming sex=1 is 
male) who reported no binge drinking in adolescence 
𝛽2(𝑀𝑎𝑙𝑒𝑖) = The association between being male and the intercept of depressive symptoms 
at the mean age of respondents who reported no binge drinking in adolescence 
𝛽5(𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖) = The association between adolescent binge drinking 
and depressive symptoms for female respondents at the mean age 
𝛽5 +  𝛽6 = The association between adolescent binge drinking and depressive symptoms 
for male respondents at the mean age 
𝛽7(𝐴𝑔𝑒𝑖𝑡 ∗ 𝑀𝑎𝑙𝑒𝑖) = Whether the slope of depressive symptoms over time for respondents 
who reported no binge drinking in adolescence varies by sex 
𝛽8(𝐴𝑔𝑒𝑖𝑡 ∗ 𝑎𝑑𝑜𝑙𝑒𝑠𝑐𝑒𝑛𝑡 𝐵𝑖𝑛𝑔𝑒 𝐷𝑟𝑖𝑛𝑘𝑖𝑛𝑔𝑖) = Whether the slope of depressive symptoms 
over time for female respondents varies by adolescent binge drinking 
frequency  
𝛽8 +  𝛽9 = Whether the slope of depressive symptoms over time for male respondents 
varies by adolescent binge drinking frequency 
Finally, in the last two sets of models, we used a time-varying measure of binge drinking 
frequency (and marijuana use frequency in a separate model) instead of the adolescent measures 
as predictors, and interacted it with age and age squared to see whether binge drinking frequency 
over time for a respondent was associated with the starting point and trend of their depressive 
symptoms over time. Next, we again tested the reverse pathways and moderation by sex.  
Potential pitfalls in this analytic approach include the complexity of the data leading to 
models failing to converge, power concerns, and lack of significant results. However, there are 
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ways to address these issues. First, if some models failed to converge, the model could likely be 
simplified. For example, it is possible that the growth curve allowing for random variation in the 
slope for age would not converge, in which case the model could be simplified to allow the age 
coefficient to have a random intercept and not a random slope. Previous similar analyses have 
been conducted using the Add Health data set, which gave us confidence that the data had 
sufficient variability for these complex models.15 Second, three-way interactions bring up 
concerns of insufficient power. However, both binge drinking and marijuana use frequencies 
appeared to have sufficient variability, in both sexes, to allay this concern. Third, if these models 
produced only non-significant results, this would still likely be a valuable contribution to the 
field given the plethora of prior conflicting results and the rigor of these analytic methods. 
Finally, it is also possible that we would find significant results for both pathways, but this would 
still be informative given the multitude of conflicting results in the field, and it could be further 
clarified with mediation analysis.  
Aim 2 Methods 
Aim 2. Using regression models, examine potential mediators (sensation seeking, stress 
biomarkers, and gender norm adherence) and a moderator (gender norm adherence) of the 
relationships between substance use and depressive symptoms and whether the relationships 
differ by biological sex.  
Study Sample 
The Add Health sample was the study sample for Aim 2, as it was for Aim 1.  
Aim 2 Measures 
Gender norm adherence: The diversity of items within the Add Health data enabled us 
to use a unique empirical measure of gendered behavior. Measuring gender as a behavior is 
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unique because historically gender has been frequently conceptualized as a trait (e.g., masculine 
personality characteristics) or as an ideology (e.g., beliefs and attitudes about the roles of men 
and women).83 Trait measures can conflate biological sex and gender, treat gender as static, and 
disregard the social aspects of gender that make gender something you do or perform in relation 
to other people rather than something you are.84–87 Ideology measures capture only someone’s 
beliefs about gender, or even what they believe are everyone else’s beliefs about gender, none of 
which may correspond to their individual gender expression. Empirically-derived measures of 
gender can offer a more individual perspective while also capturing developmental and historic 
changes in gender norms.64,88 Three prior studies have demonstrated the value of empirically-
derived measures of gender based on individual behavior and preferences relative to peers.89–91  
Using data from respondents interviewed at all four waves of Add Health, Fleming, 
Halpern, and Harris created the Adherence to Gender-typical Behavior (AGB) score, an 
empirical measure of behavioral adherence to gender norms.92 This captures the degree to which 
respondents’ reported behaviors are concordant with those of other Add Health respondents of 
their same sex within a given interview wave (and thus developmental stage) based on a large 
pool of behaviors measured at that wave. ‘Behaviors’ included a range from individual actions 
(e.g., exercising) to states of being (e.g., weight self-perception) that were shown to be highly 
correlated with biological sex, these varied slightly across the waves. These variables were then 
used in a logistic regression model to create predicted probabilities of being a biological sex 
(e.g., for prediction of being a male, a predicted probability of 0.85 indicates an 85% chance of 
being male and a 15% chance of being female). Behaviors unique to one sex—for example, 
experiencing menstruation—were excluded. None of the substance use measures used in these 
analyses were included as items in the AGB measures.  
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The process of developing the measure is similar to the methods used by Cleveland et al. 
in analyses based on Add Health data, but the newer measure includes Waves III and IV and a 
wider range of variables.89 Additionally, rather than relying on the predicted probabilities, which 
were extremely skewed (see Figure 1.3 below), we ranked males and females separately by their 
adherence scores and used their rank percentile score in our analyses. A higher percentile means 
greater adherence to the behavior typical of one’s own biological sex at a given wave. For 
example, males with a percentile of 0.95 exhibited strong adherence to male-typical behavior at 
that wave, and females with a percentile of 0.95 exhibited strong adherence to female-typical 
behavior at that wave. Two prior analyses tested the relationship between AGB and high 
frequency substance use in both cross-sectional and longitudinal models with Add Health data. 
As hypothesized males with higher adherence to male-typical behavior were more likely to 
report substance use and females with higher adherence to female-typical behavior were less 
likely to report substance use.91,93 
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Figure 1.2: Distribution of males and females by predicted probability of being male (Wave I) 
 
Inflammation: The stress response is fundamentally an inflammatory process and to 
measure inflammation we used two biomarkers, the first of which is high sensitivity C-reactive 
protein (CRP). CRP has been identified as a possible marker for how stress impacts individual 
disease risk.47,94 CRP has shown a dose-response relationship with depressive symptoms in both 
clinical and community settings.95 The connection between stress and CRP also has longitudinal 
potency. For example, childhood adversity is positively associated with enhanced inflammatory 
response to stimuli and elevated CRP and depression risk in adulthood.48,96–98 Finally, there is 
evidence that CRP levels are responsive to changes in drinking frequency and marijuana 
use.99,100  
Measures of CRP (mg/L) were collected via dried whole blood spots in Wave IV of Add 
Health. The reliability estimate of CRP was deemed acceptable (ICC = 0.70, 95% CI= 0.59, 
0.81).101 The ICC measure indicates that 70% of the variation in CRP measures is due to 
variation between, rather than within, individuals. From established guidelines, CRP levels can 
be broken into three levels: low (<1 mg/L), average (1-3 mg/L), and high (>3 mg/L).94 But, for 
mediation analyses, we needed a binary variable so the first and second categories were coded as 
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‘0’ and the high category was coded as ‘1.’ It is important to note this category of elevated CRP 
is a heterogeneous one with values from 3 to 10 mg/L signaling chronic stress, what we are 
specifically interested in, and values over 10 indicating acute stress (e.g., an infection). The wide 
range of control variables for analysis of the biomarker variables are intended to adjust for the 
very high levels of biomarkers, and their coverage for the thirty highest CRP levels was very 
good. We also re-ran the models excluding those with CRP values over 30 as a sensitivity 
analysis. Values of CRP that were flagged for inconsistency in measurement were set to missing 
(n=12).   
The second biomarker of inflammation was Epstein-Barr virus (EBV), which captures 
immune activation. Present in approximately 90% of the world population, EBV is one of the 
most common human viruses. Most people are infected in adolescence and upwards of 50% of 
people develop mononucleosis, which resolves within 2 months, but the infection maintains 
lifelong latency.102,103 The physiological stress response can reactivate latent viruses. Research 
from Glaser et al. has connected several psychological stressors to increases in antibody titers to 
latent EBV, indicating reactivation.104 Examples of the stressors associated with EBV 
reactivation include perceived stress, loneliness, discrimination, childhood abuse, medical school 
exams, marital separation or divorce, and caregiving for someone with Alzheimer’s disease.105 
Thus, EBV can be used as an immunological correlate of stress, though the mechanism of this 
relationship is not well understood.101,103,106,107 It is important to note that EBV reactivation is 
usually subclinical, meaning individuals may not experience symptoms though the levels of EBV 
are physiologically detectable.102,107 Similar to CRP, there is evidence that EBV levels are 
responsive to substance use.108  
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EBV was measured via viral capsid antigens (AU/ml) that were also collected through 
dried whole blood spots in Wave IV. The reliability estimate of EBV is excellent (ICC=0.97, 
95% CI =0.96, 0.98).101 The EBV values are highly skewed and a log transformation of the 
values improved the distribution by making it more closely resemble a normal distribution 
(mean=4.8, standard deviation=0.67). So, the log transformed EBV values were used in all 
analyses, a method which previous studies have also used.105 Values of EBV flagged for 
inconsistency in measurement were set to missing (n=2).   
  Sensation seeking: Wave III had a total of 20 items that have been used alone, or 
together, to measure the sensation seeking construct. Seven of the items are modified versions of 
items from the Disinhibition subscale of Zuckerman’s sensation seeking scale.109 However, these 
items were not presented to all respondents, only a genetic subsample.110 The other relevant 
items are aimed at assessing novelty-seeking and impulse control and ask respondents to use a 5-
point Likert scale to report how true the statement is for them (e.g., “I often try new things just 
for fun or thrills, even if most people think they are a waste of time”; Table 1.6).58 Though 
impulsivity can be conceptualized as containing both a sensation seeking construct and an 
impulse control construct, both of which can differentially predict health risk behaviors, 
exploratory and confirmatory factor analyses of all 16 items in the Add Health Wave III sample 
found all items loaded onto one factor for sensation seeking.58 Given these results, in this project, 
we used nine of the items that were asked of all respondents and that were conceptually similar, 
reversed coded items as necessary, and created a mean scale (Cronbach’s alpha=0.85, min=1, 
max=5). We created a mean scale rather than a summative scale to decrease the proportion 
missing, as most respondents were only missing one to two items in the scale, and the patterns of 
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missing did not vary by respondents’ answer to the question “Do you agree or disagree that you 
like to take risks?” indicating that items in the scale are missing at random. 
Table 1.6: Sensation seeking items (Wave III) 
Item Wording Item Response 
How true do you think the following statement is of 
you? 
 
I can do a good job of “stretching the truth” when I’m 
talking to people 
1: Not true 
I can usually get people to believe me, even when 
what I’m saying isn’t quite true 
2: A little true 
I like it when people can do whatever they want, 
without strict rules and regulations 
3: Somewhat true 
I often follow my instincts without thinking through 
all the details 
4: Pretty true 
I often try new things just for fun or thrills, even if 
most people think they are a waste of time 
5: Very true 
I sometimes get so excited that I lose control of myself 96: Refused 
When nothing new is happening, I usually start 
looking for something exciting 
98: Don’t know 
I often do things based on how I feel at the moment 99: Not applicable 
Do you agree or disagree that you like to take risks? 1: Strongly agree 
 2: Agree 
 3: Neither agree nor disagree 
 4: Disagree 
 5: Strongly Disagree 
 96: Refused 
 98: Don’t know 
 99: Not applicable 
 
Confounders: In addition to the confounders listed for Aim 1, the following additional 
confounders were added for the Aim 2 analyses: 
 Wave IV respondent education: Educational attainment of the respondent in young adulthood 
(less than high school, high school graduate, some college, or college graduate or higher) was 
used as a proxy for socioeconomic status. 
 Wave IV stressful life events (SLE): Exposure to acute and sudden onset events of limited 
duration was captured through an additive index of over 50 items, compiled in previous 
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analyses using these data.61 Example items include becoming disabled, losing a family 
member or friend, being deployed in a combat zone, and getting arrested. Exposure to SLEs 
is important to control for because such exposures could increase stress biomarkers and/or 
depressive symptoms independent of substance use frequency. In this way, SLEs are a 
potential confounder of the hypothesized relationship between stress biomarkers and 
depressive symptoms. There appeared to be sufficient variability in the index as it ranges 
from 0 to 15 (median=1, SD=1.91). The correlations between the SLE index at each wave 
and substance use frequency at that same wave were assessed to determine if the SLE indices 
needed to be added as a control variable in the growth curve analyses and the correlations 
were not sufficiently high to warrant this.       
 At a physiological level, the CRP and EBV biomarkers can be influenced by many things. 
Looking to prior analyses of the biomarkers, we compiled a list of items that are necessary to 
control for when analyzing them. The same controls were used for both CRP and EBV as 
they are both part of the same physiological response. These potential confounders 
included:101,111,112 
o Count of subclinical symptoms (0-3) 
o Count of infectious/inflammatory diseases (0-6) 
o Use of NSAID/Salicyate in the past 24 hours and/or in the past four weeks  
o Use of a Cox-2 inhibitor within the past four weeks  
o Use of inhaled corticosteroids in the past four weeks  
o Use of corticotropin/glucocorticoid medication in the past four weeks  
o Use of antirheumatic/antipsoriatic medication in the past four weeks  
o Use of immunosuppressive medication in the past four weeks 
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o Use of other anti-inflammatory medications 
o Currently pregnant  
o BMI, derived from measured height and weight 
o Cigarette smoking frequency measured as number of days on which a respondent 
smoked in the past 30 days.  
o Vigorous physical activity, a dichotomous variable, assesses whether respondents, 
in the past 24 hours, did vigorous physical activity for long enough to get out of 
breath, sweat, or get their hearts thumping. A measure of recent vigorous physical 
activity is necessary because exercise increases inflammation in the short-term.113  
Aim 2 Analyses 
The mediation analyses for Aim 2 were completed using linear and logistic regression 
models with the predictor variable measured at Wave I, the hypothesized mediator measured at 
either Wave III or IV, and the dependent variable measured at Wave IV. All of the mediation 
analyses followed the same pattern outlined below (see Figure 1.3) using the example of the 
hypothesized positive relationship between the frequency of binge drinking and depressive 
symptoms mediated by the AGB score for females. All regression models included the relevant 
hypothesized confounders as well as a lagged measure of the dependent variable, measured in 
the most proximal wave, to adjust for prior levels of the dependent variable.  
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Figure 1.3: Mediation analysis framework 
 
First, we regressed depressive symptoms at Wave IV on binge drinking frequency at 
Wave I, including a measure of depressive symptoms at Wave III. From this model, we got an 
estimate of path ‘C,’ or the total effect. Second, we regressed the AGB score from Wave III on 
binge drinking frequency at Wave I to get an estimate of path ‘A.’ Third, we regressed 
depressive symptoms at Wave IV on binge drinking frequency from Wave I and the AGB score 
from Wave III, including a measure of depressive symptoms from Wave III. From this final 
model, we got estimates of paths ‘B’ and ‘C prime.’ We looked for the estimates of paths A, B, 
and C to be statistically significant and the estimate for path C prime to be zero or noticeably 
smaller than the estimate of path C.114 This Baron and Kenny approach to mediation has several 
limitations including limiting power, not computing an estimate of the indirect effect, and 
missing mediating relationships that can exist even if the A, B, and C path estimates are not 
statistically significant.115 However, the more contemporary approach of multiplying the 
coefficients for the A and B paths together to get a point estimate of the indirect or mediated 
effect is not feasible as this then requires the use of Sobel’s z-score test to determine if the 
estimated effect is significantly different from zero. Unfortunately, Sobel’s test is not well suited 
for models with binary mediators or models with survey weights. Bootstrapping is another means 
to test the significance of the indirect effect estimate but is also infeasible with survey weights.82 
For Aim 2, we used a combination of the Baron and Kenny and contemporary mediation 
Frequency of binge drinking
M: AGB Score
Level of depressive 
symptoms
A
C Prime: Direct Effect
B
C: Total Effect
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approaches by looking to estimates of the A, B, C, and C’ paths to identify mediation but not 
disregarding models when the C path was not significant but the A and B paths were.   
The moderation analyses for Aim 2 tested if the AGB scores moderated either the Self-
Medication or Stress Models for males or females. As the AGB score is an innovative new 
measure, it is not yet clear how the construct it is capturing is involved in the Self-Medication or 
Stress Models. So, it was tested as a mediator and moderator to inform understanding of the 
measure. Moderation was tested by creating interaction terms between the independent variable 
at Wave I and the hypothesized moderator at Wave III and testing the relationship between 
interaction term and the dependent variable at Wave IV. Moderation models were also tested by 
interacting an independent variable at Wave III with a hypothesized moderator at Wave III and 
then assessing the interaction’s association with a dependent variable at Wave IV. For example, 
to test if the Stress Model was better supported for females who are more gender-adherent 
compared to females who are less gender-adherent, marijuana use frequency at Wave I was 
interacted with the AGB score at Wave III and then depressive symptoms at Wave IV were 
regressed on this interaction term for females. If the interaction term was significant and positive 
and the sum of this coefficient and the coefficient for AGB also positive, it was interpreted as 
support that the Stress Model was moderated by AGB such that the relationship between 
marijuana use frequency and later depressive symptoms was more positive for females with 
higher AGB scores compared to females with lower AGB scores. Next we did post hoc probing 
of the moderation, first by graphing predicted lines for depressive symptoms—for example, for 
females with different AGB scores. Next, we tested the simple slopes to confirm the predicted 
lines from the model parameters were significantly different from zero. 
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Potential pitfalls of this analytic approach included an inflated the type I error rate, bias, 
and a lack of significant results. Due to the high number of tests, the analysis plan was at risk of 
inflating the type I error rate. As a personal benchmark to guard for over interpretation of rare 
significant results among a large number of tests, the conservative Bonferroni correction for 
multiple tests was used as a sensitivity analysis for the results. Second, some of the hypothesized 
mediators were measured only in Wave IV, the same wave as the dependent variable, which 
could introduce some bias into the models. Simulation models have particularly highlighted 
problems when the direct or indirect effect is assessed in cross-sectional data.116 Fortunately, in 
our analytic plan, only part of the indirect effect was cross-sectional, thereby limiting the 
potential for bias. However, it is important to note we assumed the relationship between the 
hypothesized mediator and the dependent variable was instantaneous and did not vary over 
time.116 The third potential pitfall of the Aim 2 analyses was a lack of significant results as prior 
studies have connected ingredients in marijuana with decreased levels of CRP and EBV. 
However, these studies were testing the effects of specific compounds in marijuana on certain 
cells and so we hypothesized a broader analytic framework that includes the potential stress from 
using marijuana would produce different results, especially for females.100,108 
 
Sample & Power 
 
The analytic sample for the analyses is restricted to respondents interviewed at Waves I, 
III, and IV with valid sampling weights and complete data on all variables of interest (n=9,816). 
For the growth curve models, the data were restructured by age of respondent rather than by 
interview wave so that we could more accurately examine developmental trajectories.15 All 
analyses with Add Health data used weights to adjust for unequal probability of selection into the 
sample and nonresponse over time. Additionally, variance estimates were adjusted to account for 
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clustering by primary sampling unit and region. We used Stata, version 14.0 (Stata Corp, College 
Station TX, 2013) for all regression and mixed effects models.   
Table 1.7 below outlines the characteristics of the analytic sample for all of the variables 
in this project. Some points to note are first that the sample is diverse in race/ethnicity (nearly 
one third of the sample identifies as non-White) and parental educational attainment 
(approximately one third of parents had completed college, another third completed some college 
and another third had a high school degree or less). Second, there is variability in our main 
measures. For example, 29% of males and 48% of females have elevated levels of CRP. We also 
see sufficiently high levels of substance use, even at Wave I. Approximately 30% of adolescent 
males reported binge drinking in Wave I, and this jumps up to about 60% in Waves III and IV; 
the increase is from 25% to 45% for females. For marijuana use, nearly 15% of males report 
marijuana use in Wave I, and about 30% report use by Wave III; for females, the increase is from 
13% to 20%.    
Table 1.7: Characteristics of the analysis sample 
Characteristic Males (n=4323)  
n (weighted %)  
or mean (SD) 
Females (n=5493)  
n (weighted %)  
or mean (SD) 
CONTROL VARIABLES   
Race/Ethnicitya (WI)   
Hispanic 692 (12.2) 776 (10.7) 
Black 721 (12.9) 1206 (15.4) 
Asian 318 (3.6) 328 (3.3) 
Native American 94 (2.5) 96 (1.9) 
Other 38 (1.0) 43 (1.0) 
White 2460 (67.9) 3044 (67.9) 
Parental Education (WI)   
< High school 475 (10.7) 687 (11.1) 
High school  1023 (25.6) 1420 (28.4) 
< College 1298 (30.3) 1574 (28.9) 
College or higher 1527 (33.4) 1812 (31.6) 
Respondent Education (WIV) 
< High school 344 (8.4) 304 (6.4) 
High school  762 (19.4) 694 (13.0) 
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< College 1910 (42.7) 2438 (44.8) 
College or higher 1307 (29.5) 2057 (35.8) 
Age in years, m  
Wave I 15.5 (1.8) 15.3 (1.8) 
Wave III 21.9 (1.9) 21.7 (1.8) 
Wave IV 28.4 (1.9) 28.1 (1.8) 
Cigarette Use frequency  
(# days/past 30), m  
Wave I 4.6 (9.8) 4.8 (10.1) 
Wave III 9.7 (13.5) 8.6 (13.0) 
Wave IV 9.6 (13.3) 7.9 (12.6) 
Stressful Life Events Index    
(0-50) (WIV), m 2.1 (2.0) 1.8 (1.7) 
Childhood maltreatment frequency 
Never 1498 (34.8) 1732 (31.5) 
Once 427 (9.7) 557 (10.2) 
Twice 443 (10.2) 532 (9.4) 
Three times 739 (17.1) 1035 (18.5) 
Four or more times 1216 (28.3) 1637 (30.4) 
   
BIOMARKER CONTROL VARIABLES 
Count subclinical symptoms, m  0.4 (0.7) 0.5 (0.8) 
Count inflammatory diseases, m  0.4 (0.7) 0.5 (0.7) 
NSAID/Salicylate (24 hours) 1089 (25.0) 1617 (30.7) 
NSAID/Salicylate (4 wks) 104 (2.4) 168 (3.3) 
COX-2 Inhibitor (4 wks) 5 (0.0) 7 (0.0) 
Inhaled Corticosteroid (4 wks) 11 (0.0) 28 (0.0) 
Corticotropin/Glucocorticoid          
(4 wks) 
19 (0.1) 59 (1.2) 
Antirheumatic/Antipsoriatic  
(4 wks) 
8 (0.1) 25 (0.4) 
Immunosuppressives (4 wks) 4 (0.0) 13 (0.2) 
Anti-Inflammatory medications  1149 (26.4) 1734 (32.8) 
BMI   
Underweight 31 (0.8) 101 (1.9) 
Normal weight 1185 (28.2) 1853 (34.3) 
Overweight 1498 (34.0) 1413 (24.6) 
Obese 1609 (37.0) 2126 (39.2) 
Currently pregnant (WIV) N/A 345 (6.3) 
Vigorous physical activity 
(yes/no) (24 hours) 
2126 (49.7) 1798 (32.7) 
   
HYPOTHESIZED MEDIATORSb 
Sensation seeking (1-5) 
(Wave III), m  3.0 (0.9)  2.4 (0.8) 
CRP   
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<3 mg/L 3026 (70.0) 2848 (51.8) 
>3 mg/L 1297 (30.0) 2645 (48.2) 
EBV log AU/ml, m 4.7 (0.7) 4.9 (0.7) 
 MALES (n=4323)  
 Wave I Wave III Wave IV 
Depressive symptoms  
(0-27), m 
5.0 (3.8) 3.9 (3.6) 4.6 (3.7) 
Binge drinking frequency   
None 3060 (70.4) 1735(37.2) 1857(40.9) 
1 or 2 days/year 388 (9.0) 669 (15.2) 726 (17.3) 
Once per month or less 286 (6.5) 511 (12.7) 580 (13.2) 
2-3 days/month 238 (5.6) 521 (12.9) 453 (11.0) 
1-2 days/week 226 (5.6) 615 (15.6) 448 (11.0) 
3-5 days/week 86 (2.1) 223 (5.3) 195 (5.1) 
Every day/almost  39 (0.1) 49 (1.2) 64 (1.4) 
Marijuana use frequency  
None 3668 (85.4) 3121(71.1) 3394(77.1) 
1 day 158 (3.3) 211 (4.9) 171 (3.9) 
2 or 3 days 159 (3.4) 201 (4.9) 154 (4.1) 
1 day/week 69 (1.7) 118 (3.0) 45 (1.2) 
2 days/week 63 (1.5) 107 (2.5) 108 (2.5) 
3-5 days/week 88 (2.0) 229 (5.8) 165 (3.8) 
Every day/almost 118 (2.7) 336 (7.9) 286 (7.4) 
 FEMALES (n=5493)  
 Wave I Wave III Wave IV 
Depressive symptoms  
(0-27), m 
6.3 (4.5) 4.9 (4.2) 5.6 (4.3) 
Binge Drinking frequency   
None 4208 (75.2) 3240(55.4) 3222(56.0) 
1 or 2 days/year 557 (10.8) 984 (18.1) 977 (18.9) 
Once per month or less 203 (6.1) 537 (11.2) 534 (10.3) 
2-3 days/month 203 (3.8) 335 (6.9) 410 (8.0) 
1-2 days/week 136 (2.5) 297 (6.3) 247 (4.5) 
3-5 days/week 56 (1.1) 82 (1.8) 82 (1.6) 
Every day/almost  27 (0.1) 18 (0.2) 21 (0.3) 
Marijuana Use frequency  
None 4816(87.2) 4533(80.8) 4840(87.5) 
1 day 179 (3.3) 244 (4.8) 159 (3.3) 
2 or 3 days 192 (3.8) 192 (3.7) 117 (2.2) 
1 day/week 100 (1.6) 116 (2.2) 45 (6.5) 
2 days/week 68 (1.3) 114 (2.3) 73 (1.3) 
3-5 days/week 81 (1.6) 130 (2.7) 91 (2.0) 
Every day/almost  57 (1.3) 164 (3.6) 168 (3.1) 
aAll other race/ethnicities are non-Hispanic 
bAGB is not included in this table because it is a rank percentile score (e.g., min=0.01, 
max=0.99, mean=0.5)  
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Missing Data & Power 
The same analytic sample was used for both Aims 1 and 2. This increased the amount of 
missing data as we used complete case analysis, (i.e., only included respondents with survey 
weights and complete data on all variables of interest at all waves), an analytic technique 
recommended for Add Health data.117 Fortunately, the sampling weights adjust for a 
respondent’s data being missing for an entire wave, which accounts for as much as 25% of the 
missing data. When we restricted the sample to respondents interviewed at all waves with 
complete data on all of our variables of interest, we lost 20% of the sample. This proportion 
missing is not ideal, but the two options for decreasing the proportion missing were not feasible 
with the complex sampling design of Add Health. First, we considered weighting the 
respondents who were included in the analytic sample by running a logistic regression to get the 
response propensity.118 This method was deemed infeasible as we would have needed to combine 
the response propensity weight with the existing longitudinal weights in Add Health. Second, we 
considered multiple imputation through sequential regression to estimate values for AGB or the 
biomarkers, both of which had the highest proportion missing.118 This method, however, was 
also deemed infeasible because the AGB scores are composites of 25 different items at each 
wave and the biomarkers have very few corresponding variables we could use to reliably impute 
values. Additionally, as multiple imputation would result in multiple different data sets, it would 
restrict the complexity of the models we could later run.  
Our analyses had power to detect statistically meaningful changes. Using average CES-D 
scores as the example dependent variable, we would hypothesize that the mean CES-D score 
would be higher for people engaging in substance use compared to those who are not. Making 
the conservative estimate of a one-point difference in the mean CES-D score between those 
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using substances and those not, Add Health has 100% power to detect this difference with the 
level of significance set at 0.05 for two-sided hypothesis tests. Add Health has 80% power to 
detect differences as small as a 0.12 point-increase in the CES-D. We used Stata, version 14.0 
(Stata Corp, College Station TX, 2013) to perform all of the necessary calculations. As Add 
Health has a large sample size, even small differences between groups can be statistically 
significant. To guard against potential over-interpretation of significant p-values, we also looked 
for differences being conceptually meaningful.  
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CHAPTER 2 – TESTING RELATIONSHIPS BETWEEN BINGE DRINKING, 
MARIJUANA USE, AND DEPRESSIVE SYMPTOMS AND MODERATION BY 
BIOLOGICAL SEX 
 
Overview 
Objectives: We examined the longitudinal associations between substance use frequency and 
depressive symptoms from adolescence into young adulthood, and whether the associations were 
moderated by sex. 
Methods: With data from Waves I, III, and IV of the National Longitudinal Study of Adolescent 
to Adult Health (n=9816), we used growth curve models to test if depressive symptoms predicted 
binge drinking or marijuana use frequency or if substance use frequency predicted depressive 
symptoms. Moderation by sex was tested for both potential pathways.  
Results: Higher adolescent depressive symptoms, compared to no symptoms, were associated 
with a steeper predicted increase in marijuana use frequency from adolescence to young 
adulthood. Persistent binge drinking or marijuana use had concurrent positive associations with 
depressive symptoms from adolescence to young adulthood, and these associations were stronger 
for females. 
Conclusions: The results support the self-medication hypothesis for marijuana use but also the 
reverse pathway, that binge drinking and marijuana use are associated with depressive 
symptoms, especially for females. 
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Policy Implications: These results inform prevention and/or treatment steps following adolescent 
depression or substance use screening, newly covered preventive services under the Affordable 
Care Act.  
Introduction 
Both substance use and depressive symptoms increase in adolescence, are often 
comorbid, and are associated with negative outcomes.1–4,23,30 Nearly one third of U.S. high 
school students report current alcohol use, approximately one quarter report current marijuana 
use, and up to one in five have experienced a major depressive episode.2,25 Youth with a major 
depressive episode in the past year are more than twice as likely to report marijuana use 
compared to youth without a major depressive episode in the past year.31 Comorbidity between 
substance use and depression is concerning because it is associated with worse outcomes than 
either alone, including more severe mental health issues, longer depressive episodes, increases in 
substance use, delays in substance abuse recovery, and elevated suicide risk.21 
 The comorbidity between substance use and depression indicates there may be a causal 
relationship between them. Theories suggest alternative directions for this relationship. First, the 
Self-Medication Model asserts depression leads to substance use as an attempt to ameliorate 
symptoms.42 Second, our Stress Model hypothesizes substance use leads to depression by 
increasing strain in peer and parental relationships and thereby interpersonal stress.10,11 Processes 
entailed in these Models are complicated by biological sex, developmental change, and type of 
substance. In general, adolescent females are more likely to report experiencing depression than 
males.60,67 By comparison, adolescent males generally report use of a wider range of substances 
and at a higher frequency compared to females.4,25,26 Developmentally, initiation of substance 
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use is concentrated in adolescence yet the quantity and frequency of substance use typically peak 
between 18-25 years of age in the United States.4 
 Findings from previous research relevant to the Self-Medication and Stress Models differ 
across substances and by sex. Starting with the Self-Medication Model, Hooshmand et al. 
followed 4,000 U.S. adolescents through high school and found those reporting higher 
depressive symptoms early had faster increases in marijuana use, but found no significant results 
for alcohol.6 De Graaf et al., with a sample of over 7,000 late adolescents and young adults found 
that major depression predicted alcohol dependence. The study found some differences by sex, 
but did not formally test moderation of the associations by sex.119 In contrast, a study with a 
sample of over 600 African American adolescents who were surveyed annually for six years 
starting in high school found depression predicted marijuana use, but only in males.21 
Mushquash et al. with a sample of 200 undergraduate women found depressive symptoms 
predicted increases in heavy episodic drinking one week later.120 However, an analysis using 
data from the National Longitudinal Study of Adolescent to Adult Health (Add Health) found no 
evidence for depression predicting increases in substance use or sexual risk behavior, measured 
in clusters of behavior.5  
For the Stress Model, evidence is inconsistent for alcohol or marijuana predicting 
depression and for moderation by sex. In the Add Health study noted above, substance use and 
sexual risk behavior in adolescence predicted depression in emerging adulthood; this association 
was present for both experimental (females only) and frequent risk-taking behaviors (males and 
females).5 In contrast, a longitudinal survey following over 1,000 African Americans from age 
six to 42 found increased alcohol or marijuana use (loaded on a single construct) in adolescence 
predicted psychological distress in young adulthood but only for males.121 Fergusson et al. 
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examined only alcohol use, with a sample of over 1,000 late adolescents followed into emerging 
adulthood, and tested both potential directions of the association between alcohol abuse or 
dependence and depression, and found the best fitting model was leading from alcohol to 
depression; a recent review came to the same conclusion.51,53  In contrast, Mushquash et al. 
found heavy episodic drinking in a sample of undergraduate women did not predict increases in 
depressive symptoms one week later.120 For marijuana, the association appears most robust for 
frequent marijuana use; two longitudinal studies and a review found an increasing marijuana use 
trajectory, or at least weekly use, predicted later depression.7,52,122  
The large literatures on adolescent substance use and depression share several limitations, 
which this paper aims to address. First, much of the research is cross-sectional, or if longitudinal, 
is based on non-representative samples, tests only one direction, does not test moderation by sex, 
and/or captures only adolescence.6–8,18–23 This project addresses these important limitations by 
using data from the National Longitudinal Study of Adolescent to Adult Health (Add Health), a 
nationally representative sample of adolescents who have been prospectively followed into 
young adulthood. We hypothesized there would be greater evidence for the Self-Medication 
Model among males compared to females (Hypothesis 1), as a review of sex differences in 
emotion regulation found males were more likely to engage in impulsive, reward-seeking 
behavior.17,62 We also hypothesized the Stress Model would be better supported among females 
than males (Hypothesis 2), as substance use is less normative for females, and females are 
generally more sensitive to interpersonal stress than males.10,11,47,66   
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Methods 
Sample 
Add Health is a longitudinal study that includes a nationally representative sample of 
U.S. adolescents who were in grades 7-12 in the 1994-95 school year (Wave I). There have been 
four in-home interviews to date. The present analysis sample is restricted to respondents 
interviewed at Wave I, Wave III (ages 18 to 26), and Wave IV (ages 24 to 32), with valid 
sampling weights (N=12,288) and who had complete data on all variables of interest (N=9,816, 
80%). Data from Wave II were not used as Wave I seniors were not followed by design. Details 
of the Add Health study and design are described elsewhere.78 All Add Health procedures were 
approved by the Institutional Review Board at the University of North Carolina, Chapel Hill. 
These analyses were deemed exempt.   
Measures 
Depressive symptoms were measured using the nine items from the Center for 
Epidemiologic Studies Depression Scale (CES-D) available at Waves I, III, and IV. The items 
ask about frequency of symptoms in the past week from rarely (0) to most of the time (3); the 
summed score for the scale ranges from 0 to 27. Though the items ask about frequency of 
depressive symptoms in the past week, the 12-month re-test reliability is high.76 The CES-D is 
not a diagnostic tool.   
 The substances measured included alcohol (binge drinking) and marijuana. We measured 
frequency of substance use rather than ever use to better capture levels of risk taking. In Add 
Health, substance use frequency is measured with either continuous or ordinal variables with 
varying time frames. The frequency of binge drinking, defined as consuming 5 or more drinks in 
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a row, is assessed in the past 12 months with an ordinal variable ranging from 0 (never) to 6 
(every day or nearly every day). Marijuana use frequency is assessed in the past 30 days; the 
measures at Waves I and III were continuous and assessed instances of use. At Wave IV the 
measure was ordinal and assessed days of use, mirroring the binge drinking frequency measure.78 
To make the marijuana use frequency measures comparable across the waves, the measures at 
Waves I and III were recoded to capture days of use, assuming an instance of use was equivalent 
to a day of use, and adapted to match the ordinal measure at Wave IV.   
 Multiple covariates were included in the model as both depressive symptoms and 
substance use can vary across several sociodemographic characteristics. The covariates included 
respondent’s self-identified race/ethnicity (Hispanic and non-Hispanic White, Black, Asian, 
Native American, and Other) and the highest educational attainment of the parents (less than 
high school, high school graduate, some college, or college graduate or higher) as a proxy for 
socioeconomic status of the parental home.4 Frequency of child maltreatment, ranging from 
never to four or more times, was included as a potential confounder as it can be significantly 
associated with both depressive symptoms and substance use.80 Child maltreatment was defined 
as self-reported emotional, physical, or sexual abuse before age 18 or self-reported physical or 
supervisory neglect by a parent or adult caregiver at or before the time of the Wave III interview. 
Finally, binary variables were included to control for levels of the dependent variable at an age 
before the respondent’s age at Wave I, using retrospective measures from Wave I, including a 
depression diagnosis, drinking a full alcoholic beverage, and using marijuana.  
Analysis 
 The data set was structured by age instead of wave to capture the developmental 
trajectory from adolescence to young adulthood. Linear mixed effects models were used to 
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estimate growth curves of the three dependent variables: binge drinking frequency, marijuana 
use frequency, and depressive symptoms. Nine models were fit for each independent and 
dependent variable pairing. The first four models were used to estimate the growth curve of the 
dependent variable, starting with an unadjusted model, adding covariates, testing a random slope 
by age, then interacting the age and age-squared terms with sex. The next three models test a 
temporal association, whether an adolescent measure of the hypothesized predictor variable 
(controlling for pre-Wave I levels) is significantly associated with the starting point and trend in 
the growth curve of the dependent variable, and whether the association varies by sex. Finally, 
the last two models test whether a longitudinal measure (i.e., measures across all of the ages 
rather than at a specific developmental point) of the hypothesized predictor is significantly 
associated with the growth curve of the dependent variable and whether this association is 
moderated by sex. These last two models test whether there is a concurrent association (i.e., at 
each age) between the independent and dependent variables, which serves as a robustness check 
for the models testing a temporal association by clarifying whether only the adolescent measures 
of the independent variable are associated with the growth curve of the dependent variable. 
For all eligible models, we attempted to fit a random intercept by respondent ID and a 
random slope by age. We report the variance estimates for the random effects, where applicable. 
We also calculated the intraclass correlation coefficient (ICC) to get an estimate of the 
proportion of variance in the outcome that is due to variance between individuals, and report the 
percent change in the ICC across the models.  
Results 
Across the developmental trajectory from adolescence to young adulthood in the Add 
Health sample, the prevalence of binge drinking and marijuana use increases from adolescence to 
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emerging adulthood and then decreases slightly in young adulthood. For example, from ages 11 
to 13, only 9% of respondents report any binge drinking, but this increases to 55% between ages 
20 to 22 and then decreases to 38% between ages 32 to 34 (Table 2.1). For marijuana use, the 
proportion of respondents reporting any use increases from 5% at ages 11 to 13, to 25% at ages 
20 to 22, and then decreases to 17% for ages 32 to 34. This pattern is consistent with most 
previous research on developmental trends in substance use during these stages of the life 
course.4 Depressive symptoms follow an opposite pattern, starting higher in adolescence, 
decreasing in emerging adulthood and then increasing slightly in young adulthood. For example, 
the mean CES-D for ages 14 to 16 is 5.72; this decreases to 4.28 at ages 23 to 25 but then 
increases again to 5.08 between ages 29 to 31. 
  
  
5
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Table 2.1: Characteristics of the analysis sample by age 
  Age (years)a  
N (weighted percentage) 
 11-13a 14-16 17-19 20-22 23-25 26-28 29-31 32-34 
Binge drinking 
frequency  N=1494 N=5080 N=4276 N=4822 N=4378 N=4517 N=4692 N=189 
None 1376 (0.91)  3865 (0.75) 2540 (0.54) 2465 (0.47) 2182 (0.45) 2215 (0.46) 2563 (0.52) 116 (0.62) 
1-2 days/year 57 (0.04)  495 (0.10) 560 (0.14) 784 (0.16) 773 (0.18) 809 (0.19) 795 (0.17) 28 (0.13) 
≤1 x/month 19 (0.02)  305 (0.06) 382 (0.10) 494 (0.12) 499 (0.12) 530 (0.12) 514 (0.11) 11 0.04) 
2-3 days/month 17 (0.01) 176 (0.04) 346 (0.09) 417 (0.09) 396 (0.10) 443 (0.10) 353 (0.08) 12 (0.07) 
1-2 days/week 13 (0.01) 140 (0.03) 318 (0.09) 472 (0.11) 363 (0.10) 360 (0.09) 290 (0.07) 13 (0.07) 
3-5 days/week 8 (0.01) 63 (0.02) 100 (0.03) 160 (0.04) 130 (0.03) 122 (0.03) 133 (0.03) 8 (0.07) 
Every day/almost 4 (0.00) 36 (0.01) 30 (0.01) 30 (0.01) 35 (0.01) 38 (0.01) 44 (0.01) --b 
Marijuana use 
frequency          
None 1430 (0.95) 4390 (0.86) 3412 (0.78) 3705 (0.75) 3534 (0.79) 3733 (0.81) 4006 (0.85) 162 (0.83) 
1 day 22 (0.02) 178 (0.03) 201 (0.05) 227 (0.05) 188 (0.05) 142 (0.03) 157 (0.03) 7 (0.03) 
2-3 days 22 (0.02) 189 (0.04) 193 (0.05) 201 (0.05) 158 (0.04) 146 (0.04) 104 (0.02) -- 
1 day/week 5 (0.00) 88 (0.02) 106 (0.02) 122 (0.03) 84 (0.02) 51 (0.01) 34 (0.01) 3 (0.02) 
2 days/week 7 (0.00) 68 (0.01) 89 (0.03) 109 (0.02) 85 (0.02) 89 (0.02) 84 (0.02) -- 
3-5 days/week 5 (0.00) 86 (0.02) 129 (0.03) 187 (0.04) 131 (0.04) 116 (0.03) 128 (0.03) -- 
Every day/almost 3 (0.00) 81 (0.02) 146 (0.04) 271 (0.06) 198 (0.05) 240 (0.06) 179 (0.04) 11 (0.09) 
Depressive 
symptoms      
(0-27), m 4.90 (3.87) 5.72 (4.25) 5.66 (4.23) 4.52 (4.07) 4.28 (3.87) 5.12 (4.09) 5.08 (4.10) 6.08 (4.47) 
aAge is continuous in all of the statistical models but was condensed into categories for this table 
bDash indicates fewer than three respondents 
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Figure 2.1 is a plot of the key coefficients from the linear mixed effects models (see 
Appendix 2 for full model results). The data labels show the magnitude of the key coefficients. 
The coefficients are organized from highest in magnitude, at the top of the figure panel, to lowest 
in magnitude at the bottom, with a label to the right of the dot identifying the coefficient.  
The grey squares in Figure 2.1a show results from models testing the Self-Medication 
Model (i.e., the independent variable is depressive symptoms). Depressive symptoms in 
adolescence, a Wave I measure, were significantly associated with the binge drinking growth 
curve (b=0.03, p<0.001) with higher depressive symptoms in adolescence associated with higher 
binge drinking frequency in adolescence. The concurrent relationship across the ages was also 
significant (b=0.02, p<0.001). None of the interactions tested with the adolescent or time-varying 
(longitudinal) measure of depressive symptoms were significant. Depressive symptoms in 
adolescence were also significantly associated with the marijuana use frequency growth curve, 
but only when interacted with age (b=0.06, p<0.01), meaning higher depressive symptoms in 
adolescence were significantly associated with a steeper slope in marijuana use frequency with 
increasing age. The concurrent relationship for depressive symptoms and the marijuana use 
frequency growth curve was also significant (b=0.03, p<0.001). The interactions between the 
longitudinal depressive symptom measure and the substance use frequency growth curves were 
not statistically significant. Self-Medication Models fit with a random slope for age failed to 
converge.  
 The black circles in Figure 2.1b show results from analyses testing the Stress Model (i.e., 
independent variable was substance use frequency). Binge drinking frequency in adolescence 
was significantly associated with the depressive symptoms growth curve (b=0.67, p<0.001), with 
a higher binge drinking frequency in adolescence associated with a higher level of depressive 
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symptoms in adolescence. The concurrent positive relationship across the ages between binge 
drinking frequency and the depressive symptom growth curve was also significant and 
moderated by sex such that the relationship is stronger for females (b=0.25, p<0.001) compared 
to males (b=0.11, p<0.01). Marijuana use frequency in adolescence was also significantly 
positively associated with the depressive symptom growth curve (b=0.59, p<0.001). The 
concurrent relationship across the ages was also significant and moderated by sex, again 
indicating a stronger relationship for females (b=0.30, p<0.001) compared to males (b=0.12, 
p<0.001). All of the relevant models testing the Stress Model were fit with a random slope for 
age, allowing further heterogeneity in the growth curves.  
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Figure 2.1: Key coefficients from the linear mixed effects modelsa 
 
a Binge drinking frequency (BD), marijuana use frequency (MJ), Wave I (WI), dependent 
variable noted with parentheses in Figure 2.1a  
Figure 2.2 shows the predicted growth curve of marijuana use frequency across age and 
how growth varies by sex and depressive symptoms (Self-Medication Model). As can be seen, 
there is an increase in predicted marijuana use frequency across age for both males and females 
with moderate depressive symptoms in adolescence, but not for adolescents with no depressive 
symptoms. Further, the increase in marijuana use frequency among adolescents with moderate 
depressive symptoms appears greater for males compared to females.  
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Figure 2.2: Relationship between adolescent depressive symptoms and marijuana use frequency 
growth curve (Self-Medication Model)a 
 
a Adolescent (adol), dep (depressive) 
Figure 2.3 shows the predicted growth curve of depressive symptoms across age and how 
growth varies by sex and binge drinking frequency (Stress Model). The figure displays an 
increase in predicted depressive symptoms in adolescence with an increase in binge drinking 
frequency in adolescence and a higher starting point in adolescence for females compared to 
males. Similar results were found for marijuana use frequency. The solid black line in the figure 
shows the mean predicted depressive growth curve and the top two lines illustrate the variation 
in the growth curve among females from the random effects in the model. Specifically, the top 
two lines in the figure show how the predicted depressive symptom growth curve for females 
shifts if there is a one standard deviation increase in the intercept or the slope; both of the shifts 
take the predicted depressive symptoms above the threshold for likely depression (10 on the 
CES-D).   
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Figure 2.3: Relationship between adolescent binge drinking frequency and depressive symptoms 
growth curve (Stress Model)a 
 
There is meaningful within- and between-individual variation in the growth curves. The 
ICCs decreased across the models when additional predictors were added, indicating the 
predictor and control variables explained some of the between-individual variation in the 
outcome, as expected. For example, for the Self-Medication Models, the ICCs decreased by 30% 
from the unadjusted to fully-adjusted models (0.27 to 0.19) when binge drinking frequency was 
the dependent variable and by 23% (0.30 to 0.23) when marijuana use frequency was the 
outcome. For the Stress Models, the ICCs decreased by 18% (0.34 to 0.28). 
Discussion 
We used Add Health data to fit growth curve models testing both directions of the 
potential relationship between substance use and depressive symptoms from adolescence to 
young adulthood; we also tested moderation by sex. The ICCs decreased meaningfully across the 
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models, indicating our hypothesized predictor and control variables explained considerable 
variation in growth curves between respondents. Hypothesis 1 asserted there would be greater 
support for the Self-Medication Model among males compared to females, which was not 
supported in the current analysis. Rather, the findings support the Self-Medication Model for 
both males and females. There was a significant relationship between depressive symptoms in 
adolescence and the slope of marijuana use frequency from adolescence to young adulthood. The 
remaining significant associations between adolescent and longitudinal measures of depressive 
symptoms and both marijuana use and binge drinking were all concurrent associations and 
therefore do not address our directional hypothesis. Hypothesis 2 asserted the Stress Model 
would be more applicable for females compared to males, and was partially supported. When we 
tested the association between longitudinal measures of both binge drinking and marijuana use 
frequency and the depressive symptom growth curve, the association was significantly 
moderated by sex in both cases, indicating a stronger positive concurrent relationship across the 
developmental time period for females compared to males. We deem this only partial support for 
Hypothesis 2 because the associations significantly moderated by sex were concurrent and not 
directional.   
Our results supporting the Self-Medication Model for marijuana are consistent with some 
past literature as is our lack of significant results for binge drinking. For marijuana use, similar 
prior studies have found higher depressive symptoms early in adolescence are associated with 
faster increases in marijuana use during high school; in later adolescence marijuana use can be 
predicted by depressive symptoms.6,21 However, other longitudinal studies with dissimilar 
methods found marijuana use predicted depression and not the other way around, indicating 
methodological differences may further complicate the evidence for the Self-Medication and 
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Stress Models.7,52,122 Our lack of support for moderation by sex is consistent with findings from a 
study of over 7,000 late adolescents and young adults but inconsistent with findings from a study 
of over 600 African American adolescents. These patterns suggest future research should 
examine three-way interactions by age, race, and sex.21,119 For binge drinking, a review and a 
similar longitudinal study of early adolescents found no support for self-medication, but two 
studies of older adolescents found evidence for depressive symptoms predicting binge drinking 
or heavy episodic drinking.6,53,120 Results related to the question of sex differences in self-
medication with alcohol are unclear. There is more empirical support for males self-medicating, 
especially with alcohol.17 However, binge drinking is a normative social activity for males at 
these ages. If only a minority are self-medicating, the relationship may be hard to find.62 Further, 
at least one other similar longitudinal study found evidence for females self-medicating 
depressive symptoms with alcohol, though only a one-week timespan was examined, a further 
methodological complication.120     
Our finding of partial support for the Stress Model among females is consistent with 
some prior literature. Two similar longitudinal analyses following adolescents into emerging 
adulthood found both experimental substance use and substance abuse predicted later depression, 
but the reverse pathway was not supported.5,51 The Stress Model has also been supported by 
some reviews of other similar longitudinal study designs.52–54 Moderation by sex remains 
unclear. Although an analysis of Add Health data found only high frequency substance use 
predicted depression in males whereas experimental and high frequency use were predictive of 
depression in females, race appears to complicate the picture.5 A longitudinal study of African 
American and Puerto Rican women followed from adolescence into young adulthood found 
increasing marijuana use frequency predicted an increase in later depressive symptoms.7 Yet, a 
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similar longitudinal study of African American children followed into adulthood found substance 
use in adolescence predicted psychological distress in adulthood only for males.121  
The results of this study should be considered in the context of its limitations. First, the 
ordinal substance use measures were treated as continuous, though various robustness checks 
indicate the results are stable to variations in the measures (results not shown). Second, though 
linear mixed effects models remove potential bias from time-invariant unobserved 
characteristics, the results could still be biased by time-varying unobserved characteristics. Third, 
the Add Health data allow the developmental time period from adolescence into young 
adulthood to be studied; however, with only three waves of data (i.e., developmental periods) 
with the entire sample, it is more difficult to find variation in the growth curves.  
This paper addressed several limitations in past literature by using data from a nationally 
representative sample followed from adolescence into young adulthood and testing both potential 
directions of the association between substance use and depressive symptoms, as well as possible 
moderation by sex. The results indicate youth may self-medicate their depressive symptoms with 
marijuana use and that both marijuana use and binge drinking are concurrently associated with 
depressive symptoms, especially among females. So, both Models were supported and there was 
modest evidence suggesting the Stress Model is a better fit for females than males. These results 
inform efforts to screen adolescents for depression or substance use, now both covered as 
preventive services under the ACA. For example, youth screening positive for depression or an 
increase in depressive symptoms should also be screened for marijuana use, and youth, 
especially females, screening positive for persistent binge drinking or marijuana should be 
targeted for depression prevention programs or at least flagged as at risk for depressive 
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symptoms. Future research should examine moderation in these pathways by both sex and 
race/ethnicity as well as variation in results across different longitudinal methods. 
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CHAPTER 3 – SENSATION SEEKING, BIOMARKERS OF STRESS, AND 
ADHERENCE TO GENDER NORMS AS POTENTIAL MEDIATORS OF THE 
LONGITUDINAL ASSOCIATIONS BETWEEN BINGE DRINKING, MARIJUANA 
USE, AND DEPRESSIVE SYMPTOMS  
 
Overview 
Objectives: We tested potential mediators and moderators of the longitudinal associations 
between substance use frequency and depressive symptoms from adolescence into young 
adulthood, and whether the associations differed by sex. 
Methods: We used data from Waves I, III, and IV of the National Longitudinal Study of 
Adolescent to Adult Health (n=9816) to run sex-stratified regression models testing mediation 
and moderation hypotheses. Specifically, we tested if sensation seeking mediated the association 
between depressive symptoms and later substance use or if stress biomarkers mediated the 
association between substance use and later depressive symptoms. Further, we tested whether 
adherence to gender norms mediated or moderated either association.  
Results: The majority of significant results related to mediation and moderation of the 
association between depressive symptoms and later binge drinking frequency. For both males 
and females, sensation seeking and adherence to gender norms appear to mediate the association. 
For males only, adherence to gender norms appears to also moderate the relationship between 
depressive symptoms and later binge drinking. For females only, sensation seeking also seems to 
mediate the relationship between depressive symptoms and later marijuana use frequency. No 
significant results were found for the association between substance use frequency and later 
depressive symptoms.  
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Conclusions: Results indicate sensation seeking may mediate the association between depressive 
symptoms and later binge drinking frequency (males and females) as well as later marijuana use 
frequency (females only). Also, adherence to gender norms may mediate (in different directions 
for males and females) and moderate (males only) the association between depressive symptoms 
and later binge drinking frequency. 
Introduction 
Depressive symptoms and substance use are often comorbid in adolescence, suggesting a 
possible causal relationship.21 Past research examining the directional relationship between 
substance use and depressive symptoms has yielded mixed findings both in terms of which 
comes first, depression or substance use, and whether relationships differ by biological sex. 
Testing potential mediators and moderators of both hypothesized directions of the association 
could inform our understanding of underlying mechanisms and explain why linkages may vary 
for males and females.  
A predominant hypothesis as to why depressive symptoms may lead to later substance 
use is the Self-Medication Model, which asserts depressed individuals are motivated to seek 
novelty (i.e., substances) to ameliorate their symptoms.42 Therefore, sensation seeking may 
mediate this relationship. We expect a positive relationship between sensation seeking and later 
substance use for both males and females, as prior studies have found.58,59 However, we 
hypothesize the relationship between depressive symptoms and later sensation seeking will be 
negative for females and positive for males (Hypothesis 1). First, adolescent females may 
experience more severe and/or chronic depression, which could dampen motivation to seek 
novelty.5,21,60 Second, internalizing symptoms like depression are less socially acceptable for 
males compared to females, which may motivate sensation seeking in males.17,64 Further, if 
 63 
 
males do feel less masculine when struggling with depression, substance use can be a means of 
demonstrating adherence to masculine gender norms, which can endorse risk taking.22,65 Third, 
males may feel they lack other emotion regulation strategies, as supported in a recent 
review.17,61,62 Indeed, a survey of social drinkers revealed males were more likely than females to 
report drinking to regulate negative affect.63  
An alternative directional hypothesis about substance use and depression comorbidity is 
that substance use precedes depression. Past studies have tested whether substance use is 
associated with later increases in depressive symptoms, but few have articulated conceptual 
grounding for it.5–8 We term this the Stress Model because we focus on stress as a potential 
mediator linking substance use to later depression. We hypothesize stress, which we measure as 
a physiological stress response, will be positively associated with depression for both sexes.12,13 
However, we hypothesize substance use will be positively associated with stress for females and 
negatively associated for males (Hypothesis 2). First, substance use, as a risk behavior, does not 
align with female gender norms, whereas it does align with male norms.65,71 Second, substance 
use can be a normative and social behavior in adolescence, especially for males.6,62 Third, both 
alcohol and marijuana can give the illusion of relieving depressive symptoms.42,57 Fourth, 
females may have learned to expect more negative consequences from violating role norms in 
general, as parental regulation tends to be stronger and last longer for female children.66 Fifth, 
even if males and females have equal strain in parental relationships as a consequence of 
substance use, females are more perceptive of interpersonal stress and have stronger negative 
reactivity to it compared to males.10,11 Thus, we expect females are more likely to experience a 
stress response from substance use compared to males. 
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As implied above, adherence to gender norms is an important potential mediator for both 
the Self-Medication (Hypothesis 3) and Stress Models (Hypothesis 4). For Self-Medication, we 
hypothesize depressive symptoms will be positively associated with gender norm adherence for 
both males and females, though for different reasons. For males, we predict depressive 
symptoms will lead to greater adherence to masculine norms as a means of compensating for the 
vulnerability of internalizing symptoms.65 By comparison, for females, we predict depressive 
symptoms will also lead to greater adherence to feminine norms, but as a means of emotional 
regulation (e.g., talking with friends) rather than compensating.123 Because risk taking is 
“masculine,” we expect adherence to gender norms will be positively associated with substance 
use for males and negatively associated for females.64 For the Stress Model, we similarly expect 
substance use will be positively associated with gender norm adherence for males and negatively 
associated for females and that gender norm adherence will be negatively associated with 
depressive symptoms for both males and females.  
Finally, it also theoretically plausible that adherence to gender norms may moderate 
rather than mediate the associations between substance use and depressive symptoms. For 
example, depressive symptoms may be more positively associated with later substance use 
among males who subscribe more to masculine gender norms and therefore have a stronger 
incentive to self-medicate. We hypothesize the Self-Medication pathway will be moderated by 
adherence to gender norms such that the positive association will be stronger for males who are 
more gender norm-adherent compared to males who are less adherent. For females we 
hypothesize the negative association between depression and later substance use will be stronger 
among females who are more adherent compared to females who are less adherent (Hypothesis 
5).64,65 For the Stress Model, substance use may be more strongly associated with later 
 65 
 
depressive symptoms for females who are highly adherent to feminine gender norms as they may 
perceive substance use as antagonistic to these gender norms and thus have a stronger depressive 
response.10,11,18 Indeed we hypothesize the positive association between substance use and later 
depressive symptoms will be stronger for females who adhere more to feminine norms compared 
to females who are less adherent, and that the overall association will be negative for males and 
stronger for those who are more adherent to masculine norms compared to those who are less 
adherent (Hypothesis 6). 
Methods 
 Sample 
The National Longitudinal Study of Adolescent to Adult Health (Add Health) is a 
nationally representative, longitudinal school-based sample of U.S. adolescents who were in 
grades 7-12 in the 1994-95 school year (Wave I).78 Four subsequent in-home interviews have 
followed the respondents into young adulthood. The analysis sample is restricted to respondents 
interviewed in emerging adulthood (Wave III, ages 18 to 26) and young adulthood (Wave IV, 
ages 24 to 32) with valid sampling weights (N=12,288) and complete data on all variables of 
interest (N=9816, 80%). Wave II data were not used as Wave I seniors were excluded by design. 
Details of the Add Health study and design are described elsewhere.78 All Add Health protocols 
were approved by the Institutional Review Board at the University of North Carolina, Chapel 
Hill. These analyses were deemed exempt.    
Measures 
Depression: We used the Center for Epidemiologic Studies Depression Scale (CES-D), 
which measures symptoms but is not a diagnostic tool.76 Shorter versions of the scale have been 
previously validated, including a seven-item measure.124  We used the nine items available at 
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each wave as prior Add Health analyses have done. Items ask about frequency of symptoms and 
answers are scored from 0 to 3, indicating rarely to most of the time; the summed score ranges 
from 0 to 27. Though the measure captures symptom frequency over the past week, the 12-
month re-test reliability is high.76  
Substance use: Substances include alcohol (binge drinking) and marijuana. In Add 
Health, substance use frequency questions capture use patterns ranging from experimental to 
heavy. Binge drinking frequency was assessed for the past year with an ordinal variable ranging 
from 0 (none) to 6 (every day or nearly every day) at each wave. Marijuana use frequency was 
assessed for the past month with a similar ordinal variable at Wave IV, but with a continuous 
measure at Waves I and III asking about instances of use rather than days of use. To make the 
measures of marijuana use frequency comparable across the waves, days of marijuana use were 
derived (i.e., one instance of use translated to one day of use) at Waves I and III and then these 
frequencies were made ordinal to align with the measure of marijuana use at Wave IV.  
Sensation seeking: Previous exploratory and confirmatory factor analyses of 16 
sensation seeking items in Wave III found items all loaded onto one sensation seeking factor.58 
We averaged nine of the items asked of all respondents at Wave III (Cronbach’s alpha=0.85, 
min=1, max=5). Items ask respondents to identify on a 5-point Likert scale how true a statement 
is for them (e.g., “I often try new things just for fun or thrills, even if most people think they are 
a waste of time”). 
Stress: We used two biomarkers as indicators of stress at Wave IV. High sensitivity C-
reactive protein (CRP) is a biomarker for inflammation.48,96,97 Based on established guidelines, 
we coded CRP levels above 3 mg/L as indicating chronic stress.94 Epstein-Barr Virus (EBV) is a 
biomarker of immune function.78,101 EBV values were left continuous and log transformed to 
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address negative skew (mean=4.8, standard deviation=0.67), as prior studies have done.105 
Levels of CRP (mg/L) and EBV (AU/ml) were collected via dried whole blood spots in Wave IV 
of Add Health. The CRP measure has acceptable reliability (ICC = 0.70, 95% CI= 0.59, 0.81) 
and the EBV measure reliability is excellent (ICC=0.97, 95% CI =0.96, 0.98).101 A wide range of 
controls adjusted for health issues or stressful life events that could inflate CRP or EBV (see 
Chapter 1 for full details).101 
Adherence to gender norms: Adherence to gender norms was captured with an 
empirical measure of the degree to which respondents’ behaviors were concordant with the most 
gender-typical behaviors of their same-sex peers at Wave III. This innovative measure, 
Adherence to Gender-typical Behavior (AGB), was created by Fleming, Halpern, and Harris at 
all four waves of Add Health data.92 The items in AGB are highly correlated with biological sex 
and vary slightly between the waves, allowing for developmental change in the norms. The items 
include individual behaviors (e.g., exercising) and states of being (e.g., weight self-perception). 
The items were used in a logistic regression model to create predicted probabilities of being male 
(e.g., a predicted probability of 0.99 indicates a 99% chance of being male and a 1% chance of 
being female). This method of measure development has been used previously.89,91 As the 
predicted probabilities were skewed, rank percentile scores were created for males and females 
separately for the analyses (e.g., females with a percentile of 0.85 exhibited greater adherence to 
female-typical behavior at that wave).  
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Figure 3.1: Distribution of males and females by predicted probability of being male (Wave III) 
 
Controls: Substance use patterns and depressive symptoms vary by sociodemographics, 
so we controlled for respondents self-identified race/ethnicity (Hispanic and non-Hispanic 
White, Black, Asian, Native American, and Other) and educational attainment of both the 
respondent’s parents and the respondent (less than high school, high school graduate, some 
college, or college graduate or higher). Education is a proxy for socioeconomic status.4 
Respondent’s age at the wave at which the dependent variable was measured was included as 
substance use can vary substantially by age and the age ranges are fairly wide within waves. 
Also, binary variables indicating levels of the dependent variable before Wave I were created 
from a retrospective Wave I measure and included drinking an alcoholic beverage, using 
marijuana, and a depression diagnosis. Finally, frequency of childhood maltreatment (emotional, 
physical, or sexual abuse and/or supervisory neglect) was included as it can be shared risk factor 
for both substance use and depression in adulthood.80  
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Analyses 
We used linear and logistic regressions to test the mediation and moderation hypotheses. 
For the mediation models there was a dependent variable measured in young adulthood (Wave 
IV), an independent variable measured in adolescence (Wave I) and a hypothesized mediator 
measured in emerging or young adulthood (Wave III or IV). Iterative regression models tested 
the associations between the independent and dependent variables, independent variable and 
hypothesized mediator, and all three. We examined the direction and significance of the 
associations to identify mediation, blending the traditional Baron and Kenny model with the 
more contemporary approach of assessing only the estimate of the indirect effect.115 Specifically, 
we identified mediation as either changes in a significant relationship between the independent 
and dependent variables or significant relationships between the independent variable and the 
mediator as well as between the mediator and the dependent variable. For the moderation 
models, we tested moderation of the relationship between the independent and dependent 
variables between Waves I and IV as well as between Waves III and IV. We examined the 
significance of the interaction term to identify moderation, graphed the moderation relationship 
at typical values, and then tested if these slopes were significantly different from zero. All 
regression models included a lagged measure of the dependent variable to control for prior levels 
of the dependent variable. 
Results 
Table 3.1 outlines characteristics of the analytic sample. Of note, there is meaningful 
variation in the hypothesized mediators. For example, 30% of males and 48% of females have 
elevated levels of CRP. Second, females have an average level of depressive symptoms that is at 
least one point higher than the average for males across the waves. Finally, there are meaningful 
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levels of substance use, even in adolescence. For example, approximately 30% of adolescent 
males reported binge drinking in adolescence and 60% report binge drinking in young adulthood; 
binge drinking increases from 25% to 45% for females.  
Table 3.1: Characteristics of the mediation analysis sample 
Hypothesized mediatora 
MALES  
(n=4323) 
n (weighted %) 
or mean (SD)a 
FEMALES 
(n=5493)  
n (weighted %)  
or mean (SD) 
 
Sensation seeking (Wave III), m 3.0 (0.9)  2.4 (0.8) 
CRP (WIV)   
<3 mg/L 3026 (70.0) 2848 (51.8) 
>3 mg/L 1297 (30.0) 2645 (48.2) 
EBV log AU/ml (WIV), m 4.7 (0.7) 4.9 (0.7) 
 MALES (n=4323) 
 Wave I Wave III Wave IV 
Depressive symptoms (0-27), m 5.0 (3.8) 3.9 (3.6) 4.6 (3.7) 
Binge drinking frequency  
None 3060 (70.4) 1735(37.2) 1857(40.9) 
1 or 2 days/year 388 (9.0) 669 (15.2) 726 (17.3) 
Once per month or less 286 (6.5) 511 (12.7) 580 (13.2) 
2-3 days/month 238 (5.6) 521 (12.9) 453 (11.0) 
1-2 days/week 226 (5.6) 615 (15.6) 448 (11.0) 
3-5 days/week 86 (2.1) 223 (5.3) 195 (5.1) 
Every day/almost  39 (0.1) 49 (1.2) 64 (1.4) 
Marijuana use frequency   
None 3668 (85.4) 3121(71.1) 3394(77.1) 
1 day 158 (3.3) 211 (4.9) 171 (3.9) 
2 or 3 days 159 (3.4) 201 (4.9) 154 (4.1) 
1 day/week 69 (1.7) 118 (3.0) 45 (1.2) 
2 days/week 63 (1.5) 107 (2.5) 108 (2.5) 
3-5 days/week 88 (2.0) 229 (5.8) 165 (3.8) 
Every day/almost  118 (2.7) 336 (7.9) 286 (7.4) 
 FEMALES (n=5493) 
 Wave I Wave III Wave IV 
Depressive symptoms (0-27), m 6.3 (4.5) 4.9 (4.2) 5.6 (4.3) 
Binge drinking frequency  
None 4208 (75.2) 3240(55.4) 3222(56.0) 
1 or 2 days/year 557 (10.8) 984 (18.1) 977 (18.9) 
Once per month or less 203 (6.1) 537 (11.2) 534 (10.3) 
2-3 days/month 203 (3.8) 335 (6.9) 410 (8.0) 
1-2 days/week 136 (2.5) 297 (6.3) 247 (4.5) 
3-5 days/week 56 (1.1) 82 (1.8) 82 (1.6) 
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Every day/almost  27 (0.1) 18 (0.2) 21 (0.3) 
Marijuana use frequency   
None 4816(87.2) 4533(80.8) 4840(87.5) 
1 day 179 (3.3) 244 (4.8) 159 (3.3) 
2 or 3 days 192 (3.8) 192 (3.7) 117 (2.2) 
1 day/week 100 (1.6) 116 (2.2) 45 (6.5) 
2 days/week 68 (1.3) 114 (2.3) 73 (1.3) 
3-5 days/week 81 (1.6) 130 (2.7) 91 (2.0) 
Every day/almost  57 (1.3) 164 (3.6) 168 (3.1) 
aAGB is not included in this table because it is a rank percentile score (e.g., min=0.01, 
max=0.99, mean=0.5)  
 
Figure 3.2 displays the key regression results from all mediation analyses (full results in 
Appendix 3). There were no significant associations between the independent and dependent 
variables in any of the models, so results will only be presented if there were significant 
associations between the hypothesized mediator and both the independent and dependent 
variables. There were no significant results for the Stress Model. For the Self-Medication Model, 
in the models testing sensation seeking as a potential mediator, there were significant positive 
associations between depressive symptoms and sensation seeking and between sensation seeking 
and later binge drinking frequency for both males and females. There were also significant 
positive associations between depressive symptoms, sensation seeking and later marijuana use 
frequency, but only for females. In the models testing AGB as a potential mediator, there were 
only significant results for binge drinking frequency and not marijuana use frequency. The 
association between depressive symptoms and AGB was positive for females and negative for 
males. The association between AGB and binge drinking frequency was positive for males and 
negative for females.  
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Figure 3.2: Significant coefficients from the regression models testing mediation 
 
NOTE: Top coefficients with black text represent the regression results for males. Lower 
coefficients with gray text represent the regression results for females. N.S. = not significant  
 
None of the moderation models tested between adolescence and young adulthood were 
significant and only one model result was significant for the moderation models tested between 
emerging and young adulthood. For the latter, the association between depressive symptoms at 
Wave III and binge drinking frequency at Wave IV is significantly stronger for males with 
higher AGB scores compared to males with lower AGB scores (see Table 3.7.1). Figure 2 
displays the moderation pattern at typical values where the independent variable (depressive 
symptoms) and moderator (AGB) are graphed at the mean value plus and minus one standard 
deviation. We tested whether the slope of predicted values was different from zero for each AGB 
group displayed. The slope for males with a mean AGB value was not significantly different 
from zero (F=0.07, p=0.79). However, the slope for males with AGB values one standard 
deviation below the mean was negative and significantly different from zero (F=4.14, p<0.05). 
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For males with an AGB value one standard deviation above the mean the slope was not 
significantly different from zero (F=2.09, p=0.15), but the relationship is in the expected 
direction. 
Figure 3.3: AGB moderation of the association between depressive symptoms and later binge 
drinking frequency for males 
 
NOTE: The y axis in the figure was scaled from the ordinal binge drinking frequency measure to 
approximate days per month to ease interpretation.  
 
Discussion 
We used Add Health data to test three hypothesized mediators and one hypothesized 
moderator of the longitudinal relationships between binge drinking, marijuana use, and 
depressive symptoms from adolescence to young adulthood. Overall, significant possible 
mediation and moderation results were found for the Self-Medication Model but not the Stress 
Model, meaning Hypotheses 2, 4, and 6 were not supported. We found support for the 
hypotheses (1 and 3) that the relationship between depressive symptoms and later binge drinking 
frequency is mediated by AGB and sensation seeking. There is also support among males for 
AGB as a moderator of the relationship between depressive symptoms and later binge drinking 
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frequency; the relationship is positive for males with higher AGB scores and negative for males 
with lower AGB scores, supporting our Hypothesis 5 that the Self-Medication Model would be 
better supported for more gender-adherent males.  
The Self-Medication models testing sensation seeking as a mediator supported the 
hypothesized associations for males but not females. For males, the expected positive 
associations between depressive symptoms and sensation seeking, and between sensation 
seeking and substance use were found for binge drinking but not marijuana use. Prior studies 
have found connections between sensation seeking and alcohol use.59 Our findings extend that 
work, suggesting that depressive symptoms may be a proximal cause of sensation seeking. For 
marijuana use among males, our results do not support sensation seeking as a mediator. This is 
consistent with a prior analysis that found sensation seeking did not confound the association 
between depressive symptoms and marijuana use.7 Contrary to our hypotheses for females, the 
associations between depressive symptoms and sensation seeking were positive in both the binge 
drinking and marijuana use models. Sensation seeking was also positively associated with use of 
both substances, as expected. These results challenge the notion that females would be less likely 
to experience sensation seeking in response to depression.5,17,21,60 These results also indicate 
sensation seeking is a potentially relevant mediator for the relationship between depressive 
symptoms and marijuana use for females but not males.  
Counter to our expectations, no mediation associations were statistically significant for 
the Stress Model. There are several potential explanations. First, the tests of whether stress 
biomarkers mediated the association were complicated by the fact that the biomarkers were 
collected at Wave IV. This means we were testing the association between an independent 
variable that preceded both the mediator and dependent variable by 14 to 15 years, which was 
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not the case for the Self-Medication Models. Second, by using continuous measures of the 
independent and dependent variables, we were testing a subtle relationship that we are assuming 
is linear. It is possible that variations at the extremes of the distribution are more important. 
Third, developmental change may explain why depressive symptoms in adolescence were 
significantly associated with AGB in emerging adulthood and yet AGB in emerging adulthood 
was not significantly associated with depressive symptoms in young adulthood. Adolescence and 
emerging adulthood can be a time of gender intensification, where gender roles become rigid as 
identities are forming, and then later become more fluid in young adulthood.125 Therefore, 
depressive symptoms may be more strongly related to gender-typical behavior through 
adolescence into emerging adulthood as gender identities are solidifying rather than later in 
development.   
In the models testing AGB as a potential mediator of the Self-Medication Model, the 
support for our hypotheses was mixed. The association between depressive symptoms and AGB 
was positive for females, as expected, but negative for males—contrary to our hypothesis. The 
unanticipated negative association between depressive symptoms and later AGB for males could 
also be explained by gender intensification. From adolescence into emerging adulthood, when 
males may be expected to increase their gender-adherence, males struggling with depressive 
symptoms may be less able to do so. They may simply have less motivation or ability to engage 
in male-typical behaviors. Males may also have less opportunity to engage in male-typical 
behaviors as a consequence of social isolation that may result from their depressive symptoms. 
In line with our hypotheses, the association between AGB and binge drinking frequency was 
positive for males and negative for females.    
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The moderation results add nuance to the mediation results by suggesting the relationship 
between depressive symptoms and later substance use significantly varies based on a male’s 
AGB scores. Specifically, the Self-Medication Model for binge drinking may be salient only for 
gender-adherent males. Perhaps males who are more gender-adherent have stronger incentive to 
self-medicate depressive symptoms as they, or their peers, may interpret depression as a sign of 
vulnerability.64,65 Alternatively, self-medication of depressive symptoms with alcohol may be a 
reflexive emotion regulation strategy.17 Males who are less adherent to male-typical behavior 
are, due to the construction of our measure of gender-adherence, by default more adherent to 
female-typical behavior, which may include a wider array of emotion regulation tools.   
The findings of this study should be considered along with its limitations. First, some of 
the mediators were measured in emerging adulthood and some only in young adulthood meaning 
the mediators were not tested in identical temporal circumstances. Further, though we were able 
to control for prior measures of the dependent variable, we were not able to control for prior 
measures of the mediators, meaning low AGB in adolescence could precede adolescent 
depressive symptoms, for example. Second, the ordinal measures of substance use frequency 
were treated as continuous. However, we repeated the significant mediation models with the 
ordinal measures translated into an approximately continuous midpoint frequency measure, and 
the results were consistent. Third, though the length of time between the waves does enable us to 
examine the entire developmental trajectory from adolescence to young adulthood, it may reduce 
the likelihood of finding a significant association given the long time period (14 to 15 years) 
between measures at Waves I and IV, versus the shorter time periods between Waves I and III 
(approximately 7 years) and Waves III and IV (approximately 6-7 years). Finally, no significant 
associations were found between the independent and dependent variables in the mediation 
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models, perhaps due to the long timespan between them. However, several models found 
significant associations between the independent variable and the mediator and between the 
mediator and the dependent variable, which is sufficient criteria for assessing potential 
mediation.115  
This analysis used longitudinal, nationally representative data to test potential mediation 
and moderation of the relationship between substance use frequency and depressive symptoms 
from adolescence to young adulthood. We found support for sensation seeking and AGB as 
potential mediators in the Self-Medication Model. We also found AGB may act as a moderator 
of the linkage between depressive symptoms and binge drinking among males. In contrast, we 
found no evidence to support stress or AGB as potential mediators in the Stress Model.  
These findings have implications for public health and future research. First, the USPSTF 
recently updated its depression screening guidelines to include adolescents, and the ACA lists 
depression and substance use screening as covered preventive services.2,38 The results from the 
Self-Medication mediation models indicate adolescents screening positive for depression or an 
increase in depressive symptoms could also be screened for sensation seeking to target substance 
use prevention programs accordingly. Second, the results from the models testing gender 
adherence as a mediator and moderator indicate depression and substance use 
prevention/treatment programs could benefit from tailoring on biological sex or even aiming to 
be gender-transformative by challenging the gender norms that promote substance use and self-
medication.126 Future research should test support for the Stress Model overall as well as other 
mediators (e.g., indicators of social rather than biological stress).  
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CHAPTER 4– CONCLUSIONS & IMPLICATIONS FOR CARE 
 
Conclusions 
 
In Chapter 2, linear mixed effects models were used to evaluate the Self-Medication and 
Stress Models and test whether hypothesized associations are moderated by sex. Findings 
support the Self-Medication Model for marijuana use for males and females, and provided 
modest support for the Stress Model for both binge drinking and marijuana use, especially for 
females. In Chapter 3, regression models stratified by sex were used to test mediation and 
moderation hypotheses to better understand the processes embedded in the Self-Medication and 
Stress Models. It appears sensation seeking may mediate self-medication processes involving 
binge drinking (indirect effect estimate B=0.24) and marijuana (B=0.14) for females, but only 
binge drinking for males (B=0.16). It remains unclear what mediates self-medication with 
marijuana in males. Adherence to Gender-typical Behavior also appears to play a role in self-
medication with binge drinking for both males (B=-0.012) and females (B=-0.15). The complex 
sampling design in Add Health precluded testing whether these indirect effect estimates are 
significantly different from zero and it is possible the estimate for AGB for males is not large 
enough to indicate mediation. The moderation results help us interpret these mediation results 
because they indicate the self-medication of depressive symptoms with binge drinking may only 
be relevant for males with above average adherence to gender norms.  
From these findings, the conclusions of these analyses are multiple. First, adolescents 
may self-medicate depressive symptoms with substance use, possibly via sensation seeking, but 
this may only be relevant for gender-adherent males. Second, depressive symptoms may increase 
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gender-adherent behavior for females and decrease it for males, both of which are then likely to 
decrease later binge drinking. Third, persistent binge drinking or marijuana use from adolescence 
into young adulthood appears to be concurrently positively linked with depressive symptoms, 
especially for females.   
Across all models, two results were particularly surprising. First, it is not clear why the 
Self-Medication Model was indirectly supported for binge drinking in the mediation models but 
not in the growth curve models. However, the lack of significant direct effects between 
depressive symptoms and later binge drinking in the mediation models still make the results 
consistent. The results interpreted as support of potential mediation of this relationship by 
sensation seeking and AGB could instead indicate depressive symptoms are associated with 
sensation seeking and AGB, which are then associated with binge drinking and that there is in 
fact no direct relationship between depressive symptoms and later binge drinking. Second, across 
all models only two results provide modest support for the Stress Model. From the growth curve 
models, the longitudinal measures of both marijuana use and binge drinking frequencies were 
positively associated with the depressive symptom growth curve, and this association was 
significantly moderated by biological sex. These findings indicate significant positive concurrent 
associations between substance use frequency and depressive symptoms that were stronger for 
females compared to males. The other result providing modest support for the Stress Model 
came from the regression models testing if stress biomarkers or AGB mediated the Stress Model. 
No models yielded significant associations between both the independent variable and mediator, 
and between the mediator and the dependent variable, but one finding warrants attention. For 
females, adolescent marijuana use frequency was significantly positively associated with EBV 
 80 
 
levels in young adulthood, as we hypothesized, indicating a link between marijuana use and 
stress for females.  
The lack of significant results for the Stress Model is surprising, especially as a prior 
study using data from Add Health found support for the Stress Model and evidence against the 
Self-Medication Model. In comparing their methods to the ones used in these papers, one key 
difference emerges. Their study was examining the relationship between depression and clusters 
of experimental and higher risk behaviors including both substance use and sexual risk 
behaviors.5 It is possible sexual risk behaviors alone were driving the association with later 
depression or that the combination of sexual risk and substance use are important to the 
association. In general, another main methodological difference between these and prior analyses 
is that many papers measured depression or substance use dichotomously, capturing those with 
real or probable depression diagnoses and/or very high levels of substance use or even 
abuse/dependence. By using continuous measures of both substance use frequency and 
depressive symptoms, we were testing for smaller, fine-grained associations that were assumed 
to be linear across the distributions of each measure (e.g., as binge drinking frequency increases, 
later depressive symptoms increase linearly). It is possible that the relationship between 
substance use and depression is not linear across the distribution and that there are points on the 
distribution at which point the relationship becomes much stronger, something binary measures 
are better positioned to capture.     
  
Innovation 
The analytic methods for this project addressed many existing gaps in the literature. First, 
the analyses in Chapters 2 and 3 tested both potential directions of the association between 
substance use and depressive symptoms as well as differences in the association by sex, whereas 
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the majority of prior studies did not. Second, the use of growth curve analyses in Chapter 2 
represents a methodological improvement upon much prior literature. Third, the use of 
longitudinal data capturing the age range from 11 to 34 enabled us to examine the interplay of 
substance use and depressive symptoms across the developmental trajectory, where prior studies 
are heavily concentrated in adolescence. Finally, the use of Add Health data maximized the 
generalizability of these results for the field as it is a large, diverse, and nationally representative 
sample.   
The use of unique mediators furthered the innovation of this project. A new measure of 
gendered behavior norms was tested as a potential mediator. Historically, gender has been 
conceptualized and measured as a trait, an ideology, or even as the stress related to adhering to 
gender norms.83 While valuable, static measures miss both developmental and historical changes 
in gender norms and fail to capture how gender influences behavior at an individual level.64,88 
The AGB measure captures the degree to which respondents’ reported behaviors are concordant 
with those of other Add Health respondents of their same sex at a given point in time.92 AGB 
was tested as a potential mediator and moderator in both the Stress and Self-Medication Models 
and thus helped explain sex differences in the results from Chapter 2. From prior analyses we 
know the AGB is significantly positively associated with substance use for males and 
significantly negatively associated with substance use for females; these results align with 
similar previous analyses using trait or ideology measures of gender thus buffering the construct 
validity of the measure.71–74,93 This empirical approach to measuring gender based on individual 
behavior and preferences relative to peers has been endorsed by previous research in the field.89–
91 
 82 
 
This study also used biomarkers as objective measures of stress, a hypothesized mediator. 
The biomarker data in Add Health allowed us to measure respondent’s inflammation and 
immune responses as biological indicators of stress. These measures offered insight that is not 
available through the self-reported measures of perceived stress as prior research shows the level 
of stress individuals perceive and/or report can be strongly influenced by their sex and the gender 
norms they are ascribing to.10,11,69 Biomarker data are able to get beneath the skin and more 
accurately assess a respondent’s stress level and warrant future use, despite the lack of 
significant findings in this project.   
Limitations 
 
The analyses in this project had limitations concentrated in data constraints, analytic 
constraints, conceptual grounding, and measurement error. First, with observational rather than 
experimental data, we cannot infer causality from the associations identified. Second, though 
growth curve models present numerous advantages over both regression and analysis of variance 
methods, including the ability to examine individual trajectories over time, control for time-
invariant unobservables, improved ability to test reciprocal relationships, and increased statistical 
power, the models are still vulnerable to endogeneity from time-varying unobservables.6,21,81 For 
example, a genetic predisposition to substance use and depressive symptoms, if time invariant, 
was controlled but it is possible that a time-varying unobservable that is associated with both 
substance use and depressive symptoms could be driving the observed associations. More 
statistically advanced methods were available to analyze these data; however, these methods did 
not align with the research questions as well as growth curve modeling. For example, latent class 
growth analysis and growth mixture modeling are powerful methods for analyzing 
developmental trajectories over time. However, what distinguishes them from growth curve 
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analyses is the presence of a categorical latent variable that then enables estimation of different 
growth curves for different classes of respondents.127 Examining different growth curve patterns 
is valuable but did not fit with the aims of this project as the methods are not as well suited for 
examining relationships between growth curves nor for examining moderation. Further, the 
models can find local solutions and struggle to converge, and with only three time points of data, 
it is unlikely we would find curves more diverse than increasing, decreasing, or remaining 
consistent.127 The last analytic constraint is that the analyses had 80% power to detect differences 
in depressive symptoms, for example, as small as 0.12 and smaller differences than this were 
significant and interpreted. However, the lower power for these smaller differences means there 
was a higher chance of failing to reject the null hypothesis when it was false (type II error), 
which is not ideal though tolerable.   
Third, the conceptual bases for the analyses were grounded in the Life Course Model, but 
focused only on individual change over time and did not consider the individual’s context, which 
almost certainly influence the key variables of interest. For example, parental alcohol 
socialization (e.g., permissive messages, attitude towards children sipping alcohol) can be 
associated with differentiation in susceptibility to initiation of alcohol use among elementary 
school children.128–130 Parental characteristics therefore may increase the risk of alcohol use of 
Add Health respondents before the Wave I data were collected. Similarly, information on the 
respondent’s peers and their substance use is not included and it likely influences substance use 
frequency.131 Though highly relevant for substance use, the individual’s context was beyond the 
scope of the research questions of this project. Fortunately, the growth curve analyses helped 
control for parental socialization and peer substance use to the extent these factors were time 
invariant.  
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A fourth limitation of this work is vulnerability to measurement error. For example, the 
complete list of items for the CES-D and sensation seeking scale were not available either for the 
whole sample or at all waves of interest, meaning condensed scales were used. However both 
measures had high Cronbach’s alpha values indicating good reliability/coherence. Also, the 
substance use frequency measures were originally ordinal or were transformed to be ordinal in 
the case of marijuana use frequency in Waves I and III and yet were analyzed as continuous 
measures. This was a constraint in the data but multiple sensitivity analyses using midpoint 
frequency measures, which were more continuous, and comparing the results or the BIC 
estimates indicated the measures were comparable. The measures used to capture the frequency 
of child maltreatment were diverse, though a shared limitation of these measures is that children 
may not remember it or the maltreatment can happen before children are capable of forming 
memories, meaning the measure will not control for all child maltreatment. Finally, the index of 
stressful life events was useful as a control variable for the biomarker mediation analyses, though 
the measure did not capture how respondents felt about the assumed stressors in their lives (e.g., 
unplanned pregnancy), nor did it weight some experiences (e.g., being deployed to a combat 
zone) more than others (e.g., getting arrested). Fortunately, we had repeated measures of most 
variables, and all of the key variables of interest, which helped to decrease measurement error.32 
Implications for Health 
 
The conclusions of these analyses, that adolescents—depending on gender-adherence—
may self-medicate depressive symptoms with substance use, and that persistent substance use—
especially for females—seems concurrently positively linked with depressive symptoms, have 
implications for health. Specifically, how to target and integrate screening adolescents for 
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substance use and depressive symptoms as well as how to tailor prevention and/or treatment 
programs by sex and/or gender.  
Screening adolescents for either substance use or depression is uncommon in the United 
States. A survey of pediatricians revealed fewer than half report screening for substance use and 
fewer than a quarter felt comfortable providing comprehensive screening or offering a referral to 
treatment.33,36 For depression screening, a survey of physicians estimated they screen only 46% 
of their patients and this statistic is likely much lower for adolescent patients.34 Infrequent 
screening means cases are missed and care is not received. Less than 10% of adolescents with 
substance use problems receive treatment, and a review from the USPSTF in 2009 estimated the 
vast majority of adolescents with depression received no treatment of any kind.2,33,35 The lack of 
screening and treatment for both conditions is problematic. The National Institute of Mental 
Health estimates half of all substance use and mental health cases begin by age 14, so 
deficiencies in screening and treatment in adolescence miss opportunities to prevent these 
conditions or to treat them early.2,35–37  
 The importance of screening adolescents for substance use and mental health issues is not 
a new concept. In 1998 the Society for Adolescent Medicine published a position paper asserting 
that the growth of managed care provided an opportunity for adolescent health care to include 
more screenings, prevention, and coordinated care. Substance use and mental health were 
included as necessary screens.132 The American Academy of Pediatrics (AAP), the American 
Medical Association, the Maternal and Child Health Bureau, the Surgeon General, and the 
Centers for Medicare and Medicaid Services (CMS) all endorse screening adolescents for 
substance use and/or mental health issues.36,37 Fortunately, the ACA recently strengthened the 
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policy framework to provide screening by covering alcohol, drug use, and depression screening 
for children and depression and alcohol misuse screening for adults.38  
However, just because screening services are covered (meaning insurance companies 
cannot charge a copay for them) does not mean providers will offer the screening.38 Indeed, other 
supportive policies existed before the ACA; the AAP includes psychological screening in their 
Bright Futures screening guidelines from infancy until age 21, and CMS includes substance use 
and mental health screening under the Early and Periodic Screening, Diagnostic and Treatment 
benefits for well child exams.37 Despite these recommendations screening has remained low. 
Physician knowledge of the screening guidelines is important but not the only barrier. In one 
study physicians in community health centers reported screening 64% of their patients for 
depression—indicating awareness of the guidelines—but only documented screening 3% of 
them, though these clinics lacked electronic medical records, which likely decreases  
compliance.133 Focus groups with pediatricians across a wide range of practice settings identified 
a lack of time, uncertainty about how to respond to a positive screen, and perceived lack of 
referral or treatment resources as the main barriers to screening adolescents for both substance 
use and depression.2,39 Indeed, a national survey of residency programs found less than one third 
of pediatric residency programs required training in how to diagnose and treat substance use 
disorders.134 Fortunately, both the National Institute on Drug Abuse (NIDA) and the AAP have 
advocated for training physicians how to provide screening, brief interventions, and referral to 
treatment (SBIRT) for substance use and depression in adolescents.36,37 A meta-analysis of brief 
interventions for heavy alcohol use found brief interventions were as effective as more extensive 
interventions with a 27% average effect size, which represents the proportion of standard 
deviation change in alcohol consumption.135 Further, randomized trials of SBIRT training for 
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physicians indicate they can be effective in changing physician behavior and that the 
interventions are implementable.136     
As more physicians are trained to provide SBIRT and the policy support for screening 
grows stronger, more cases are likely to be identified, thereby increasing the need to provide and 
improve treatment. In a sample of adolescents in a managed care plan, 81% who sought 
substance use treatment had a primary care visit in the previous year so screening in primary care 
has an opportunity to catch cases.35 One study of substance use screening of adolescents in 
primary care found that 15% of patients screened positive for a substance use problem and that 
the lifetime prevalence of depression among adolescents could be as high as 20%.2,137 As more 
adolescents are screened, more cases will likely be detected, and evidence suggests adolescents 
who screen positive are likely to pursue treatment.2 More adolescents seeking treatment provides 
an opportunity to integrate substance use and mental health care. As estimates of comorbidity in 
clinical samples are as high as 50%, these cases are more the rule than the exception.33,35 Despite 
the prevalence of comorbidity, substance use and mental health care are typically isolated from 
each other in the United States, even though evidence suggests trying to treat the conditions in 
isolation results in a higher risk of treatment failure.138,139 Further, integrating substance use and 
psychiatric care into primary care can produce better outcomes and is even capable of preventing 
some conditions from developing in the first place.35 Given this, it is encouraging that many 
policy and research institutions are advocating for integration (e.g., the Agency for Healthcare 
Research and Quality, American Society for Addiction Medicine, Substance Abuse and Mental 
Health Services Administration), and recent Federal parity laws ensure coverage of mental health 
and substance use treatment equal to the coverage of other medical issues.35  
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 While screening all adolescents for all substance use and mental health problems and full 
integration of care is ideal, the time constraints of physicians and resource constraints in the 
system remain. Not only are universal programs costly and difficult to implement, the resources 
are likely better spent on the smaller proportion of adolescents at elevated risk rather than on all 
adolescents.36 The results of this study provide insight into how to target screening and 
integrated care to those most at risk. For example, the findings indicate adolescents screening 
positive for depression or an increase in depressive symptoms should also be screened for 
marijuana use and potentially linked to marijuana use programs in addition to depression 
treatment. Also, it seems screening for binge drinking could be targeted towards youth screening 
positive in sensation seeking and/or increases depressive symptoms. Sensation seeking screening 
of pre-adolescents has been recommended as a means of catching those most at risk of substance 
use and several screening tools exist with good psychometrics and acceptability.140 If 
implemented, this could inform further targeting of who to screen for substance use among those 
who have already screened positive for depression or an increase in depressive symptoms.   
The results from this study also inform how substance use and depressive symptoms, and 
the relationship between them, can function differently for males and females. These differences 
indicate prevention and treatment programs could benefit from tailoring by sex, as NIDA has 
indicated.126 For example, as males tend to have and employ fewer emotional regulation 
strategies than females, prevention and treatment programs would do well to teach more 
emotional regulation strategies to males.17 Also, beyond targeting certain services towards males 
or females, challenging harmful gender norms could boost overall program efficacy. For 
example, as adherence to masculine norms can make substance use and self-medication more 
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likely, programs would do well to try to challenge the links between masculinity and substance 
use (e.g., “real men can hold their liquor”) with gender transformative programs.64,141  
 Increases in screening for substance use and depression and increases in integrated 
screening, prevention and treatment will increase costs, but they will likely be far cheaper than 
the costs of maintaining the status quo. The costs of depression in the United States are estimated 
to be approximately $210 billion annually. Although this cost estimate is not specific to 
adolescents, it is still relevant as untreated depression is likely to persist or relapse.142 Underage 
drinking costs the United States approximately $68 billion per year; drug use among adolescents 
and adults is estimated to cost $181 billion per year; and adding in lost productivity, social 
problems (e.g., violence), and broader health implications brings the total cost of alcohol and 
drug abuse to $600 billion annually.35,143 To put these numbers in perspective, the Department of 
Defense budget for 2017 is $582 billion, and this is the largest portion of discretionary spending 
for the Federal government.144 In short, we can afford to do better.  
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APPENDIX 2.1: ANALYSES 
The appendices include further detail on statistical analyses and results from Chapters 2 
(Appendix 2) and 3 (Appendix 3). This information was not included in the chapters either 
because it was not central to the research questions posed in the chapters or because space 
constraints did not allow all of the details to be included.  
Cigarette smoking frequency was examined as a potential confounder and, though it is 
correlated with other forms of substance use, it does not share a strong correlation with 
depressive symptoms. Further, several of the models were tested with and without a control for 
smoking frequency and the results changed only very slightly, so smoking frequency was left out 
as a control variable in these analyses.  
Fitting linear mixed effects models is an iterative process, and through this process we 
tried to find the model that best fit the data. With only three waves of data and measures of 
substance use frequency with constrained variation, the models testing a random slope by age 
when substance use frequency measures were the dependent variable did not converge, so we did 
not proceed to testing random slope by age squared. When depressive symptoms were the 
dependent variable, the models testing a random slope for age did converge, though the estimate 
of the variance for age was very small in magnitude, so we also did not test a random slope for 
age squared in these models.  
For testing the simple slopes of the significant and relevant moderation results, the 
contrast statement was used for interactions with at least one categorical variable. For 
interactions between continuous variables, it was determined if the slope was significant 
different from zero by looking to the coefficient for the key predictor in the model before the 
interaction term was added. The contrast results indicate the interactions between longitudinal 
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measures of substance use frequency and sex in the depressive symptom growth curve models 
produced simple slopes for males and females that were both significantly different from zero. 
When depressive symptoms were tested as a predictor for the marijuana use frequency growth 
curves (Table 2.3.1), the interaction term between an adolescent measure of depressive 
symptoms and age was significant (B=0.06, p<0.01, Model 6), though the coefficient for the 
adolescent depressive symptom measure in Model 5 was not statistically significant, indicating at 
certain levels of depressive symptoms the slope would not significantly differ from zero.  
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APPENDIX 2.2: BINGE DRINKING FREQUENCY GROWTH CURVES 
Hypothesis 1.3 for binge drinking, that binge drinking frequency will show a non-linear 
increase then decrease from adolescence to young adulthood and that it will be moderated by sex 
such that frequencies will be higher for males compared to females, was supported. In Model 1 
(Table 2.2.1) the coefficients for age (B=0.46, p<0.001) and age squared (B=-0.01, p<0.001) 
were significant and retained significance when the covariates were added in Model 2. Further, 
the interactions between biological sex and both age (B=0.31, p<0.001) and age squared (B=-
0.01, p<0.001) were significant, indicating the gap between male and female binge drinking 
frequency, on average, increases by a third of a point on the binge drinking frequency category 
rank measure with each one year increase in age, though this pattern has some non-linearity.  
The binge drinking frequency growth curves also revealed significant differences in 
adolescent (Wave I) levels by sociodemographic characteristics and in different ways than the 
demographic patterns for the marijuana use frequency and depressive symptom growth curves. 
Compared to Whites, Black (B=-0.45, p<0.001), Asian (B=-0.36, p<0.001), and Hispanic (B=-
0.12, p<0.05) respondents had significantly lower adolescent binge drinking frequencies. For 
parental educational attainment, only respondents whose parents did not graduate high school 
had significantly lower adolescent binge drinking frequencies (B=-0.15, p<0.01). Respondents 
who experienced childhood maltreatment (emotional, physical, sexual, neglect) had significantly 
higher on average binge drinking frequencies in adolescence, though there did not seem to be a 
pattern by frequency, from most to least: three times (B=0.17, p<0.001), once (B=0.13, p<0.05), 
and four or more times (B=0.11, p<0.01). Finally, respondents who reported drinking an 
alcoholic beverage before Wave I had, on average, a starting binge drinking frequency score that 
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was 0.66 (p<0.001) points higher on the binge drinking category rank score compared to 
respondents who did report drinking an alcoholic beverage before Wave I. 
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Table 2.2.1: Linear mixed effects models of binge drinking frequency with depressive symptoms tested as a predictora 
 
 
 
M1: 
Uncondtlb 
M2: 
Covariatec 
M4:  
Age x Sex 
M5:  
Dep sympt 
(WI) 
M6:  
Dep sympt 
(WI) x 
Age 
M7:  
Dep sympt 
(WI) x 
Age x Sex 
M8:  
Dep sympt 
(longit) 
M9:  
Dep sympt 
(longit) x 
Sex 
Age 0.46*** 0.45*** 0.33*** 0.50*** 0.56*** 0.43*** 0.46*** 0.46*** 
 (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) 
Age^2 -0.01*** -0.01*** -0.01*** -0.01*** -0.01*** -0.01*** -0.01*** -0.01*** 
 (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) 
Sex (1=Male, 
0=Female) 
 0.49*** -3.01*** 0.49*** 0.50*** -2.36*** 0.50*** 0.55*** 
  (0.03) (0.37) (0.03) (0.03) (0.42) (0.03) (0.05) 
Race/ethnicity 
(White=referent) 
        
Hispanic  -0.12* -0.12* -0.13** -0.13** -0.13** -0.13** -0.13** 
  (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) 
Black  -0.45*** -0.45*** -0.46*** -0.46*** -0.46*** -0.46*** -0.46*** 
  (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) 
Asian  -0.36*** -0.36*** -0.38*** -0.37*** -0.37*** -0.37*** -0.37*** 
  (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) 
Native American  0.11 0.11 0.11 0.11 0.11 0.10 0.10 
  (0.09) (0.09) (0.09) (0.09) (0.09) (0.09) (0.09) 
Other  -0.13 -0.12 -0.13 -0.13 -0.12 -0.13 -0.13 
  (0.17) (0.17) (0.17) (0.17) (0.17) (0.17) (0.17) 
Parental education 
(WI) 
(college=referent) 
        
< High school  -0.15** -0.15** -0.17*** -0.17*** -0.17** -0.18*** -0.18*** 
  (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) 
High school  -0.06 -0.06 -0.08* -0.08* -0.08* -0.08* -0.08* 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
< College  -0.06 -0.07 -0.07 -0.07 -0.07 -0.07* -0.07* 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
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Childhood 
maltreatment 
frequency 
(none=referent) 
        
Once  0.13* 0.13* 0.13* 0.12* 0.12* 0.12 0.12 
  (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) 
Twice  0.07 0.07 0.06 0.06 0.06 0.05 0.06 
  (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) 
Three times  0.17*** 0.18*** 0.17*** 0.16*** 0.17*** 0.15*** 0.15*** 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
Four or more 
times 
 0.11** 0.12** 0.10** 0.09* 0.10** 0.08* 0.08* 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
Drank alcoholic 
beverage before WI 
 0.66*** 0.66*** 0.63*** 0.65*** 0.65*** 0.65*** 0.65*** 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
Age x Sex   0.31***   0.25***   
   (0.04)   (0.04)   
Age^2 x Sex   -0.01***   -0.01***   
   (0.00)   (0.00)   
Depression 
diagnosis before WI 
   -0.07 -0.06 -0.06 -0.10 -0.10 
    (0.08) (0.08) (0.08) (0.08) (0.08) 
Dep sympt (WI)    0.03*** 0.42* <-0.01   
    (0.00) (0.19) (0.21)   
Age x Dep sympt 
(WI) 
    -0.04 0.01   
     (0.02) (0.03)   
Dep sympt (WI) x 
Sex 
     0.74   
      (0.40)   
Age x Dep sympt 
(WI) x Sex 
     -0.10   
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      (0.05)   
Age^2 x Dep sympt 
(WI) 
    <0.01 <-0.01   
     (0.00) (0.00)   
Age^2 x Dep sympt 
(WI) x Sex 
     0.003*   
      (0.00)   
Dep sympt (longit)       0.02*** 0.02*** 
       (0.00) (0.00) 
Dep sympt (longit) 
x Sex 
       -0.01 
        (0.01) 
Constant -4.17*** -4.38*** -2.97*** -5.06*** -5.63*** -4.22*** -4.54*** -4.56*** 
 (0.18) (0.18) (0.24) (0.18) (0.20) (0.24) (0.18) (0.18) 
Variance estimates (SE)               
Respondent ID 0.56 0.36 0.37 0.37 0.36 0.37 0.36 0.36 
 (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) 
Residual 1.51 1.51 1.49 1.50 1.50 1.48 1.50 1.50 
 (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in parentheses 
aDepressive symptoms (Dep sympt), longitudinal measure (longit), standard error (SE) unconditional (uncondtl) 
bStandard errors are beneath the coefficients in parentheses 
cA random slope for age was tested, but did not meaningfully improve model fit and so was removed from all models 
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APPENDIX 2.3: MARIJUANA USE FREQUENCY GROWTH CURVES 
Hypothesis 1.3 for marijuana use—that marijuana use frequency will show a non-linear 
increase then decrease from adolescence to young adulthood, and that it will be moderated by 
sex such that frequencies will be higher for males compared to females—was supported. In 
Models 1 and 2 (Table 2.3.1) the coefficients were significant with and without the covariates for 
age (B=0.30, p<0.001) and age squared (B=-0.01, p<0.001). Additionally, the interaction terms 
between biological sex and age (B=0.23, p<0.001) and age squared (B=-0.01, p<0.001) were 
significant, indicating the gap between male and female marijuana use frequency, on average, 
increases by a third of a point on the marijuana use frequency category rank score with each one 
year increase in age, though there is non-linearity.  
The marijuana frequency growth curves also showed significant variation by certain 
sociodemographic characteristics and variation that differed from the binge drinking frequency 
and depressive symptom growth curves. Only respondents identifying as Asian had significantly 
different marijuana use frequencies in adolescence compared to Whites (B=-0.15, p<0.01). 
Marijuana use frequency in adolescence was not found in our models to significantly vary by 
parental education. Compared to respondents who reported no childhood maltreatment 
frequency, those who reported maltreatment happened three times (B=0.19, p<0.001) or four or 
more times (B=0.21, p<0.001) had significantly higher marijuana use frequency in adolescence. 
Finally, those who reported first using marijuana before Wave I had significantly higher 
marijuana use frequency in adolescence (B=1.08, p<0.001).  
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Table 2.3.1: Linear mixed effects models of marijuana use frequency with depressive symptoms tested as a predictora 
 
M1: 
Uncondtl 
M2: 
Covariateb 
M4:  
Age x Sex 
M5:  
Dep 
sympt 
(WI) 
M6:  
Dep 
sympt 
(WI) x 
Age 
M7:  
Dep 
sympt 
(WI) x 
Age x Sex 
M8:  
Dep sympt 
(longit) 
M9:  
Dep sympt 
(longit)x 
Sex 
Age 0.30*** 0.30*** 0.20*** 0.31*** 0.33*** 0.22*** 0.31*** 0.31*** 
 (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) 
Age^2 -0.01*** -0.01*** -0.005*** -0.01*** -0.01*** -0.005*** -0.01*** -0.01*** 
 (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) (0.00) 
Sex (1=Male, 
0=Female) 
 0.28*** -2.30*** 0.29*** 0.29*** -2.06*** 0.31*** 0.30*** 
  (0.03) (0.36) (0.03) (0.03) (0.40) (0.03) (0.04) 
Race/ethnicity 
(White=referent) 
        
Hispanic  0.01 0.01 0.01 <0.01 0.01 -0.01 -0.01 
  (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) 
Black  0.03 0.03 0.03 0.03 0.03 0.01 0.01 
  (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) (0.03) 
Asian  -0.15** -0.15** -0.15** -0.15** -0.15** -0.17*** -0.17*** 
  (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) 
Native American  0.08 0.08 0.08 0.08 0.08 0.07 0.07 
  (0.10) (0.10) (0.10) (0.10) (0.10) (0.10) (0.10) 
Other  0.03 0.04 0.04 0.03 0.04 0.04 0.04 
  (0.14) (0.14) (0.14) (0.14) (0.14) (0.13) (0.13) 
Parental education 
(WI) 
(college=referent) 
        
< High school  -0.03 -0.03 -0.04 -0.03 -0.03 -0.07 -0.07 
  (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) 
High school  -0.05 -0.05 -0.05 -0.05 -0.05 -0.06 -0.06 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
< College  -0.01 -0.01 -0.02 -0.02 -0.02 -0.03 -0.03 
  
9
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  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
Childhood 
maltreatment 
frequency 
(none=referent) 
        
Once  0.06 0.06 0.06 0.05 0.06 0.04 0.04 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
Twice  0.05 0.05 0.04 0.04 0.04 0.02 0.02 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
Three times  0.19*** 0.19*** 0.19*** 0.19*** 0.19*** 0.16** 0.16** 
  (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) 
Four or more times  0.21*** 0.21*** 0.20*** 0.20*** 0.20*** 0.16*** 0.16*** 
  (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) (0.04) 
Marijuana use before 
WI 
 1.08*** 1.08*** 1.07*** 1.07*** 1.07*** 1.06*** 1.06*** 
  (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) (0.06) 
Age x Sex   0.23***   0.21***   
   (0.04)   (0.04)   
Age^2 x Sex   -0.005***   -0.004***   
   (0.00)   (0.00)   
Depression 
diagnosis before WI 
   0.26* 0.26* 0.26* 0.19 0.19 
    (0.12) (0.12) (0.12) (0.12) (0.12) 
Dep sympt (WI)    0.01 -0.45* -0.44*   
    (0.00) (0.18) (0.18)   
Age x Dep sympt 
(WI) 
    0.06** 0.06**   
     (0.02) (0.02)   
Dep sympt (WI) x 
Sex 
     -0.38   
      (0.40)   
Age x Dep sympt 
(WI) x Sex 
     0.05   
  
1
0
0
 
      (0.05)   
Age^2 x Dep sympt 
(WI) 
    -0.002** -0.001**   
     (0.00) (0.00)   
Age^2 x Dep sympt 
(WI) x Sex 
     <0.01   
      (0.00)   
Dep sympt (longit)       0.03*** 0.03*** 
       (0.00) (0.00) 
Dep sympt (longit) x 
Sex 
       <0.01 
        (0.01) 
Constant -2.67*** -2.97*** -1.92*** -3.13*** -3.33*** -2.19*** -3.16*** -3.16*** 
 (0.17) (0.18) (0.17) (0.18) (0.20) (0.20) (0.18) (0.19) 
Variance estimates 
(SE)                 
Respondent ID 0.65 0.47 0.48 0.48 0.47 0.48 0.46 0.46 
 (0.03) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) (0.02) 
Residual 1.51 1.51 1.49 1.51 1.51 1.49 1.50 1.50 
 (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) (0.05) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in parentheses 
aDepressive symptoms (Dep sympt), longitudinal measure (longit), standard error (SE), unconditional (uncondtl) 
bA random slope for age was tested, but did not meaningfully improve model fit and so was removed from all models 
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APPENDIX 2.4: DEPRESSIVE SYMPTOM GROWTH CURVES 
Hypothesis 1.4, that the depressive symptom trajectory will show a decline from 
adolescence to young adulthood and will be moderated by sex such that the levels of depressive 
symptoms will be higher among females compared to males, was partially supported.21 From 
Model 1 (Table 2.4.1) of the depressive symptom growth curves, the coefficient for age was -
0.33 (p<0.001), indicating a decline in depressive symptoms from adolescence to young 
adulthood; this coefficient retained significance when the covariates were added in Model 2. The 
interaction term between age and sex in Model 4 was not statistically significant, though the 
coefficient for males was -2.18 (p<0.05), indicating the starting points in adolescence for 
depressive symptoms are significantly different. That the interaction term is not significant 
means the gap between higher levels for females compared to males does not change with age. 
Tables 2.4.2 and 2.4.3 outline the full results when binge drinking and marijuana use frequency, 
respectively, were tested as predictors of the depressive symptom growth curves. These results 
were discussed in detail in Chapter 2.  
The depressive symptom growth curves also revealed significant differences by 
sociodemographic characteristics and in ways that vary from the binge drinking and marijuana 
use frequency growth curves. Compared to Whites, with the exception of respondents identifying 
as an ‘Other’ race/ethnicity, all racial/ethnic minority groups had higher average adolescent 
depressive symptoms, from highest to lowest: Asian (B=0.77, p<0.001), Black (B=0.65, 
p<0.001), Native American (B=0.61, p<0.05), and Hispanic (B=0.46, p<0.05). Compared to 
respondents whose parents have a college degree or more, respondents whose parents have lower 
educational attainment had higher adolescent depressive symptoms, from highest to lowest: less 
than high school (B=1.40, p<0.001), high school (B=0.74, p<0.001), less than college (B=0.39, 
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p<0.001). Compared to respondents who did not report experiencing any childhood 
maltreatment, increasing frequency of childhood maltreatment showed step-wise increases in 
adolescent depressive symptom levels. Respondents who experienced maltreatment once had, on 
average, CES-D score that was 0.60 (p<0.001) points higher. Those who experienced it twice 
had scores that were 0.82 (p<0.001) points higher; those who experienced maltreatment three 
times had scores 0.97 (p<0.001) points higher. Those with four or more experiences had scores 
1.84 (p<0.001) points higher than the scores for respondents who did not experience childhood 
maltreatment. Finally, respondents who reported first getting diagnosed with depression at an age 
before their age at Wave I had, on average, a starting CES-D score that was 2.74 (p<0.001) 
points higher compared to respondents who did not have a depression diagnosis at all or before 
Wave I. 
Table 2.4.1: Linear mixed effects models of depressive symptoms 
 M1: 
Unconditional 
M2: 
Covariates 
M3: 
Random 
slope for 
age 
M4: Age x 
Sex 
Age -0.33*** -0.30*** -0.33*** -0.38*** 
 (0.05) (0.05) (0.05) (0.07) 
Age^2 0.01*** 0.01*** 0.01*** 0.01*** 
 (0.00) (0.00) (0.00) (0.00) 
Sex (1=Male, 
0=Female) 
 -0.86*** -0.86*** -2.18* 
  (0.09) (0.09) (1.00) 
Race/ethnicity 
(White=referent) 
    
Hispanic  0.46** 0.45** 0.45** 
  (0.17) (0.17) (0.17) 
Black  0.65*** 0.65*** 0.65*** 
  (0.10) (0.10) (0.10) 
Asian  0.77*** 0.77*** 0.77*** 
  (0.15) (0.15) (0.15) 
Native American  0.61* 0.61* 0.61* 
  (0.26) (0.26) (0.26) 
Other  -0.08 -0.08 -0.07 
  (0.44) (0.44) (0.44) 
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Parental education 
(WI) 
(college=referent) 
    
< High school  1.40*** 1.40*** 1.40*** 
  (0.18) (0.18) (0.18) 
High school  0.74*** 0.73*** 0.73*** 
  (0.11) (0.11) (0.11) 
< College  0.39*** 0.39*** 0.39*** 
  (0.11) (0.11) (0.11) 
Childhood 
maltreatment 
frequency 
(none=referent) 
    
Once  0.61** 0.60** 0.60** 
  (0.20) (0.20) (0.20) 
Twice  0.82*** 0.81*** 0.81*** 
  (0.14) (0.14) (0.14) 
Three times  0.97*** 0.97*** 0.97*** 
  (0.12) (0.12) (0.12) 
Four or more times  1.83*** 1.83*** 1.83*** 
  (0.11) (0.11) (0.11) 
Depression diagnosis 
before WI 
 2.74*** 2.75*** 2.75*** 
  (0.38) (0.38) (0.38) 
Age x Sex    0.12 
    (0.09) 
Age^2 x Sex    <-0.01 
    (0.00) 
Constant 8.71*** 7.23*** 7.54*** 8.09*** 
 (0.48) (0.52) (0.52) (0.71) 
Variance estimates 
(SE)a 
        
Respondent ID 5.65 4.20 9.30 9.27 
 (0.21) (0.20) (2.23) (2.24) 
Residual 10.77 10.70 10.29 10.29 
 (0.23) (0.24) (0.29) (0.29) 
Age   0.01 0.01 
   (0.00) (0.00) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, 
standard errors in parentheses  
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Table 2.4.2: Linear mixed effects models of depressive symptoms with binge drinking frequency 
tested as a predictora  
 
M5: Binge 
drinking 
(WI) 
M6: Binge 
drinking 
(WI) x Age 
M7: Binge 
drinking 
(WI) x Age 
x Sex 
M8: Binge 
drinking 
(longit) 
M9: Binge 
drinking 
(longit) x 
Sex 
Age -0.32*** -0.32*** -0.34*** -0.44*** -0.44*** 
 (0.05) (0.05) (0.06) (0.05) (0.05) 
Age^2 0.01*** 0.01*** 0.01*** 0.01*** 0.01*** 
 (0.00) (0.00) (0.00) (0.00) (0.00) 
Sex (1=Male, 
0=Female) -0.96*** -0.96*** -1.41 -0.99*** -0.85*** 
 (0.08) (0.08) (0.98) (0.09) (0.10) 
Race/ethnicity 
(White=referent)      
Hispanic 0.51** 0.51** 0.51** 0.51** 0.51** 
 (0.16) (0.16) (0.16) (0.16) (0.16) 
Black 0.79*** 0.79*** 0.79*** 0.85*** 0.86*** 
 (0.10) (0.10) (0.10) (0.10) (0.10) 
Asian 0.82*** 0.82*** 0.82*** 0.85*** 0.85*** 
 (0.15) (0.15) (0.15) (0.15) (0.15) 
Native 
American 0.48 0.49 0.49 0.50* 0.49 
 (0.25) (0.25) (0.25) (0.25) (0.25) 
Other -0.09 -0.09 -0.09 -0.10 -0.09 
 (0.40) (0.39) (0.40) (0.42) (0.42) 
Parental 
education (WI) 
(college=referent)      
< High school 1.40*** 1.40*** 1.40*** 1.52*** 1.52*** 
 (0.16) (0.16) (0.16) (0.16) (0.16) 
High school 0.65*** 0.65*** 0.65*** 0.71*** 0.71*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
< College 0.39*** 0.39*** 0.39*** 0.42*** 0.42*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
Childhood 
maltreatment 
frequency 
(none=referent)      
Once 0.60** 0.60** 0.60** 0.59** 0.58** 
 (0.19) (0.19) (0.19) (0.19) (0.19) 
Twice 0.80*** 0.80*** 0.79*** 0.80*** 0.80*** 
 (0.13) (0.13) (0.13) (0.13) (0.14) 
Three times 0.95*** 0.96*** 0.95*** 0.95*** 0.95*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
 105 
 
Four or more 
times 1.83*** 1.83*** 1.82*** 1.82*** 1.82*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
Depression 
diagnosis before 
WI 2.79*** 2.78*** 2.76*** 2.83*** 2.82*** 
 (0.37) (0.37) (0.37) (0.37) (0.37) 
Drank alcoholic 
beverage before 
WI <-0.01 <-0.01 -0.01 0.13 0.13 
 (0.10) (0.10) (0.10) (0.10) (0.10) 
Binge drinking 
(WI) 0.67*** -2.27 -7.32   
 (0.05) (4.26) (6.22)   
Age x Binge 
drinking (WI)  0.38 1.08   
  (0.54) (0.80)   
Binge drinking 
(WI) x Sex   5.98   
   (8.96)   
Age x Sex   0.05   
   (0.09)   
Age x Binge 
drinking (WI) x 
Sex   -0.89   
   (1.13)   
Age^2 x Binge 
drinking (WI)  -0.01 -0.03   
  (0.02) (0.03)   
Age^2 x Sex   <-0.01   
   (0.00)   
Age^2 x Binge 
drinking (WI) x 
Sex   0.03   
   (0.04)   
Binge drinking 
(longit)    0.16*** 0.25*** 
    (0.03) (0.04) 
Binge drinking 
(longit) x Sex     -0.14** 
     (0.05) 
Constant 7.11*** 7.08*** 7.25*** 8.63*** 8.54*** 
 (0.50) (0.50) (0.68) (0.51) (0.51) 
Variance 
estimates (SE)           
Respondent ID 10.07 10.05 9.82 11.05 10.79 
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(2.25) (2.26) (2.25) (2.30) (2.29) 
Residual 10.01 10.01 10.00  10.13 10.14 
 (0.27) (0.27) (0.27) (0.27) (0.27) 
Age 0.01 0.01 0.01 0.01 0.01 
 (0.00) (0.00) (0.00) (0.00) (0.00) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aLongitudinal measure (longit), standard error (SE) 
 
Table 2.4.3: Linear mixed effects models of depressive symptoms with marijuana frequency 
tested as a predictora  
 
M5: 
Marijuana 
use (WI) 
M6: 
Marijuana 
use (WI) x 
Age 
M7: 
Marijuana 
use (WI) x 
Age x Sex 
M8: 
Marijuana 
use (longit) 
M9: 
Marijuana 
use (longit) 
x Sex 
Age -0.34*** -0.33*** -0.36*** -0.43*** -0.43*** 
 (0.05) (0.05) (0.06) (0.05) (0.05) 
Age^2 0.01*** 0.01*** 0.01*** 0.01*** 0.01*** 
 (0.00) (0.00) (0.00) (0.00) (0.00) 
Sex (1=Male, 
0=Female) -0.96*** -0.95*** -1.68 -1.00*** -0.89*** 
 (0.08) (0.08) (0.97) (0.09) (0.09) 
Race/ethnicity 
(White=referent)      
Hispanic 0.48** 0.48** 0.48** 0.48** 0.48** 
 (0.16) (0.16) (0.16) (0.17) (0.16) 
Black 0.77*** 0.77*** 0.78*** 0.77*** 0.78*** 
 (0.10) (0.10) (0.10) (0.10) (0.10) 
Asian 0.79*** 0.80*** 0.80*** 0.83*** 0.83*** 
 (0.14) (0.14) (0.14) (0.15) (0.14) 
Native 
American 0.43 0.43 0.43 0.45 0.45 
 (0.25) (0.25) (0.25) (0.25) (0.25) 
Other -0.14 -0.14 -0.14 -0.11 -0.11 
 (0.39) (0.39) (0.39) (0.39) (0.40) 
Parental 
education (WI) 
(college=referent)      
< High school 1.46*** 1.46*** 1.46*** 1.49*** 1.50*** 
 (0.16) (0.16) (0.16) (0.16) (0.16) 
High school 0.70*** 0.70*** 0.69*** 0.71*** 0.71*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
< College 0.41*** 0.41*** 0.41*** 0.41*** 0.41*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
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Childhood 
maltreatment 
frequency 
(none=referent)      
Once 0.60** 0.60** 0.59** 0.60** 0.61** 
 (0.19) (0.19) (0.19) (0.19) (0.19) 
Twice 0.80*** 0.80*** 0.79*** 0.80*** 0.80*** 
 (0.13) (0.13) (0.13) (0.13) (0.13) 
Three times 0.96*** 0.96*** 0.96*** 0.94*** 0.94*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
Four or more 
times 1.80*** 1.80*** 1.80*** 1.77*** 1.77*** 
 (0.11) (0.11) (0.11) (0.11) (0.11) 
Depression 
diagnosis before 
WI 2.70*** 2.70*** 2.69*** 2.70*** 2.68*** 
 (0.36) (0.36) (0.36) (0.37) (0.36) 
Marijuana use 
before WI 0.43*** 0.44*** 0.43*** 0.47*** 0.47*** 
 (0.12) (0.12) (0.12) (0.12) (0.12) 
Marijuana use 
(WI) 0.59*** -1.30 -6.55   
 (0.05) (5.05) (6.61)   
Age x Marijuana 
use (WI)  0.29 1.03   
  (0.63) (0.84)   
Age x Sex   0.07   
   (0.09)   
Marijuana use 
(WI) x Sex   5.02   
   (9.69)   
Age x Marijuana 
use (WI) x Sex   -0.80   
   (1.21)   
Age^2 x 
Marijuana use 
(WI)  -0.01 -0.04   
  (0.02) (0.03)   
Age^2 x Sex   <-0.01   
   (0.00)   
Age^2 x 
Marijuana use 
(WI) x Sex   0.03   
   (0.04)   
Marijuana use 
(longit)    0.19*** 0.30*** 
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(0.02) (0.04) 
Marijuana use 
(longit) x Sex     -0.18*** 
     (0.05) 
Constant 7.46*** 7.37*** 7.67*** 8.49*** 8.43*** 
 (0.49) (0.50) (0.68) (0.50) (0.50) 
Variance 
estimates (SE)           
Respondent ID 10.51 10.41 10.33 11.06 11.13 
 (2.24) (2.25) (2.24) (2.25) (2.25) 
Residual 10.06 10.07 10.06 10.12 10.11 
 (0.27) (0.27) (0.27) (0.27) (0.27) 
Age 0.01 0.01 0.01 0.01 0.01 
 (0.00) (0.00) (0.00) (0.00) (0.00) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aLongitudinal measure (longit), standard error (SE) 
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APPENDIX 3.1: HYPOTHESES 
Aim 2. Using regression models, examine potential mediators (sensation seeking, stress 
biomarkers, and gender norm adherence) and a moderator (gender norm adherence) of the 
relationships between substance use and depressive symptoms and whether the relationships 
differ by biological sex. 
 Self-Medication Model 
Hypothesis 2.1: Level of depressive symptoms will be positively associated with the level 
of sensation seeking for males. The level of sensation seeking for males will be positively 
associated with the frequency of binge drinking. In this way, the positive relationship between 
the level of depressive symptoms and frequency of binge drinking will be mediated by the level 
of sensation seeking. The same hypothesis was tested for marijuana use frequency.7,17,58,61–63,145    
  Hypothesis 2.2: Level of depressive symptoms will be negatively associated with the 
level of the level of sensation seeking for females. The level of sensation seeking among females 
will be positively associated with the frequency of binge drinking. In this way, the negative 
relationship between the level of depressive symptoms and frequency of binge drinking will be 
mediated by the level of sensation seeking. The same hypothesis was tested for marijuana use 
frequency.7,17,58,60,145   
Hypothesis 2.3: Level of depressive symptoms will be positively associated with the 
AGB score for males. The AGB score for males will be positively associated with the frequency 
of binge drinking. In this way, the positive relationship between the level of depressive 
symptoms and frequency of binge drinking will be mediated by the AGB score. The same 
hypothesis was tested for marijuana use frequency.17,61–63  
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  Hypothesis 2.4:  Level of depressive symptoms will be positively associated with the 
AGB score for females. The AGB score for females will be negatively associated with the 
frequency of binge drinking. In this way, the negative relationship between the level of 
depressive symptoms and frequency of binge drinking will be mediated by the AGB score. The 
same hypothesis was tested for marijuana use frequency.17,60   
 Hypothesis 2.5: The positive association between the level of depressive symptoms and 
binge drinking frequency will be moderated by the AGB score such that the association will be 
stronger for males who are more gender norm-adherent compared to males who are less 
adherent.64,65 The same hypothesis was tested for marijuana use frequency. 
Hypothesis 2.6: The negative association between the level of depressive symptoms and 
binge drinking frequency will be moderated by the AGB score such that the association will be 
stronger for females who are more gender norm-adherent compared to females who are less 
adherent.64,65 The same hypothesis was tested for marijuana use frequency. 
Stress Model Hypotheses 
Hypothesis 2.7: Frequency of binge drinking will be associated with lower odds of 
elevated CRP and lower levels of EBV for males. Elevated CRP and EBV levels for males will 
be positively associated with the level of depressive symptoms. In this way, the negative 
relationship between the frequency of binge drinking and the level of depressive symptoms will 
be mediated by elevated CRP and levels of EBV. The same hypothesis was tested for marijuana 
use frequency.65,96,101,146  
 Hypothesis 2.8: Frequency of binge drinking will be associated with higher odds of 
elevated CRP and higher levels of EBV for females. Elevated CRP and EBV levels for females 
will be positively associated with the level of depressive symptoms. In this way, the positive 
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relationship between the frequency of binge drinking and the level of depressive symptoms will 
be mediated by elevated CRP and levels of EBV. The same hypothesis was tested for marijuana 
use frequency.18,96,101 
Hypothesis 2.9: Frequency of binge drinking will be positively associated with the AGB 
score for males. The AGB score for males will be negatively associated with the level of 
depressive symptoms. In this way, the negative relationship between the frequency of binge 
drinking and the level of depressive symptoms will be mediated by the AGB score. The same 
hypothesis was tested for marijuana use frequency.64,65,70,146  
  Hypothesis 2.10:  Frequency of binge drinking will be negatively associated with the 
AGB score for females. The AGB score for females will be negatively associated with the level 
of depressive symptoms. In this way, the positive relationship between the frequency of binge 
drinking and the level of depressive symptoms will be mediated by the AGB score.18 The same 
hypothesis was tested for marijuana use frequency.  
 Hypothesis 2.11: The negative association between binge drinking frequency and level of 
depressive symptoms will be moderated by the AGB score such that the association will be 
stronger for males who are more gender norm-adherent compared to males who are less 
adherent. The same hypothesis was tested for marijuana use frequency.  
 Hypothesis 2.12: The positive association between binge drinking frequency and level of 
depressive symptoms will be moderated by the AGB score such that the association will be 
stronger for females who are more gender norm-adherent compared to females who are less 
adherent.10,11,18 The same hypothesis was tested for marijuana use frequency.  
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APPENDIX 3.2: ANALYSES 
In creating the binary measure for CRP, we included values over 30 mg/L, trusting the 
numerous control variables would correctly adjust for the very high scores that likely indicate 
illness. However, as a sensitivity analysis, the relevant mediation models for CRP were repeated 
with the values over 30 excluded. Fortunately, the results changed very little in both magnitude 
and significance.  
Given the high number of tests employed for Aim 2, we used the conservative Bonferroni 
correction as a personal guard against over-interpretation of the results. When this was applied to 
our mediation results, we lost the significant associations between binge drinking frequency and 
both sensation seeking and AGB for males and also between sensation seeking and marijuana 
use frequency for females. Given this, the results from the mediation analyses in Chapter 3 
should be interpreted with caution and further similar research is needed to buffer these results.     
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APPENDIX 3.3: SENSATION SEEKING MEDIATION FOR SELF-MEDICATION 
MODEL 
 
Table 3.3.1 and 3.3.2 include results from the regression models testing Hypotheses 2.1 
and 2.2, respectively. Hypothesis 2.1 was partially supported, as depressive symptoms at Wave I 
were positively associated with level of sensation seeking in Wave III (B=0.02, p<0.001) and the 
level of sensation seeking was positively associated with binge drinking frequency (B=0.08, 
p<0.05). Sensation seeking was not significantly associated with marijuana use frequency, 
contrary to the hypothesis. Hypothesis 2.2 was also partially supported as sensation seeking was 
positively associated with both binge drinking frequency (B=0.12, p<0.001) and marijuana use 
frequency (B=0.07, p<0.05), as hypothesized. However, depressive symptoms at Wave I were 
positively, rather than negatively, associated with sensation seeking (B=0.02, p<0.001).  
Table 3.3.1: Linear regression testing mediation of the Self-Medication Model by sensation 
seeking, Malesa 
 
MALES 
  Binge drinking frequency Marijuana use frequency 
 
M1b M2 M3 M1 M2 M3 
Depressive 
symptoms (WI) 0.01 0.02*** 0.01 -0.01 0.02*** -0.01 
 
(0.01) (0.00) (0.01) (0.01) (0.00) (0.01) 
Sensation seeking 
(WIII)   
 
0.08* 
 
 0.08 
 
  
 
(0.04) 
 
 (0.04) 
Binge drinking 
frequency (WIII) 0.37*** 
 
0.36*** 
 
  
 (0.02) 
 
(0.02) 
 
  
Marijuana use 
frequency (WIII)   
 
 0.44*** 
 
0.44*** 
 
  
 
 (0.02) 
 
(0.03) 
 
WIV WIII WIV WIV WIII WIV 
Age  
-
0.12*** 
-
0.06*** -0.12*** 
-
0.08*** 
-
0.06*** 
-
0.07*** 
 
(0.02) (0.01) (0.02) (0.02) (0.01) (0.02) 
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Race/ethnicity 
(White=referent)   
 
    
Hispanic -0.01 -0.02 -0.01 0.15 -0.02 0.15 
 
(0.10) (0.06) (0.10) (0.12) (0.06) (0.12) 
Black -0.20* 
-
0.18*** -0.20* 0.12 
-
0.18*** 0.14 
 
(0.10) (0.04) (0.10) (0.12) (0.04) (0.12) 
Asian -0.14 0.04 -0.16 0.06 0.04 0.05 
 
(0.12) (0.07) (0.12) (0.13) (0.07) (0.13) 
Native 
American 0.02 0.21 0.01 -0.38* 0.21 -0.39* 
 
(0.23) (0.13) (0.23) (0.17) (0.13) (0.17) 
Other -0.64* 0.08 -0.64* -0.17 0.08 -0.18 
 
(0.30) (0.15) (0.29) (0.24) (0.15) (0.23) 
Parental 
education (WI) 
(college=referent)   
 
    
< High school -0.07 -0.23** -0.05 -0.28* -0.23** -0.27* 
 
(0.12) (0.07) (0.12) (0.13) (0.07) (0.13) 
High school -0.06 -0.08 -0.05 -0.17 -0.08 -0.17 
 
(0.08) (0.05) (0.08) (0.10) (0.05) (0.10) 
< College 0.01 -0.04 0.02 -0.06 -0.04 -0.06 
 
(0.08) (0.04) (0.08) (0.08) (0.04) (0.08) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 0.04 0.21** 0.01 0.54*** 0.21** 0.52*** 
 
(0.14) (0.07) (0.14) (0.14) (0.07) (0.14) 
High school 0.16 0.06 0.16 0.40*** 0.06 0.40*** 
 
(0.10) (0.06) (0.10) (0.10) (0.06) (0.10) 
< College 0.10 0.07 0.09 0.20* 0.07 0.19* 
 
(0.07) (0.05) (0.07) (0.08) (0.05) (0.08) 
Childhood 
maltreatment 
frequency 
(none=referent)   
 
    
Once 0.19 0.18** 0.18 0.11 0.18** 0.10 
 
(0.11) (0.05) (0.11) (0.12) (0.05) (0.12) 
Twice -0.06 0.21** -0.08 -0.00 0.21** -0.02 
 115 
 
 
(0.12) (0.07) (0.12) (0.10) (0.07) (0.10) 
Three times -0.06 0.23*** -0.07 0.02 0.23*** 0.00 
 
(0.08) (0.05) (0.08) (0.08) (0.05) (0.08) 
Four or more 
times 0.01 0.32*** -0.02 0.14 0.32*** 0.12 
 
(0.08) (0.05) (0.08) (0.07) (0.05) (0.07) 
Drank alcoholic 
beverage before 
WI 0.69*** 
 
0.69*** 
 
  
 (0.09) 
 
(0.09) 
 
  
Marijuana use 
before WI   
 
 0.68*** 
 
0.67*** 
 
  
 
 (0.12) 
 
(0.12) 
Constant 4.06*** 4.09*** 3.70*** 2.25*** 4.09*** 1.88** 
 
(0.57) (0.24) (0.55) (0.55) (0.24) (0.59) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Depressive symptomsSubstance use frequency; M2: Depressive symptomsSensation 
seeking; M3: Depressive symptomsSubstance use frequency, controlling for sensation seeking 
 
Table 3.3.2: Linear regression testing mediation of the Self-Medication Model by sensation 
seeking, Femalesa 
 
FEMALES 
  Binge drinking frequency Marijuana use frequency 
 
M1b M2 M3 M1 M2 M3 
Depressive 
symptoms (WI) -0.00 0.02*** -0.00 0.01 0.02*** 0.00 
 
(0.01) (0.00) (0.01) (0.00) (0.00) (0.00) 
Sensation seeking 
(WIII) 
 
 0.12*** 
 
 0.07* 
 
  (0.03) 
 
 (0.03) 
Binge drinking 
frequency (WIII) 0.34*** 
 
0.32*** 
 
  
 (0.02) 
 
(0.02) 
 
  
Marijuana use 
frequency (WIII) 
 
  0.40*** 
 
0.39*** 
 
   (0.03) 
 
(0.03) 
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WIV WIII WIV WIV WIII WIV 
Age  
-
0.10*** 
-
0.06*** 
-
0.09*** -0.03* 
-
0.06*** -0.03* 
 
(0.01) (0.01) (0.01) (0.01) (0.01) (0.01) 
Race/ethnicity 
(White=referent) 
 
     
Hispanic -0.01 0.01 -0.02 -0.11 0.01 -0.11 
 
(0.07) (0.05) (0.07) (0.07) (0.05) (0.07) 
Black 
-
0.17*** -0.00 
-
0.18*** 0.11 -0.00 0.10 
 
(0.05) (0.04) (0.05) (0.06) (0.04) (0.06) 
Asian 0.02 0.10 -0.00 -0.17* 0.10 -0.18* 
 
(0.13) (0.06) (0.13) (0.08) (0.06) (0.08) 
Native 
American 0.48* 0.13 0.47* -0.02 0.13 -0.03 
 
(0.19) (0.08) (0.20) (0.15) (0.08) (0.15) 
Other -0.02 -0.14 -0.01 -0.12 -0.14 -0.11 
 
(0.23) (0.11) (0.23) (0.11) (0.11) (0.12) 
Parental 
education (WI) 
(college=referent) 
 
     
< High school -0.20** -0.12 -0.19* 0.01 -0.12 0.01 
 
(0.07) (0.06) (0.07) (0.08) (0.06) (0.08) 
High school -0.07 -0.08* -0.07 -0.02 -0.08* -0.01 
 
(0.07) (0.04) (0.07) (0.06) (0.04) (0.06) 
< College -0.07 -0.06 -0.06 0.03 -0.06 0.03 
 
(0.06) (0.04) (0.06) (0.05) (0.04) (0.05) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school -0.21* 0.15* -0.24* 0.13 0.15* 0.12 
 
(0.10) (0.06) (0.10) (0.10) (0.06) (0.10) 
High school -0.04 0.09* -0.06 0.15 0.09* 0.15 
 
(0.08) (0.04) (0.08) (0.08) (0.04) (0.08) 
< College 0.03 0.10** 0.02 0.16*** 0.10** 0.16*** 
 
(0.05) (0.04) (0.05) (0.04) (0.04) (0.04) 
 117 
 
Childhood 
maltreatment 
frequency 
(none=referent) 
 
     
Once 0.08 0.19*** 0.06 -0.02 0.19*** -0.04 
 
(0.08) (0.05) (0.08) (0.07) (0.05) (0.07) 
Twice 0.10 0.14* 0.08 -0.02 0.14* -0.03 
 
(0.07) (0.06) (0.07) (0.07) (0.06) (0.07) 
Three times 0.04 0.09* 0.04 -0.01 0.09* -0.02 
 
(0.06) (0.04) (0.06) (0.07) (0.04) (0.07) 
Four or more 
times 0.04 0.25*** 0.02 0.07 0.25*** 0.05 
 
(0.05) (0.04) (0.05) (0.06) (0.04) (0.06) 
Drank alcoholic 
beverage before 
WI 0.59*** 
 
0.59*** 
 
  
 (0.06) 
 
(0.06) 
 
  
Marijuana use 
before WI 
 
  0.43*** 
 
0.42*** 
 
   (0.11) 
 
(0.11) 
Constant 3.41*** 3.47*** 2.95*** 0.81* 3.47*** 0.53 
 
(0.33) (0.24) (0.35) (0.33) (0.24) (0.35) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Depressive symptomsSubstance use frequency; M2: Depressive symptomsSensation 
seeking; M3: Depressive symptomsSubstance use frequency, controlling for sensation seeking 
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APPENDIX 3.4: AGB MEDIATION FOR SELF-MEDICATION MODEL 
  
Tables 3.4.1 and 3.4.2 display the results testing Hypotheses 2.3 and 2.4, respectively. 
Hypothesis 2.3 was partially supported, as the AGB score for males was positively associated 
with later binge drinking frequency (B=0.15, p<0.05), though not with marijuana use frequency. 
Contrary to our hypothesis, depressive symptoms at Wave I were negatively, rather than 
positively, associated with AGB scores in both the binge drinking and marijuana models 
(B=0.01, p<0.01). Hypothesis 2.4 was supported. As predicted, depressive symptoms at Wave I 
were positively associated with AGB scores in Wave III (B=0.01, p<0.001) and the AGB scores 
were negatively associated with binge drinking frequency (B=-0.16, p<0.001), though not with 
marijuana use frequency.    
Table 3.4.1: Linear regression testing mediation of the Self-Medication Model by AGB, Malesa 
 MALES 
  Binge drinking frequency Marijuana use frequency 
  M1b M2 M3 M1 M2 M3 
Depressive 
symptoms (WI) 0.01 -0.01** 0.02 -0.01 -0.01** -0.01 
 (0.01) (0.00) (0.01) (0.01) (0.00) (0.01) 
AGB (WIII)   0.15*   -0.05 
   (0.06)   (0.07) 
Binge drinking 
frequency (WIII) 0.37***  0.36***    
 (0.02)  (0.02)    
Marijuana use 
frequency (WIII)    0.44***  0.45*** 
    (0.02)  (0.03) 
 WIV WIII WIV WIV WIII WIV 
Age  
-
0.12*** -0.01* 
-
0.12*** 
-
0.08*** -0.01* 
-
0.08*** 
 (0.02) (0.01) (0.02) (0.02) (0.01) (0.02) 
Race/ethnicity 
(White=referent)       
Hispanic -0.01 0.00 -0.01 0.15 0.00 0.15 
 (0.10) (0.03) (0.10) (0.12) (0.03) (0.12) 
Black -0.20* 0.03 -0.22* 0.12 0.03 0.12 
 (0.10) (0.03) (0.10) (0.12) (0.03) (0.12) 
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Asian -0.14 -0.09** -0.14 0.06 -0.09** 0.05 
 (0.12) (0.03) (0.12) (0.13) (0.03) (0.13) 
Native 
American 0.02 0.03 0.02 -0.38* 0.03 -0.38* 
 (0.23) (0.07) (0.23) (0.17) (0.07) (0.17) 
Other -0.64* 0.08 -0.65* -0.17 0.08 -0.16 
 (0.30) (0.11) (0.29) (0.24) (0.11) (0.23) 
Parental 
education (WI) 
(college=referent)       
< High school -0.07 -0.07* -0.06 -0.28* -0.07* -0.29* 
 (0.12) (0.04) (0.12) (0.13) (0.04) (0.13) 
High school -0.06 0.01 -0.06 -0.17 0.01 -0.17 
 (0.08) (0.03) (0.08) (0.10) (0.03) (0.10) 
< College 0.01 -0.02 0.02 -0.06 -0.02 -0.06 
 (0.08) (0.03) (0.08) (0.08) (0.03) (0.08) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 0.04 0.12* 0.02 0.54*** 0.12* 0.54*** 
 (0.14) (0.05) (0.14) (0.14) (0.05) (0.14) 
High school 0.16 0.05 0.16 0.40*** 0.05 0.40*** 
 (0.10) (0.04) (0.10) (0.10) (0.04) (0.10) 
< College 0.10 0.08* 0.09 0.20* 0.08* 0.20* 
 (0.07) (0.03) (0.07) (0.08) (0.03) (0.08) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.19 0.06 0.18 0.11 0.06 0.11 
 (0.11) (0.03) (0.11) (0.12) (0.03) (0.12) 
Twice -0.06 0.07 -0.07 -0.00 0.07 0.00 
 (0.12) (0.04) (0.12) (0.10) (0.04) (0.11) 
Three times -0.06 0.08* -0.06 0.02 0.08* 0.02 
 (0.08) (0.03) (0.08) (0.08) (0.03) (0.08) 
Four or more 
times 0.01 0.09*** -0.00 0.14 0.09*** 0.14 
 (0.08) (0.03) (0.08) (0.07) (0.03) (0.07) 
Drank alcoholic 
beverage before 
WI 0.69***  0.69***    
 (0.09)  (0.09)    
Marijuana use 
before WI    0.68***  0.68*** 
    (0.12)  (0.12) 
Constant 4.06*** 1.10*** 3.86*** 2.25*** 1.10*** 2.32*** 
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(0.57) (0.14) (0.57) (0.55) (0.14) (0.55) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Depressive symptomsSubstance use frequency; M2: Depressive symptomsAGB; M3: 
Depressive symptomsSubstance use frequency, controlling for AGB 
 
Table 3.4.2: Linear regression testing mediation of the Self-Medication Model by AGB, 
Femalesa 
 FEMALES 
  Binge drinking frequency Marijuana use frequency 
  M1b M2 M3 M1 M2 M3 
Depressive 
symptoms (WI) -0.00 0.01*** -0.00 0.01 0.01*** 0.01 
 (0.01) (0.00) (0.01) (0.00) (0.00) (0.00) 
AGB (WIII)   
-
0.16***   -0.03 
   (0.04)   (0.05) 
Binge drinking 
frequency (WIII) 0.34***  0.33***    
 (0.02)  (0.02)    
Marijuana use 
frequency (WIII)    0.40***  0.40*** 
    (0.03)  (0.03) 
 WIV WIII WIV WIV WIII WIV 
Age  
-
0.10*** 0.02*** 
-
0.10*** -0.03* 0.02*** -0.03* 
 (0.01) (0.01) (0.01) (0.01) (0.01) (0.01) 
Race/ethnicity 
(White=referent)       
Hispanic -0.01 -0.01 -0.02 -0.11 -0.01 -0.11 
 (0.07) (0.04) (0.07) (0.07) (0.04) (0.07) 
Black 
-
0.17*** -0.08** 
-
0.19*** 0.11 -0.08** 0.10 
 (0.05) (0.03) (0.05) (0.06) (0.03) (0.06) 
Asian 0.02 -0.14** -0.01 -0.17* -0.14** -0.17* 
 (0.13) (0.04) (0.13) (0.08) (0.04) (0.08) 
Native 
American 0.48* -0.05 0.48* -0.02 -0.05 -0.02 
 (0.19) (0.06) (0.19) (0.15) (0.06) (0.15) 
Other -0.02 -0.01 -0.03 -0.12 -0.01 -0.12 
 (0.23) (0.08) (0.22) (0.11) (0.08) (0.12) 
Parental 
education (WI) 
(college=referent)       
< High school -0.20** 0.02 -0.19** 0.01 0.02 0.01 
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 (0.07) (0.03) (0.07) (0.08) (0.03) (0.08) 
High school -0.07 0.02 -0.07 -0.02 0.02 -0.01 
 (0.07) (0.03) (0.07) (0.06) (0.03) (0.06) 
< College -0.07 0.04 -0.06 0.03 0.04 0.03 
 (0.06) (0.02) (0.06) (0.05) (0.02) (0.05) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school -0.21* 0.10** -0.21* 0.13 0.10** 0.13 
 (0.10) (0.04) (0.10) (0.10) (0.04) (0.10) 
High school -0.04 0.07* -0.04 0.15 0.07* 0.15 
 (0.08) (0.03) (0.08) (0.08) (0.03) (0.08) 
< College 0.03 0.05 0.04 0.16*** 0.05 0.16*** 
 (0.05) (0.03) (0.05) (0.04) (0.03) (0.04) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.08 -0.03 0.07 -0.02 -0.03 -0.02 
 (0.08) (0.03) (0.08) (0.07) (0.03) (0.07) 
Twice 0.10 -0.02 0.09 -0.02 -0.02 -0.02 
 (0.07) (0.03) (0.07) (0.07) (0.03) (0.07) 
Three times 0.04 0.06* 0.05 -0.01 0.06* -0.01 
 (0.06) (0.02) (0.06) (0.07) (0.02) (0.07) 
Four or more 
times 0.04 0.03 0.05 0.07 0.03 0.07 
 (0.05) (0.02) (0.05) (0.06) (0.02) (0.06) 
Drank alcoholic 
beverage before 
WI 0.59***  0.59***    
 (0.06)  (0.06)    
Marijuana use 
before WI    0.43***  0.43*** 
    (0.11)  (0.11) 
Constant 3.41*** 0.21 3.45*** 0.81* 0.21 0.81* 
 (0.33) (0.12) (0.33) (0.33) (0.12) (0.33) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Depressive symptomsSubstance use frequency; M2: Depressive symptomsAGB; M3: 
Depressive symptomsSubstance use frequency, controlling for AGB 
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APPENDIX 3.5: CRP AND EBV MEDIATION FOR STRESS MODEL 
 Tables 3.5.1 through 3.5.4 display the results for the regression models testing 
Hypotheses 2.7 and 2.8. Hypothesis 2.7 was not supported; among males there were no 
significant associations between either binge drinking frequency or marijuana use frequency and 
CRP or EBV, or between CRP or EBV and depressive symptoms. Hypothesis 2.8 was also 
largely not supported, as there were no significant associations between substance use frequency 
and CRP or between CRP and depressive symptoms. However, for EBV, marijuana use 
frequency was significantly positively associated with later EBV (B=0.02, p<0.05), in 
accordance with our hypothesis, but EBV was not significantly associated with depressive 
symptoms. 
Table 3.5.1: Regression testing mediation of the Stress Model by high sensitivity C-reactive 
protein, Malesa 
 MALES 
  Binge drinking frequency Marijuana use frequency 
 M1b M2c M3 M1 M2 M3 
Binge drinking 
frequency (WI) 0.08 -0.01 0.05    
 (0.05) (0.04) (0.05)    
Marijuana use 
frequency (WI)    0.08 -0.03 0.05 
    (0.05) (0.04) (0.05) 
CRP (>3 mg/L)   -0.04   -0.04 
   (0.16)   (0.16) 
Depressive 
symptoms (WIII) 0.40***  0.37*** 0.40***  0.37*** 
 (0.02)  (0.02) (0.02)  (0.02) 
Age WIV WIII WIV WIV WIII WIV 
 0.08* 0.02 0.10* 0.09* 0.02 0.10* 
 (0.04) (0.03) (0.04) (0.04) (0.03) (0.04) 
Race/ethnicity 
(White=referent)       
Hispanic 0.02 -0.02 0.08 0.01 -0.01 0.07 
 (0.20) (0.15) (0.18) (0.20) (0.15) (0.18) 
Black 0.68** 0.19 0.57* 0.66** 0.20 0.55* 
 (0.22) (0.17) (0.22) (0.22) (0.17) (0.21) 
Asian 0.39 -0.35 0.60 0.36 -0.34 0.58 
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 (0.32) (0.19) (0.33) (0.32) (0.19) (0.33) 
Native American 0.28 0.28 -0.09 0.28 0.29 -0.09 
 (0.38) (0.34) (0.34) (0.38) (0.34) (0.34) 
Other -0.62 -0.09 -0.48 -0.64 -0.08 -0.49 
 (0.35) (0.43) (0.29) (0.35) (0.43) (0.29) 
Parental education 
(WI) 
(college=referent)       
< High school 0.30 -0.04 0.44 0.31 -0.04 0.44 
 (0.23) (0.19) (0.23) (0.23) (0.19) (0.23) 
High school 0.32 0.11 0.32 0.33 0.11 0.32 
 (0.17) (0.14) (0.17) (0.17) (0.14) (0.17) 
< College 0.18 -0.03 0.19 0.18 -0.04 0.20 
 (0.15) (0.14) (0.15) (0.15) (0.14) (0.15) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 1.14*** 0.48* 0.80** 1.14*** 0.49* 0.80** 
 (0.30) (0.21) (0.30) (0.30) (0.22) (0.30) 
High school 0.82*** 0.46** 0.79*** 0.82*** 0.47** 0.79*** 
 (0.20) (0.16) (0.21) (0.20) (0.16) (0.21) 
< College 0.45** 0.21 0.31* 0.45** 0.21 0.31* 
 (0.14) (0.18) (0.14) (0.14) (0.18) (0.14) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.34 -0.26 0.21 0.34 -0.26 0.20 
 (0.23) (0.17) (0.21) (0.23) (0.17) (0.21) 
Twice 0.40 0.22 0.23 0.40 0.22 0.23 
 (0.23) (0.17) (0.24) (0.23) (0.17) (0.24) 
Three times 0.97*** -0.18 0.78*** 0.97*** -0.18 0.78*** 
 (0.17) (0.15) (0.16) (0.17) (0.15) (0.16) 
Four or more 
times 1.17*** -0.01 0.84*** 1.17*** -0.00 0.84*** 
 (0.20) (0.12) (0.19) (0.20) (0.12) (0.19) 
Stressful life events 
scale (WIV)  0.07* 0.32***  0.07* 0.32*** 
  (0.03) (0.04)  (0.03) (0.04) 
Count subclinical 
symptoms  0.34*** 0.44***  0.34*** 0.44*** 
  (0.07) (0.11)  (0.07) (0.11) 
Count infectious/ 
inflammatory 
diseases  0.09 0.46***  0.09 0.46*** 
  (0.08) (0.10)  (0.08) (0.10) 
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NSAID or 
Salicylate, past 24 
hrs  0.52 -0.89  0.53 -0.91 
  (0.50) (0.80)  (0.50) (0.81) 
Past 4 weeks  0.03 -0.35  0.04 -0.37 
  (0.28) (0.36)  (0.28) (0.36) 
COX-2 Inhibitor  -0.22 
-
4.38***  -0.20 
-
4.43*** 
  (1.04) (0.97)  (1.03) (0.95) 
Inhaled 
corticosteorids  1.10 -0.19  1.10 -0.20 
  (0.76) (0.91)  (0.76) (0.91) 
Corticotropin or 
glucocorticoid  0.88 -1.74**  0.90 -1.78** 
  (0.62) (0.64)  (0.62) (0.63) 
Antirheumatic or 
antipsoriasitic   2.21 2.05  2.20 2.09 
  (1.21) (1.50)  (1.22) (1.54) 
Immunosuppressive  -1.54 0.40  -1.53 0.36 
  (1.31) (1.23)  (1.31) (1.24) 
Anti-inflammatory  -0.25 0.91  -0.26 0.93 
  (0.52) (0.79)  (0.52) (0.79) 
Physical activity 
past 24 hours  0.02 -0.32*  0.02 -0.31* 
  (0.09) (0.14)  (0.09) (0.14) 
Currently pregnant 
(WIV)       
       
BMI (WIV)  0.84*** -0.12  0.84*** -0.12 
  (0.07) (0.10)  (0.07) (0.10) 
Cigarette smoking 
frequency WIV WIII WIV WIV WIII WIV 
 0.02** 0.01* 0.01 0.02** 0.01** 0.01 
 (0.01) (0.00) (0.01) (0.01) (0.00) (0.01) 
Depression 
diagnosis before 
WI 1.16  0.67 1.09  0.62 
 (0.59)  (0.54) (0.59)  (0.54) 
Constant -0.84 -4.84*** -1.29 -0.98 
-
4.86*** -1.39 
 (1.14) (0.69) (1.16) (1.14) (0.71) (1.13) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
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bM1: Substance use frequencyDepressive symptoms; M2: Substance use frequencyC-
reactive protein (CRP); M3: Substance use frequencyDepressive symptoms, controlling for 
CRP 
cM1 and M3 use linear regression and M2 uses logistic regression so the coefficients are log 
odds 
 
 Table 3.5.2: Regression testing mediation of the Stress Model by high sensitivity C-reactive 
protein, Femalesa 
 FEMALES 
  Binge drinking frequency Marijuana use frequency 
 M1b M2c M3 M1 M2 M3 
Binge drinking 
frequency (WI) 0.08 -0.04 0.05    
 (0.09) (0.04) (0.08)    
Marijuana use 
frequency (WI)    0.08 -0.04 0.05 
    (0.07) (0.04) (0.06) 
CRP (>3 mg/L)   0.02   0.02 
   (0.15)   (0.15) 
Depressive 
symptoms (WIII) 0.35***  0.30*** 0.35***  0.31*** 
 (0.02)  (0.02) (0.02)  (0.02) 
Age WIV WIII WIV WIV WIII WIV 
 0.02 -0.03 0.03 0.02 -0.04 0.04 
 (0.04) (0.02) (0.04) (0.04) (0.02) (0.04) 
Race/ethnicity 
(White=referent)       
Hispanic 0.30 0.09 0.26 0.29 0.10 0.25 
 (0.29) (0.13) (0.25) (0.29) (0.13) (0.25) 
Black 0.55** -0.07 0.32 0.54** -0.06 0.32 
 (0.20) (0.12) (0.19) (0.20) (0.12) (0.20) 
Asian 0.64 -0.49** 0.66 0.63 -0.49** 0.66 
 (0.37) (0.17) (0.34) (0.37) (0.17) (0.34) 
Native American 0.61 0.30 0.38 0.61 0.30 0.38 
 (0.45) (0.29) (0.39) (0.45) (0.29) (0.39) 
Other -0.70 0.58 -0.66 -0.72 0.59 -0.67 
 (0.49) (0.41) (0.45) (0.50) (0.41) (0.45) 
Parental education 
(WI) 
(college=referent)       
< High school 0.66 -0.03 0.67* 0.67 -0.03 0.67* 
 (0.35) (0.14) (0.32) (0.35) (0.14) (0.31) 
High school 0.16 -0.02 0.10 0.17 -0.03 0.10 
 (0.18) (0.11) (0.17) (0.18) (0.11) (0.16) 
< College 0.34 -0.07 0.28 0.35 -0.07 0.29 
 (0.19) (0.11) (0.18) (0.19) (0.10) (0.18) 
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Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 2.15*** 0.06 1.39*** 2.16*** 0.06 1.40*** 
 (0.38) (0.18) (0.36) (0.37) (0.17) (0.35) 
High school 1.15*** 0.04 0.83*** 1.16*** 0.05 0.83*** 
 (0.21) (0.15) (0.22) (0.21) (0.15) (0.22) 
< College 0.44** -0.07 0.19 0.44** -0.07 0.19 
 (0.17) (0.13) (0.17) (0.17) (0.13) (0.17) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.58* -0.00 0.52* 0.58* -0.00 0.52* 
 (0.25) (0.16) (0.23) (0.24) (0.17) (0.23) 
Twice 0.22 -0.07 0.07 0.23 -0.07 0.08 
 (0.25) (0.14) (0.24) (0.24) (0.15) (0.23) 
Three times 0.67** -0.19* 0.50* 0.68** -0.20* 0.50* 
 (0.21) (0.09) (0.20) (0.21) (0.09) (0.20) 
Four or more 
times 1.13*** -0.23* 0.75*** 1.13*** -0.23* 0.75*** 
 (0.18) (0.11) (0.17) (0.18) (0.11) (0.17) 
Stressful life events 
scale (WIV)  -0.00 0.53***  -0.00 0.52*** 
  (0.03) (0.05)  (0.03) (0.05) 
Count subclinical 
symptoms  0.28*** 0.70***  0.28*** 0.70*** 
  (0.06) (0.10)  (0.06) (0.10) 
Count infectious/ 
inflammatory 
diseases  -0.02 0.18  -0.02 0.18 
  (0.07) (0.10)  (0.07) (0.10) 
NSAID or 
Salicylate, past 24 
hrs  0.01 -0.32  0.02 -0.33 
  (0.33) (0.63)  (0.34) (0.64) 
Past 4 weeks  0.21 -0.67  0.20 -0.67 
  (0.27) (0.49)  (0.27) (0.49) 
COX-2 Inhibitor  0.11 0.10  0.09 0.14 
  (0.75) (1.44)  (0.75) (1.43) 
Inhaled 
corticosteorids  0.63 -0.97  0.62 -0.94 
  (0.68) (1.03)  (0.68) (1.03) 
Corticotropin or 
glucocorticoid  -0.14 -0.38  -0.13 -0.39 
  (0.50) (0.76)  (0.50) (0.76) 
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Antirheumatic or 
antipsoriasitic   -0.10 0.98  -0.08 0.97 
  (0.60) (1.12)  (0.60) (1.11) 
Immunosuppressive  1.05 -2.51  1.02 -2.49 
  (0.85) (1.33)  (0.84) (1.32) 
Anti-inflammatory  0.17 0.86  0.16 0.87 
  (0.36) (0.63)  (0.36) (0.64) 
Physical activity 
past 24 hours  -0.22* -0.22  -0.22* -0.22 
  (0.09) (0.13)  (0.09) (0.13) 
Currently pregnant 
(WIV)  1.17*** 0.18  1.17*** 0.18 
  (0.16) (0.26)  (0.16) (0.27) 
BMI (WIV)  1.04*** -0.11  1.04*** -0.11 
  (0.05) (0.09)  (0.05) (0.09) 
Cigarette smoking 
frequency WIV WIII WIV WIV WIII WIV 
 0.01* -0.00 0.00 0.01* -0.00 -0.00 
 (0.01) (0.00) (0.01) (0.01) (0.00) (0.01) 
Depression 
diagnosis before 
WI 1.90**  1.48* 1.89**  1.47* 
 (0.61)  (0.59) (0.61)  (0.59) 
Constant 1.75 
-
2.42*** 1.02 1.63 
-
2.40*** 0.94 
 (1.20) (0.52) (1.16) (1.18) (0.51) (1.12) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Substance use frequencyDepressive symptoms; M2: Substance use frequencyC-
reactive protein (CRP); M3: Substance use frequencyDepressive symptoms, controlling for 
CRP 
cM1 and M3 use linear regression and M2 uses logistic regression so the coefficients are log 
odds 
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Table 3.5.3: Linear regression testing mediation of the Stress Model by Epstein-Barr Virus, 
Malesa 
 MALES 
  Binge drinking frequency Marijuana use frequency 
 M1b M2 M3 M1 M2 M3 
Binge drinking 
frequency (WI) 0.08 -0.01 0.05    
 (0.05) (0.01) (0.05)    
Marijuana use 
frequency (WI)    0.08 -0.00 0.05 
    (0.05) (0.01) (0.05) 
EBV   -0.01   -0.01 
   (0.08)   (0.08) 
Depressive 
symptoms (WIII) 0.40***  0.37*** 0.40***  0.37*** 
 (0.02)  (0.02) (0.02)  (0.02) 
Age WIV WIII WIV WIV WIII WIV 
 0.08* 0.02** 0.10* 0.09* 0.02* 0.10* 
 (0.04) (0.01) (0.04) (0.04) (0.01) (0.04) 
Race/ethnicity 
(White=referent)       
Hispanic 0.02 0.06 0.08 0.01 0.06 0.07 
 (0.20) (0.05) (0.18) (0.20) (0.05) (0.18) 
Black 0.68** 0.17*** 0.57* 0.66** 0.17*** 0.55* 
 (0.22) (0.03) (0.22) (0.22) (0.03) (0.22) 
Asian 0.39 0.03 0.61 0.36 0.04 0.59 
 (0.32) (0.05) (0.33) (0.32) (0.05) (0.33) 
Native American 0.28 0.04 -0.10 0.28 0.04 -0.10 
 (0.38) (0.08) (0.34) (0.38) (0.08) (0.34) 
Other -0.62 -0.04 -0.48 -0.64 -0.04 -0.49 
 (0.35) (0.10) (0.29) (0.35) (0.10) (0.29) 
Parental education 
(WI) 
(college=referent)       
< High school 0.30 0.01 0.44 0.31 0.02 0.44 
 (0.23) (0.06) (0.23) (0.23) (0.06) (0.23) 
High school 0.32 0.08* 0.32 0.33 0.08* 0.32 
 (0.17) (0.04) (0.17) (0.17) (0.04) (0.17) 
College 0.18 0.05 0.19 0.18 0.05 0.20 
 (0.15) (0.03) (0.15) (0.15) (0.03) (0.15) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 1.14*** 0.02 0.80** 1.14*** 0.02 0.80** 
 (0.30) (0.06) (0.30) (0.30) (0.06) (0.30) 
High school 0.82*** 0.03 0.79*** 0.82*** 0.04 0.79*** 
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 (0.20) (0.05) (0.21) (0.20) (0.05) (0.21) 
College 0.45** -0.01 0.31* 0.45** -0.01 0.31* 
 (0.14) (0.04) (0.14) (0.14) (0.04) (0.14) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.34 -0.07 0.21 0.34 -0.07 0.20 
 (0.23) (0.05) (0.21) (0.23) (0.05) (0.20) 
Twice 0.40 0.01 0.23 0.40 0.01 0.23 
 (0.23) (0.05) (0.24) (0.23) (0.05) (0.24) 
Three times 0.97*** -0.02 0.78*** 0.97*** -0.02 0.78*** 
 (0.17) (0.04) (0.16) (0.17) (0.04) (0.16) 
Four or more 
times 1.17*** 0.05 0.84*** 1.17*** 0.05 0.84*** 
 (0.20) (0.03) (0.19) (0.20) (0.03) (0.19) 
Stressful life events 
scale (WIV)  0.00 0.32***  -0.00 0.32*** 
  (0.01) (0.04)  (0.01) (0.04) 
Count subclinical 
symptoms 0.00 0.44***  0.00 0.44***  
 (0.02) (0.11)  (0.02) (0.11)  
Count infectious/ 
inflammatory 
diseases 0.00 0.45***  0.00 0.46***  
 (0.02) (0.10)  (0.02) (0.10)  
NSAID or 
Salicylate, past 24 
hrs  -0.26 -0.90  -0.26 -0.92 
  (0.15) (0.80)  (0.15) (0.80) 
Use in past 4 
weeks  -0.01 -0.36  -0.01 -0.37 
  (0.11) (0.36)  (0.11) (0.36) 
COX-2 Inhibitor  -0.80** 
-
4.39***  -0.79* 
-
4.43*** 
  (0.30) (0.96)  (0.30) (0.95) 
Inhaled 
corticosteorids  -0.36 -0.20  -0.35 -0.21 
  (0.37) (0.91)  (0.37) (0.91) 
Corticotropin or 
glucocorticoid  -0.04 -1.75**  -0.04 -1.78** 
  (0.18) (0.63)  (0.18) (0.63) 
Antirheumatic or 
antipsoriasitic   -0.57** 2.03  -0.57** 2.07 
  (0.17) (1.50)  (0.18) (1.54) 
Immunosuppressive  0.58* 0.42  0.58* 0.38 
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(0.26) (1.23)  (0.26) (1.24) 
Anti-inflammatory 0.27 0.91  0.28 0.93 
  (0.16) (0.78)  (0.16) (0.78) 
Physical activity 
past 24 hours  -0.02 -0.32*  -0.02 -0.31* 
  (0.03) (0.14)  (0.03) (0.14) 
Currently pregnant 
(WIV)       
       
BMI (WIV)  0.04* -0.13  0.04* -0.12 
  (0.02) (0.09)  (0.02) (0.09) 
Cigarette smoking 
frequency WIV WIII WIV WIV WIII WIV 
 0.02** 0.00 0.01 0.02** 0.00 0.01 
 (0.01) (0.00) (0.01) (0.01) (0.00) (0.01) 
Depression 
diagnosis before 
WI 1.16  0.67 1.09  0.62 
 (0.59)  (0.54) (0.59)  (0.54) 
Constant -0.84 4.00*** -1.25 -0.98 4.05*** -1.34 
 (1.14) (0.19) (1.15) (1.14) (0.20) (1.12) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Substance use frequencyDepressive symptoms; M2: Substance use frequencyEpstein-
Barr Virus (EBV); M3: Substance use frequencyDepressive symptoms, controlling for EBV 
 
Table 3.5.4: Linear regression testing mediation of the Stress Model by Epstein-Barr Virus, 
Femalesa 
 FEMALES 
  Binge drinking frequency Marijuana use frequency 
 M1b M2 M3 M1 M2 M3 
Binge drinking 
frequency (WI) 0.08 0.01 0.05    
 (0.09) (0.01) (0.08)    
Marijuana use 
frequency (WI)    0.08 0.02* 0.05 
    (0.07) (0.01) (0.06) 
EBV   -0.02   -0.02 
   (0.09)   (0.09) 
Depressive 
symptoms (WIII) 0.35***  0.30*** 0.35***  0.31*** 
 (0.02)  (0.02) (0.02)  (0.02) 
Age WIV WIII WIV WIV WIII WIV 
 0.02 0.01 0.03 0.02 0.01 0.04 
 (0.04) (0.01) (0.04) (0.04) (0.01) (0.04) 
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Race/ethnicity 
(White=referent)       
Hispanic 0.30 0.07 0.26 0.29 0.07 0.26 
 (0.29) (0.04) (0.25) (0.29) (0.04) (0.26) 
Black 0.55** 0.18*** 0.33 0.54** 0.18*** 0.32 
 (0.20) (0.04) (0.19) (0.20) (0.04) (0.19) 
Asian 0.64 0.02 0.66 0.63 0.02 0.66 
 (0.37) (0.06) (0.34) (0.37) (0.06) (0.34) 
Native American 0.61 0.05 0.38 0.61 0.05 0.38 
 (0.45) (0.10) (0.39) (0.45) (0.10) (0.39) 
Other -0.70 0.07 -0.65 -0.72 0.07 -0.67 
 (0.49) (0.13) (0.45) (0.50) (0.13) (0.45) 
Parental education 
(WI) 
(college=referent)       
< High school 0.66 0.05 0.67* 0.67 0.05 0.67* 
 (0.35) (0.04) (0.32) (0.35) (0.04) (0.31) 
High school 0.16 0.05 0.10 0.17 0.06 0.11 
 (0.18) (0.03) (0.17) (0.18) (0.03) (0.16) 
College 0.34 0.02 0.28 0.35 0.02 0.29 
 (0.19) (0.03) (0.18) (0.19) (0.03) (0.18) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 2.15*** 0.05 1.39*** 2.16*** 0.04 1.40*** 
 (0.38) (0.06) (0.36) (0.37) (0.06) (0.35) 
High school 1.15*** 0.03 0.83*** 1.16*** 0.02 0.83*** 
 (0.21) (0.04) (0.22) (0.21) (0.04) (0.22) 
College 0.44** -0.02 0.19 0.44** -0.02 0.19 
 (0.17) (0.04) (0.17) (0.17) (0.04) (0.17) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.58* 0.03 0.52* 0.58* 0.03 0.52* 
 (0.25) (0.05) (0.23) (0.24) (0.05) (0.23) 
Twice 0.22 -0.02 0.07 0.23 -0.02 0.08 
 (0.25) (0.04) (0.24) (0.24) (0.04) (0.23) 
Three times 0.67** -0.00 0.49* 0.68** -0.00 0.50* 
 (0.21) (0.03) (0.20) (0.21) (0.03) (0.19) 
Four or more 
times 1.13*** 0.01 0.75*** 1.13*** 0.01 0.75*** 
 (0.18) (0.03) (0.17) (0.18) (0.03) (0.17) 
Stressful life events 
scale (WIV)  0.00 0.53***  -0.00 0.52*** 
  (0.01) (0.05)  (0.01) (0.05) 
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Count subclinical 
symptoms  -0.00 0.71***  -0.00 0.71*** 
  (0.02) (0.10)  (0.02) (0.10) 
Count infectious/ 
inflammatory 
diseases  0.03 0.18  0.03 0.18 
  (0.02) (0.10)  (0.02) (0.10) 
NSAID or 
Salicylate, past 24 
hrs  0.13 -0.32  0.13 -0.32 
  (0.10) (0.63)  (0.10) (0.64) 
Use in past 4 
weeks  0.06 -0.67  0.07 -0.67 
  (0.07) (0.49)  (0.07) (0.49) 
COX-2 Inhibitor  0.50 0.11  0.51 0.15 
  (0.31) (1.45)  (0.31) (1.44) 
Inhaled 
corticosteorids  -0.14 -0.97  -0.13 -0.94 
  (0.20) (1.03)  (0.20) (1.03) 
Corticotropin or 
glucocorticoid  0.23 -0.38  0.23 -0.38 
  (0.12) (0.76)  (0.12) (0.76) 
Antirheumatic or 
antipsoriasitic   0.47** 0.99  0.45** 0.98 
  (0.16) (1.12)  (0.16) (1.11) 
Immunosuppressive  -0.66* -2.52  -0.65* -2.50 
  (0.29) (1.32)  (0.29) (1.32) 
Anti-inflammatory  -0.13 0.86  -0.13 0.87 
  (0.10) (0.63)  (0.11) (0.64) 
Physical activity 
past 24 hours  -0.02 -0.22  -0.02 -0.22 
  (0.03) (0.13)  (0.03) (0.13) 
Currently pregnant 
(WIV)  -0.10* 0.18  -0.10* 0.18 
  (0.05) (0.26)  (0.05) (0.26) 
BMI (WIV)  0.03* -0.10  0.03* -0.10 
  (0.01) (0.08)  (0.01) (0.08) 
Cigarette smoking 
frequency WIV WIII WIV WIV WIII WIV 
 0.01* 0.003** -0.00 0.01* 0.002** -0.00 
 (0.01) (0.00) (0.01) (0.01) (0.00) (0.01) 
Depression 
diagnosis before 
WI 1.90**  1.48* 1.89**  1.47* 
 (0.61)  (0.59) (0.61)  (0.59) 
Constant 1.75 4.50*** 1.12 1.63 4.52*** 1.05 
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(1.20) (0.17) (1.22) (1.18) (0.17) (1.21) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Substance use frequencyDepressive symptoms; M2: Substance use frequencyEpstein-
Barr Virus (EBV); M3: Substance use frequencyDepressive symptoms, controlling for EBV 
 134 
 
APPENDIX 3.6: AGB MEDIATION FOR STRESS MODEL 
Tables 3.6.1 and 3.6.2 display the results of the regression models testing Hypotheses 2.9 
and 2.10, respectively. Hypothesis 2.9 was largely not supported, as for males there was only one 
significant association between binge drinking frequency and AGB (B=0.03, p<0.01). 
Hypothesis 2.10 was also largely not supported, as there was again only one significant 
association between binge drinking frequency and AGB (B=-0.02, p<0.05). Both of these 
significant associations were in accordance with our hypotheses, but AGB in emerging 
adulthood was not significantly associated with depressive symptoms in young adulthood, 
contrary to the hypothesized pattern.  
Table 3.6.1: Linear regression testing mediation of the Stress Model by Adherence to Gender-
typical Behavior, Malesa 
 MALES 
  Binge drinking frequency Marijuana use frequency 
 M1b M2 M3 M1 M2 M3 
Binge drinking 
frequency (WI) 0.10 0.03** 0.10    
 (0.05) (0.01) (0.05)    
Marijuana use 
frequency (WI)    0.10 0.01 0.11 
    (0.05) (0.01) (0.05) 
AGB3F   -0.21   -0.20 
   (0.14)   (0.14) 
Depressive 
symptoms (WIII) 0.41***  0.40*** 0.40***  0.40*** 
 (0.02)  (0.02) (0.02)  (0.02) 
 WIV WIII WIV WIV WIII WIV 
Age  0.07 
-
0.02*** 0.07 0.08 -0.02** 0.07 
 (0.04) (0.01) (0.04) (0.04) (0.01) (0.04) 
Race/ethnicity 
(White=referent)       
Hispanic -0.05 -0.00 -0.04 -0.06 -0.00 -0.06 
 (0.20) (0.03) (0.20) (0.20) (0.03) (0.20) 
Black 0.63** 0.03 0.63** 0.60** 0.02 0.60** 
 (0.22) (0.03) (0.22) (0.22) (0.03) (0.22) 
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Asian 0.38 -0.09** 0.37 0.34 
-
0.10*** 0.32 
 (0.33) (0.03) (0.32) (0.32) (0.03) (0.32) 
Native American 0.30 0.01 0.31 0.30 0.02 0.31 
 (0.38) (0.07) (0.38) (0.38) (0.07) (0.38) 
Other -0.66* 0.08 -0.64* -0.69* 0.07 -0.67* 
 (0.32) (0.11) (0.31) (0.32) (0.11) (0.31) 
Parental 
education (WI) 
(college=referent)       
< High school 0.29 -0.08* 0.27 0.30 -0.08* 0.28 
 (0.23) (0.04) (0.23) (0.23) (0.04) (0.23) 
High school 0.32 0.01 0.32 0.33 0.01 0.33 
 (0.17) (0.03) (0.17) (0.17) (0.03) (0.17) 
< College 0.17 -0.02 0.17 0.18 -0.02 0.18 
 (0.15) (0.03) (0.15) (0.15) (0.03) (0.15) 
Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 1.34*** 0.09* 1.35*** 1.33*** 0.10* 1.35*** 
 (0.29) (0.05) (0.29) (0.30) (0.05) (0.30) 
High school 0.95*** 0.04 0.95*** 0.95*** 0.04 0.95*** 
 (0.19) (0.04) (0.19) (0.20) (0.04) (0.20) 
< College 0.54*** 0.07* 0.55*** 0.54*** 0.07* 0.55*** 
 (0.14) (0.04) (0.15) (0.14) (0.04) (0.15) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.36 0.05 0.38 0.36 0.05 0.37 
 (0.23) (0.03) (0.23) (0.23) (0.03) (0.23) 
Twice 0.43 0.06 0.45 0.42 0.06 0.44 
 (0.24) (0.04) (0.24) (0.24) (0.04) (0.24) 
Three times 0.98*** 0.07* 1.00*** 0.98*** 0.07* 0.99*** 
 (0.17) (0.03) (0.17) (0.17) (0.03) (0.17) 
Four or more 
times 1.21*** 0.07** 1.22*** 1.20*** 0.07** 1.21*** 
 (0.20) (0.03) (0.20) (0.20) (0.03) (0.20) 
Depression 
diagnosis before 
WI 1.22*  1.21* 1.14*  1.13 
 (0.58)  (0.58) (0.57)  (0.58) 
Constant -0.49 1.25*** -0.14 -0.67 1.16*** -0.37 
 (1.15) (0.15) (1.17) (1.14) (0.14) (1.16) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
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aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Substance use frequencyDepressive symptoms; M2: Substance use 
frequencyAdherence to Gender-typical Behavior (AGB); M3: Substance use 
frequencyDepressive symptoms, controlling for AGB 
 
Table 3.6.2: Linear regression testing mediation of the Stress Model by Adherence to Gender-
typical Behavior, Femalesa 
 FEMALES 
  Binge drinking frequency Marijuana use frequency 
 M1b M2 M3 M1 M2 M3 
Binge drinking 
frequency (WI) 0.10 -0.02* 0.10    
 (0.08) (0.01) (0.08)    
Marijuana use 
frequency (WI)    0.11 0.00 0.11 
    (0.07) (0.01) (0.07) 
AGB3F   0.18   0.17 
   (0.16)   (0.16) 
Depressive 
symptoms (WIII) 0.35***  0.35*** 0.35***  0.35*** 
 (0.02)  (0.02) (0.02)  (0.02) 
 WIV WIII WIV WIV WIII WIV 
Age  0.02 0.03*** 0.01 0.02 0.03*** 0.02 
 (0.04) (0.01) (0.04) (0.04) (0.01) (0.04) 
Race/ethnicity 
(White=referent)       
Hispanic 0.21 -0.00 0.21 0.20 -0.00 0.20 
 (0.30) (0.04) (0.30) (0.30) (0.04) (0.30) 
Black 0.47* -0.08** 0.48* 0.45* -0.08** 0.47* 
 (0.20) (0.03) (0.20) (0.20) (0.02) (0.20) 
Asian 0.59 -0.13** 0.61 0.58 -0.13** 0.61 
 (0.37) (0.05) (0.37) (0.37) (0.05) (0.37) 
Native American 0.61 -0.05 0.62 0.61 -0.05 0.62 
 (0.46) (0.06) (0.46) (0.45) (0.06) (0.45) 
Other -0.73 -0.02 -0.72 -0.75 -0.02 -0.75 
 (0.48) (0.08) (0.48) (0.49) (0.08) (0.49) 
Parental 
education (WI) 
(college=referent)       
< High school 0.66 0.02 0.66 0.67 0.02 0.66 
 (0.35) (0.03) (0.35) (0.35) (0.03) (0.35) 
High school 0.17 0.03 0.16 0.18 0.03 0.18 
 (0.18) (0.03) (0.18) (0.18) (0.03) (0.18) 
< College 0.35 0.04 0.34 0.36 0.04 0.35 
 (0.19) (0.02) (0.19) (0.19) (0.02) (0.19) 
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Respondent 
education 
(college=referent) WIV WIII WIV WIV WIII WIV 
< High school 2.31*** 0.14*** 2.31*** 2.31*** 0.12*** 2.30*** 
 (0.39) (0.04) (0.39) (0.37) (0.04) (0.37) 
High school 1.26*** 0.09** 1.26*** 1.26*** 0.08** 1.26*** 
 (0.20) (0.03) (0.20) (0.20) (0.03) (0.20) 
< College 0.52** 0.05 0.51** 0.52** 0.05 0.51** 
 (0.16) (0.03) (0.16) (0.16) (0.03) (0.16) 
Childhood 
maltreatment 
frequency 
(none=referent)       
Once 0.58* -0.02 0.59* 0.58* -0.03 0.59* 
 (0.25) (0.03) (0.25) (0.24) (0.03) (0.24) 
Twice 0.21 -0.00 0.22 0.22 -0.01 0.23 
 (0.25) (0.04) (0.24) (0.24) (0.04) (0.24) 
Three times 0.69** 0.06** 0.68** 0.70** 0.06** 0.69** 
 (0.21) (0.02) (0.21) (0.21) (0.02) (0.21) 
Four or more 
times 1.15*** 0.05* 1.15*** 1.15*** 0.04 1.16*** 
 (0.18) (0.02) (0.18) (0.18) (0.02) (0.18) 
Depression 
diagnosis before 
WI 1.97**  1.96** 1.95**  1.94** 
 (0.61)  (0.61) (0.61)  (0.61) 
Constant 1.89 0.13 1.90 1.76 0.18 1.76 
 (1.19) (0.12) (1.19) (1.17) (0.12) (1.16) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
aWave I (WI), Wave III (WIII), Wave IV (WIV) 
bM1: Substance use frequencyDepressive symptoms; M2: Substance use 
frequencyAdherence to Gender-typical Behavior (AGB); M3: Substance use 
frequencyDepressive symptoms, controlling for AGB 
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APPENDIX 3.7: AGB MODERATION OF THE SELF-MEDICATION MODEL 
 Table 3.7.1 displays the only significant moderation result, which supported Hypothesis 
2.5. There was significant interaction between AGB and depressive symptoms at Wave III 
(B=0.05, p<0.05). Hypotheses 2.6, 2.11, and 2.12 were not supported. 
Table 3.7.1: Linear regression testing moderation of the Self-Medication Model for binge 
drinking frequency by AGB for malesa 
Depressive symptoms (WIII) -0.04* 
 (0.02) 
AGB (WIII) -0.05 
 (0.10) 
Depressive symptoms (WIII) x AGB (WIII) 0.05* 
 (0.02) 
Binge drinking frequency (WIII) 0.36*** 
 (0.02) 
Age (WIV) -0.11*** 
 (0.02) 
Race/ethnicity (White=referent)  
Hispanic -0.00 
 (0.10) 
Black -0.21* 
 (0.10) 
Asian -0.11 
 (0.12) 
Native American 0.01 
 (0.22) 
Other -0.64* 
 (0.29) 
Parental education (WI) (college=referent)  
< High school -0.04 
 (0.12) 
High school -0.06 
 (0.08) 
< College 0.03 
 (0.08) 
Respondent education (WIV) 
(college=referent)  
< High school 0.05 
 (0.14) 
High school 0.18 
 (0.10) 
< College 0.10 
 (0.07) 
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Childhood maltreatment frequency 
(none=referent)  
Once 0.20 
 (0.11) 
Twice -0.05 
 (0.12) 
Three times -0.05 
 (0.08) 
Four or more times 0.02 
 (0.08) 
Drank alcoholic beverage before WI 0.68*** 
 (0.09) 
Constant 3.92*** 
 (0.56) 
*** p<0.001, ** p<0.01, * p<0.05; numbers are regression coefficients, standard errors in 
parentheses 
 aWave I (WI), Wave III (WIII), Wave IV (WIV) 
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